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ABSTRACT
Evaluating Utilization of Beta-Blockers as Secondary Prevention for Post
Myocardial Infarction in a Medicaid Population
Ancilla W. Fernandes
Acute myocardial infarction (AMI) is associated with high mortality and costs to the US
healthcare system. Beta-blockers are known to reduce mortality and re-infarction rates
when used for long-term prevention following an AMI. They are recommended by the
American College of Cardiology (ACC)/American Heart Association (AHA) guidelines
in post-AMI patients. However, this therapy is both underused (error of omission in
eligible patients) and misused (error of commission in ineligible patients). This study
involved two phases. Phase one included evaluating utilization of beta-blockers in a
Medicaid population and determining the effect of their utilization on patient outcomes
such as mortality, morbidity, utilization of healthcare services and expenditures. Phase
two involved determining the association of physician-related factors such as knowledge
of contraindications, willingness to prescribe, physician demographics and physician
practice characteristics on their beta-blocker prescribing behavior. Phase one of the study
revealed 37% inappropriate (misuse and underuse) utilization. During the 12-month
follow-up after the incident AMI the appropriately prescribed group had a significantly
lower all-cause mortality and lower, but insignificant, cardiac mortality compared to the
inappropriately prescribed group. The appropriately prescribed group had significantly
higher cardiovascular morbidity and higher utilization in the follow-up period. However,
there were indications that the appropriate group was more severely ill as compared to the
inappropriate group. Thus, the increase in morbidity and utilization could be due to
patient severity rather than appropriate therapy. In phase two, a survey was mailed to
1,019 physicians involved in post-AMI care in WV, of which 261(25.61%) responded.
Physician knowledge of contraindications was not associated with their self-reported
beta-blocker prescribing behavior. Physicians’ willingness to prescribe was positively
associated with their beta-blocker prescribing behavior. Younger age and affiliation with
a larger hospital were associated with better beta-blocker prescribing behavior.
Multivariate analysis including knowledge, willingness to prescribe, demographics and
practice characteristics revealed that willingness to prescribe was the only significant
predictor of their beta-blocker prescribing behavior. Findings of this phase indicated a
profile of general specialty/family practice physician, older in age, non-university or nonhospital affiliated, and attached to a smaller hospital as the target for interventions to
improve beta-blocker prescribing behavior.
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CHAPTER ONE
INTRODUCTION

Acute Myocardial Infarction (AMI), also known as “heart attack” is defined as the
death of heart muscle due to loss of blood supply (Bellenir, 2000). Coronary artery
disease (CAD) is the primary underlying process that leads to an AMI (Stringer & Lopez,
1999). It is the number one killer among both men and women in the United States
(Stringer & Lopez, 1999). Each year approximately 900,000 people experience an AMI.
Apart from being a serious health issue, coronary disease is also responsible for severe
economic losses in the United States. For instance, in 1997, the financial consequence
due to coronary artery disease to the U.S. healthcare system was estimated to be
approximately $91 billion (Stringer & Lopez, 1999). Thus, therapeutic interventions that
reduce mortality and improve morbidity, as well as primary and secondary prevention
strategies, could have a significant impact on the US healthcare system.
Of the 900,000 people who suffer from an AMI every year, over 800,000 people
survive (Bradford, Chen & Krumholz, 1999). Therapy with beta-blockers has shown to
be an effective means of reducing mortality following a heart attack (Bradford, et al.,
1999). Prophylaxis with beta-blockers after the onset of an AMI has been reported to be
effective since the 1960s (Snow, 1965). Thousands of patients have participated in
randomized trials which have demonstrated that cardiovascular mortality and reinfarction rates decrease with beta-blocker use following an AMI (Bradford, et al., 1999).
There is also strong evidence that beta-blockers are safe and effective therapies.
However, there are certain conditions, such as bradycardia, hypotension and

1

atrioventricular (AV) block in patients where there is evidence that therapy is not useful
or may be harmful [American College of Cardiology (ACC)/American Heart Association
(AHA), 1996]. The national cardiology consensus committees have acknowledged this
fact by publishing recommendations for its use in patients to whom it is beneficial and
listing those conditions, in the presence of which, this therapy should not be used
(ACC/AHA, 1996).
Despite the benefits of beta-blocker therapy and the established guidelines for
proper use, they are not prescribed appropriately in patients after an AMI (Bradford, et
al., 1999). Many patients who are eligible and should receive prescription for betablocker therapy at discharge do not get a prescription (error of omission or under use).
While it is not as well documented, there are a few reports that suggest that sometimes
patients who have contraindications and are not eligible for therapy receive a prescription
for beta-blockers (error of commission or misuse) (Brand, Newcomer, Freiburger, &
Tian, 1995). This inappropriate prescribing of a useful therapeutic agent can affect
patient outcomes such as morbidity, mortality, and increase healthcare utilization and
costs. Thus, this study will assess the effects of inappropriate prescribing of betablockers for secondary prevention following an AMI. This study will also assess
practitioner knowledge and willingness to prescribe long-term beta-blocker therapy in
post AMI patients. The following sections will concentrate on beta-blocker therapy,
evidence of its inappropriate prescribing, consequences of inappropriate prescribing, and
the physician’s role in drug prescribing.
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Beta-blocker Therapy
By definition, beta-blockers block beta-receptors (Khan, 2000). Structurally they
resemble catecholamines. They competitively inhibit beta-receptors depending on the
ratio of their concentration to catecholamine concentration. When given to an AMI
patient, they are known to rapidly reduce systolic blood pressure, by reducing cardiac
output (Plosker & Clissold, 1992). They are also known to reduce myocardial oxygen
demand. These beneficial effects are believed to decrease the incidence of
cerebrovascular complications and new myocardial infarctions, thus providing clinical
efficacy. Beta-blockers also have certain adverse effects such as fatigue, sexual
dysfunction, nightmares and difficulty to detect hypoglycemia in diabetes.
Numerous studies have provided evidence that beta-blocker therapy is effective
following an AMI (Bradford, et al., 1999). In a meta-analysis of 65 studies, Yusuf et al.
concluded that long-term beta-blocker therapy for perhaps a year or so following
discharge after an AMI reduces the odds of death and re-infarction by about 25% (Yusuf,
Peto, Lewis, Collins & Sleight, 1985). Hjalmarson’s review of data from 5 clinical trials
reported a 36% reduction in mortality in two studies, a 26% reduction in one study, and a
13-14% reduction in mortality in the other two studies (Hjalmarson, 1988). Goldstein
reported that the beneficial effects of oral beta-blocker therapy were maintained for at
least six years after myocardial infarction, and discontinuation was associated with
accelerated mortality (Goldstein, 1996). He also reported a reduction in cardiovascular
mortality, re-infarction rate, and sudden death due to beta-blocker use following an AMI.
Furberg and Byinton examined data from the Beta-Blocker Heart Attack Trial
(BHAT) (Furberg & Byinton, 1983). They examined the difference in outcomes between
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patients in the tails of the distribution of expected mortality risk. They found a relative
risk reduction of 40% in the group receiving beta-blocker agents in this limited set of
patients. Olsson et al., analyzed individual patient level data from 5 randomized trials
(Olsson, et al., 1992). They found an overall reduction in relative risk of mortality of
19%. Also, a higher benefit to women (23%) was observed as compared to men (16%).
The reduction in total mortality was mainly due to a reduction in sudden cardiac deaths.
These studies also reported reductions in re-infarction rates, angina pectoris severity, and
congestive heart failure severity (Bradford, Chen & Krumholz, 1999).
The ACC/ AHA relied on the evidence of these beneficial effects to develop
guidelines for beta-blocker use for secondary prevention after an AMI (ACC/AHA, 1996
& 1999). These guidelines suggest that all patients, except those with absolute
contraindications to beta-blocker therapy, should begin treatment within a few days of
AMI and continue it indefinitely. The absolute contraindications for beta-blocker use are
few and include AV block, bradycardia, and hypotension (ACC/AHA, 1996 & 1999,
Philips et al., 2000). However, a variety of conditions are listed as relative
contraindications. These include: heart rate less than 60 bpm, systolic arterial pressure
less than 100 mm Hg, moderate or severe left ventricular (LV) failure, signs of peripheral
hypoperfusion, PR interval greater than 0.24 second, second or third degree AV block,
severe chronic obstructive pulmonary disease (COPD), history of asthma, insulin
dependent diabetes mellitus (IDDM), and severe peripheral vascular disease (ACC/AHA,
1996). Though patients with relative contraindications are recommended to receive
therapy, they need to be monitored for adverse reactions.
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Evidence of Inappropriate Prescribing
Considerable variation in beta-blocker use for secondary prevention following an
AMI has been reported. Rogers et al., examined the National Registry of Myocardial
Infarction (NRMI) to investigate beta-blocker use from 1990 to 1993 (Rogers et al.,
1994). Oral beta-blockers were used in only 36% of registered thrombolytic recipients,
whereas in patients who did not receive thrombolysis, the utilization was 30%. Soumerai
et al., and Krumholz et al., reported results of two recent studies investigating betablocker use. The first study linked Medicare claims data to two databases covering
pharmaceutical usage in New Jersey for these Medicare patients. This study reported that
while 70% of the patients were eligible for therapy, only 21% of these patients received a
prescription for beta-blockers (Soumerai, McLaughin, Speilgelman, Hertzmark, Thibault
& Goldman, 1997). The second study collected data through an intensive chart review of
Medicare AMI patients selected from the Cooperative Cardiovascular Project (CCP).
The CCP collected data on over 200,000 patients in 45 states over an 8-month period
from 1994 to 1995. This study reported an eligible population of about 39%, of which
only 50% had a prescription of beta-blocker at discharge (Krumholz, Radford, Wang,
Chen, Heiat, & Marciniak, 1998).
A geographical variation in beta-blocker usage has also been established. There
was a significant state and region variation in beta-blocker utilization in the CCP
(Krumholz et al., 1998). The 5 states with the highest use were Connecticut (77.1%),
Massachusetts (74.2%), Maine (68.3%), New Hampshire (68.9%), and Vermont (66.7%).
The lowest use occurred in Mississippi (30.2%), Puerto Rico (32.1%), Oklahoma
(33.5%), Arkansas (33.5%), and Nevada (36.4%). Meehan et al., examined variations in
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a small area using data from six hospitals in Connecticut (Meehan, Hennen, Radford,
Petrillo, Elstein, & Ballard, 1995). The overall utilization of therapy was 41% among
eligible patients. Also, there was a large variation based on hospitals. The utilization
varied from 39-54% for the low-mortality hospitals to 29-33% for the high mortality
hospitals. Pilote et al., also reported regional variation when data from the Global
Utilization of Streptokinase and Tissue Plasminogen Activator for Occluded Coronary
Arteries trial (GUSTO-1) was analyzed (Pilote et al., 1995). They found that New
England had the highest utilization of therapy with 71% of patients receiving a betablocker prescription at discharge. In comparison, the Mountain and South Central
regions had the lowest utilization at 47% and 49%, respectively. Other studies have
reported below optimal beta-blocker utilization for certain patient subgroups such as the
elderly, women, and blacks (Fishkind, Paris, & Aronow, 1997; Pashos, Normand,
Garfinkle, Newhouse, Epenstein, & McNeil, 1994, for details see Chapter 2).
In contrast to the under use in eligible patients, there is also evidence of
prescribing of beta-blocker therapy to patients in the presence of contraindications.
Brand et al., reported that about 11% of patients were prescribed therapy in the presence
of contraindications (Brand et al., 1995). Another study reported 24% utilization in
patients with potential contraindications (Sial, Malone, Freeman, Battiola, Nachodsky &
Goodwin, 1994).
Thus, despite established guidelines for beta-blocker therapy as secondary
prevention following an AMI, there are several reports of instances where eligible
patients are not prescribed therapy – thereby establishing under use, and a few reports of
patients who are not eligible for therapy being prescribed therapy – thereby establishing
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misuse. Both under use and misuse of therapy are examples of inappropriate use and
non-adherence of the 1999 ACC/AHA guidelines.

Consequences of Inappropriate Prescribing
The inappropriate utilization of any medication can result in adverse patient
outcomes. Medication use or prescribing can be considered inappropriate based on a
wide variety of criteria such as medication use without indication, medication use with
contraindication, over or under dosing, incorrect directions, drug-drug interactions, drugdisease interactions, therapeutic duplication, and longer or shorter duration of therapy
than necessary (Schmader, Hanlon, Landsman, Samsa, Lewis & Weinberger, 1997). For
beta-blocker use as a secondary preventive agent in post AMI patients, inappropriate
prescribing is usually a result of under use (error of omission) or misuse (error of
commission). When patients eligible for beta-blocker use receive a prescription, lower
mortality rates have been reported. For example, Krumholz et al., reported a 14% lower
risk of mortality at 1 year after discharge, among eligible patients who received a
prescription for beta-blockers at discharge, when compared to eligible patients who did
not receive a prescription (Krumholz et al., 1998). In other words, under use was
associated with higher mortality. Similarly, Soumerai et al, reported a 43% lower
mortality rate among beta-blocker recipients compared to non-recipients (Soumerai et al.,
1997). Additionally, this study also reported that beta-blocker recipients were rehospitalized 22% less often than non-recipients. Thus, in this study, under use was
associated with higher mortality and higher re-infarction rates. Other healthcare
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utilization variables such as physician visits, emergency room visits, length of stay and
expenditures have not been investigated so far with regards to under use.
While there is no information on the consequences of misuse of beta-blocker
therapy, several studies dealing with other chronic diseases suggest some of the potential
consequences of misuse of drug therapy. Shireman et al., demonstrated that drug
utilization patterns for asthma, when not consistent with established guidelines, had
undesirable outcomes (Shireman, Heaton, Gay, Cluxton & Moomaw, 2002). Patients
receiving excessive doses of beta agonists, an agent that should be used on an as-needed
basis, had significantly greater emergency department visits. Anis et al., reported that
those asthma patients with inappropriate medication use (defined as excessive use of beta
agonists, an as-needed medication, and below optimal use of corticosteroid, a
recommended medication), were more likely to be admitted to a hospital, and required
more emergency room admissions compared to patients with appropriate medication use
(Anis, et al., 2001). This study also reported that those patients with excessive use of
beta-agonists visited a significantly greater number of physicians for their prescriptions.
A study exploring the monetary effects of inappropriate medication use reported that 77%
of the cost of albumin, a plasma expander, was related to inappropriate use which was
defined as use when not necessary, or use when other less expensive therapeutic options
were available (Remohi, Arcos, Ramos, Palome, & Aznar, 2000). An investigation of an
increase in prescription drug expenditures associated with peptic ulcer disease in
Vermont’s Medicaid program was also related to inappropriate use (Soons, Lynch,
Seagrave & Rolley, 1997). Physicians were prescribing H2 antagonists for greater than
the recommended 6 to 8 weeks in 60% of the cases, resulting in a 21% increase of
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prescription expenditures for gastrointestinal drugs. Finally, a study focusing on 12
major categories of drugs used to treat chronic diseases among older patients revealed
that under supply and over supply of medication affected healthcare utilization (Stroupe,
Murray, Stump & Callahn, 2000). Patients with under supply and over supply of
medication had greater emergency department visits and hospital admissions compared to
patients with a normal supply of medication. Thus, there is evidence that inappropriate
medication use can affect patient outcomes. However, there are no studies investigating
the outcomes of inappropriate beta-blocker therapy and therefore there is a need to
undertake such an investigation.

Physicians’ Role in Drug Prescribing
Many studies have attempted to understand physician’s role in beta-blocker
therapy. Ayanian et al., examined treatment decisions of cardiologists, internists and
family practitioners for their patients with AMI (Ayanian, Hauptman, Guadagnoli,
Antman, Pashas & McNeil, 1994). They found that cardiologists were much more likely
to prescribe beta-blockers compared to either internists or family practitioners. Another
study compared cardiologists’ compliance with practice guidelines for beta-blocker use
after an AMI. Of the 60% of patients, who were eligible for beta-blocker therapy, only
48% actually received therapy (Brand, et al., 1995). This study also reported that 11% of
patients with contraindications were prescribed beta-blockers. Jollis et al., studied
physician specialty and treatment outcomes using the CCP data (Jollis et al., 1996). They
found that cardiologists were more aggressive in their treatments and used more
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resources compared to other physicians. Also, their patients had lower mortality rates
and better outcomes compared to patients of other physician specialties.
Similar information on other chronic disease treatments reveal that in addition to
some of the above characteristics, there are other physician traits that affect prescribing
behavior. For example, there is wide variability in preventive aspirin use among teaching
and non-teaching hospitals (Venturini, Romero & Tognoni, 1999). Similarly, younger
physicians are more likely to select hypertensive agents consistent with guideline
recommendations compared to older physicians (Mehta, Wilcox & Schulman, 1999). A
study that characterized physicians who frequently but inappropriately prescribed longacting benzodiazepines to the elderly, demonstrated that these physicians were more
likely to be generalists, have graduated before 1979, practiced in long-term care settings
and graduated from medical school from a particular region (Monette, Tamblyn, Mclead
& Gayton, 1997).
In addition to demographic and practice-related factors, knowledge, opinions and
beliefs of physicians have also been related to prescribing behavior. For example, a study
investigating the reasons for under prescribing of beta-blockers in post AMI patients
reported that physicians believed that the adverse effects of beta-blockers would result in
a negative quality of life (Kennedy & Rosensen, 1995). Additionally, they had
exaggerated concerns about the relative contraindications, despite reports of benefits to
patients with these conditions. This study also reported that commercial influences of
pharmaceutical companies contributed to negative attitudes of physicians regarding betablocker therapy.
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There is evidence that despite knowledge of guidelines, certain beliefs of
physicians may affect prescribing behavior. For example, Huse et al. explored how well
physicians who treat hypertension know the indications and contraindications for
particular antihypertensive therapies, and how closely their opinions and practices agreed
with national guidelines for their use (Huse, Roht, Alpert & Hartz, 2001). The study
revealed that the degree of specialization and knowledge of indications and
contraindications were positively related. However, this knowledge did not result in
adherence to treatment guidelines. This was primarily due to study physician’s beliefs
that the adverse effects of some therapies would affect patient compliance.
Knowledge has also been reported to affect prescribing behavior through
interaction with practice characteristics of physicians. For example, a study assessed
physician’s knowledge, attitudes and prescribing behaviors with regard to the association
between Chlamydia pneumoniae and cardiovascular diseases (Sanchez, Jernigan,
Strausbaugh, Slemp, Perilla, & Dowell, 2001). A higher knowledge score was
documented among infectious disease specialists and cardiologists than generalists. The
study also reported higher knowledge score among those physicians who saw relatively
more patients with a myocardial infarction. Additionally, the results revealed that
previous experience with managing cardiovascular disease was a good predictor of
awareness, knowledge, and the probability of treating patients with anti-microbial agents.
In addition to demographics, practice characteristics, knowledge, attitudes,
opinions and beliefs, the interaction of all of these factors can also affect prescribing
behavior. Thus, it is important to investigate how these factors individually, and in
combination, affect prescribing behavior among physicians for beta-blockers following
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an AMI. Identification of these physician factors could explain the underlying causes of
inappropriate prescribing behavior, which would facilitate the targeting of appropriate
educational efforts.

STATEMENT OF PROBLEM
Beta-blockers have been demonstrated to yield better health outcomes when used
for secondary prevention in post AMI patients. However, in many instances it is
inappropriately prescribed in such patients. There is evidence of under-prescribing in
patients who should be prescribed, and there is some, although limited, evidence of
prescribing in patients with contraindications. Many studies have investigated the effect
of under prescribing of therapy on mortality and morbidity. However, these have
examined data from clinical trials, which could be different from real life use or have
investigated the elderly population in Medicare, which is a unique population segment.
There has been very little literature examining the effects of this under prescribing on
healthcare utilization and expenditures. Additionally, literature that examines patient
outcomes due to misuse of therapy is lacking. Thus, there is a need to determine the
effect of inappropriate prescribing on patient outcomes.
In addition to examining the effects of inappropriate prescribing on patient
outcomes, this study will also explore the association of physicians’ knowledge and
willingness to prescribe beta-blocker therapy with their prescribing behavior. Previous
studies have found ample variation of medication use by physician characteristics
(demographic, practice and knowledge). However, there is a need to understand how
these factors interact individually and in combination with prescribing behavior for beta-
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blockers post AMI. An understanding of these physician factors would facilitate in
developing and targeting educational efforts towards changing prescribing behavior to be
consistent with the published guidelines.

CONCEPTUAL FRAMEWORK
In Phase I, the study will evaluate the impact of appropriate and inappropriate
prescribing of beta-blocker therapy by physicians, following an AMI, on patient
outcomes and utilization of health services. In Phase II, the study will determine
physician-related factors that are related to beta-blocker prescribing in post-AMI patients.
Phase I will involve the use of secondary data and Phase II will require primary data
collection (Figure 1).

Phase I
The following sections will describe the rational for selection of the Medicaid
population for this study, cohort definition, classification of patients, risk adjustment and
evaluation of patient outcomes that will be required for this phase of the study.

Selection of Medicaid Population
This study will examine and compare the effects of appropriate and inappropriate
prescribing of beta-blockers therapy as a post AMI secondary preventive agent on patient
outcomes in a Medicaid population. Medicaid programs provide health insurance
coverage to its members for physician visits, inpatient and outpatient hospitalizations,
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Figure 1: Conceptual Framework

Prescriber Characteristics
-Willingness to Prescribe
-Knowledge of Contraindications
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Health Care
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Health Care
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of practice

AMI: Acute myocardial infarction, ACC: American College of Cardiology, AHA: American Heart
Association, ER: Emergency room
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laboratory tests, nursing home care, family planning services and supplies, home health
care and pharmaceuticals. Thus, a retrospective analysis of Medicaid claims data can
provide all necessary information about study patients in one place. Also, the effect of
post AMI beta-blocker use has not been previously investigated in this population. While
AMI has been established as a condition prevalent in the elderly, there is substantial
evidence that it is common among younger people, too. Consequently the age of the
patient population (less than 65 years of age) is not as big a disadvantage. In support, a
recent study at the University of Michigan revealed that more than 1 in 10 patient with
AMI is less than 46 years old. (Doughty, et al., 2002). Specifically, data from the West
Virginia (WV) Medicaid population will be utilized for Phase I of this study.

Cohort Definition
The WV Medicaid program maintains data on each medical and pharmaceutical
paid claim for its recipients from providers for health care services. The data includes the
date when the service was provided, type of service, amount paid, type of provider, and
recipient number. Information about utilization and expenditures for services for
individual recipients can be retrieved for various time periods from the claims data. For
this study, paid claims data from January 1, 1996 to June 30, 2001 will be used. All AMI
patients who are less than 64 years of age and are not in managed care during the years
1997, 1998, 1999, and up to June 30, 2000 will be extracted. Recipients who are 65 years
or older will not be included to avoid the issue of incomplete information since they will
have Medicare as their primary payer for health services. For similar reasons, patients
who are part of managed care will also be excluded.
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For this cohort of AMI patients, those patients whose information is missing after
being initially present will be used to investigate the effect of appropriate or inappropriate
beta-blocker prescribing on mortality. Patients who have follow-up information and are
continuously eligible for a period of 12 months after the incidence of AMI will be
considered to study the effect of appropriate or inappropriate beta-blocker prescribing on
morbidity and health care utilization. The age-limit is set at 64 to avoid including those
patients who will become eligible for Medicare, during the period of follow-up after
being initially present. Claims data for services, prescriptions, and hospitalizations for a
period of one year before the incident AMI will be extracted for each patient. This
information will be used for risk adjustment of the patient, and to determine eligibility of
the patient to receive beta-blockers after an AMI. Therefore, for each patient being
investigated for morbidity and health care utilization, there will be one year of data prior
to the incident AMI and one year of data following the incident AMI (Figure 2).

Classification of Patients
The AHA/ACC guidelines divide patients into three classes with respect to any
therapy and/or procedure - Class I, Class II and Class III (ACC/AHA, 1996). Class I
includes those patients with conditions for which there is evidence and/or general
agreement that the therapy is beneficial, useful, and effective. Class II is sub-divided into
IIa and IIb. Class IIa includes patients with conditions for which the weight of
evidence/opinion is in favor of usefulness/efficacy of therapy and Class IIb includes
patients with conditions for which usefulness/efficacy of therapy is less well established
by evidence/opinion. Class III includes patients with conditions in the presence of which
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Figure 2: Time Line for Phase I

Hospitalized AMI

Outcomes in follow-up period of 12 months
• Mortality
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• Utilization
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Up to June 30, 2001

Jan 1, 1997 to
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AMI: Acute myocardial infarction
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there is evidence and/or general agreement that a therapy is not useful/effective, and in
some cases may be harmful. For beta-blocker therapy, Class I patients are non low-risk
without a clear contraindication to beta-blocker therapy and survivors of non-ST-segment
elevation (ACC/AHA, 1999). Class IIa includes low-risk patients without a clear
contraindication to beta-blocker therapy and survivors of non-ST-segment elevation
AMI. Class IIb are patients with moderate or severe left ventricular failure. Patients with
relative contraindications to beta-blocker therapy are also included in this class, provided
they are monitored closely. None of these patients belong to Class III. Apart from the
above classifications, these guidelines also state that high-risk patients would be those
with evidence of large or anterior infarction. Additionally, low risk patients include those
without: previous infarction, anterior infarction, advanced age, complex ventricular
ectopy, or hemodynamic evidence of LV systolic dysfunction.
Based on the above guidelines and recent reports, for all practical purposes
patients can be classified as Class I, Class II and Class III for receiving beta-blocker
prescription for secondary prevention following an AMI (ACC/AHA, 1999; Philips et al.,
2000). A Class I and Class II patient for beta-blocker therapy at hospital discharge is one
who has no absolute contraindications to therapy. Patients with relative contraindications
are also included in this category (Class II). A patient would be Class III for beta-blocker
therapy at hospital discharge if the patient has absolute contraindications to beta-blocker
therapy. For study purposes, patient data during the year before the incident AMI and at
the time of the incident AMI will be utilized from claims for this classification.
After classifying the patients into the afore-mentioned three categories, the
prescription of beta-blockers during discharge can be determined from the prescription
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claims data. Based on appropriate and inappropriate prescribing criteria described above,
the AMI patients in the study can be further divided into two groups - the appropriately
prescribed and the inappropriately prescribed. Patients who are classified as Class I and
Class II and receive therapy and patients who are classified as Class III and do not
receive therapy will be categorized as “appropriately prescribed”. In contrast to this,
patients who are classified as Class I and Class II and do not receive therapy and patients
who are classified as Class III but receive therapy will be categorized as “inappropriately
prescribed”.

Risk Adjustment
In observational studies, investigators have no control over inherent risks that
patients bring into the study. Therefore, large differences on observed covariates in the
selected groups may exist, and these differences can lead to biased estimates of
outcomes. An important statistical technique developed to overcome this kind of
selection bias is estimation of propensity scores. This method involves estimating the
conditional probability of an event such as receiving specific therapy, on a treatment
outcome, based on observable characteristics. The propensity score calculated from
observational characteristics of patients are then used to reduce bias and increase
precision. The three commonly used techniques that use propensity scores are matching,
stratification (also called sub-classification), and regression adjustment (D’Agostinio,
1998). Each of these techniques is a way of making an adjustment for covariates prior to
(matching and stratification) or during (stratification and regression adjustment)
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calculation of the treatment effect. While the method of calculation of the propensity
score is the same in all three techniques, the application is different.
In matching, control subject selection is based on whether they match with the
treated subjects on background covariates that the investigator believes need to be
controlled (D’Agostinio, 1998). However, it is often difficult to find subjects similar in
all important covariates even when there are only a few background covariates of interest.
In stratification, the subjects are grouped into strata determined by the observed
background characteristics (D’Agostinio, 1998). Once strata are defined, treated and
control subjects in the same stratum are compared directly. The number of strata depends
on the number of covariates. For example, if all the covariates are dichotomous then
there would be 2k subclasses for k covariates. If k is large, then some strata might
contain subjects from only the treated group, which would make it impossible to estimate
a treatment effect in that stratum. In regression adjustment, a large set of background
covariates are used to estimate the propensity score, which is then used to adjust the final
estimate of the treatment effect (D’Agostinio, 1998). Here the investigator can include
only a subset of the most important variables and the propensity score in the final model.
The proposed study involves two groups of patients, those that were appropriately
prescribed beta-blocker therapy and those that were inappropriately prescribed betablocker therapy. Irrespective of whether the patients receive therapy appropriately or not,
there are certain patient characteristics that affect prognosis and outcomes after an AMI.
For example, a younger patient (age <50) is likely to have a better recovery from an AMI
when compared to an older patient. This would be true regardless of whether the patient
received beta-blocker therapy appropriately or not. Similarly, a patient who has had a
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previous AMI would have a worse prognosis, and thus would have more adverse
outcomes after an AMI. There are a variety of such patient conditions and characteristics
that affect patient outcomes after an AMI but are not related to beta-blocker prescribing.
It is possible that patients in the two groups, appropriately prescribed and inappropriately
prescribed, differ based upon these characteristics. These characteristics require to be
adjusted for patients before the effect of appropriate and inappropriate prescribing on
outcomes can be determined. Therefore, selection bias due to the inherent risk of patients
in this study needs to be accounted for to get a more precise effect of
appropriate/inappropriate prescribing of beta-blocker therapy on patient outcomes. A
propensity score that combines all background covariates will be utilized to adjust for
differences in the study groups. This propensity score can then be utilized in all the
analysis where the effect of appropriate/inappropriate prescribing on patient outcomes
will be assessed.
The different characteristics which will be utilized in estimating this propensity
score are demographic characteristics such as age, gender, and/or race; presence of
relative contraindications for beta-blocker therapy; medical history such as presence of
diabetes, hypertension, previous AMI, previous congestive heart failure, previous
angioplasty or open heart surgery, stroke; procedures during the incident AMI such as
percutaneous coronary transluminal angioplasty (PCTA), and coronary artery bypass
graft (CABG); length of stay during incident AMI; other discharge medications such as
aspirin, Angiotensin converting enzyme (ACE) inhibitors, calcium channel blockers, and
loop diuretics; and use of beta-blockers before the incident AMI. These characteristics
have been demonstrated to affect outcomes for AMI patients (Soumerai et al., 1997).
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Due to the large number of characteristics and conditions that need to be adjusted,
regression adjustment would be the best method of applying the estimated propensity
score.

Evaluation of Outcomes
Beta-blocker therapy when appropriately used for secondary prevention following
an AMI has been demonstrated to reduce cardiovascular morbidity and mortality. Thus,
the selected cohort of appropriately prescribed and inappropriately prescribed patients
will be followed to detect changes in cardiovascular mortality and morbidity related to
the use of beta-blocker therapy. Beta-blockers are associated with maximum reduction of
risk for cardiovascular death and morbidity in the first few years after an AMI (Philips et
al., 2000, Goldman et al., 1988). The protective effect provided by beta-blockers has
been reported to subside in the subsequent years. In this study, the patients will be
followed for a period of one year after the incidence of AMI. Another reason for
restricting the follow-up period to 1 year is that the number of continuously eligible
patients decreases as the number of years increase. Thus, when multiple years are
involved, the number of patients in the cohort would be small and pose problems of
power for statistical tests.
Medicaid data contains information on the diagnostic and therapeutic procedures
performed on all continuously eligible patients who have utilized health care services.
Patients, who stop having information after being present in the system initially, do so for
several reasons. They may have become ineligible to receive Medicaid benefits, have
moved away, or died (which can be confirmed with death certificate information
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available from the WV Bureau of Vital Statistics and the National Death Index (NDI)).
However, the unique ID of those patients with missing information during the follow-up
period can be used to determine the actual reason for the missing information. If the
person with the missing information is confirmed to be dead from Vital Statistics records,
the cause of death can be obtained from their death certificates. If the cause is related to
cardiovascular illness such as an AMI, heart failure, stroke, angina, other forms of
ischemia, essential hypertension, coronary artery disease/artherosclerosis or cardiogenic
shock, these patients will be involved in investigating the effect of
appropriate/inappropriate prescribing of beta-blockers on mortality using survival
analysis. An increase in mortality in the inappropriately prescribed group will be proof
of poor outcomes in this group.
Among patients with follow-up information, those eligible in the 12-month period
after the incident AMI will be examined for morbidity and the extent of health care
utilization. Claims associated with cardiac conditions and procedures will be extracted to
study outcomes in the follow-up period. An increase in cardiac conditions for the
inappropriately prescribed group compared to the appropriately prescribed group will
provide evidence of poor outcomes associated with morbidity for this group. The various
patient characteristics that affect treatment outcomes will be adjusted for by using them
to estimate a propensity score. This score along with group status (inappropriate or
appropriate) can then be included in a survival analysis where the dependent variable will
be the time to first hospitalization due to an event. Here the event will be any
cardiovascular event such as a successive AMI, heart failure, stroke, angina, and other
forms of ischemia, essential hypertension, cardiogenic shock, disease of endocardium,
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conduction disorders, or cardiomyopathy. In addition to the incidence of these conditions
in the follow-up period, survival analysis will be used to evaluate the distribution of the
time to incidence of these events. Studying the distribution of incidence will give a better
idea about the effect of appropriate and inappropriate beta-blocker prescribing on
outcomes. This is preferable to assessing differences in patients outcomes based on
number of incidence of morbidity data alone.
Similarly, to study the effect on healthcare service utilization for the above
mentioned cardiac conditions, the number of physician visits, hospitalization episodes,
length of stay, and emergency room visits will be compared between patients in the
appropriately prescribed and inappropriately prescribed cohorts. The hypothesis is that
there is no difference in utilization of these services between the inappropriately
prescribed group and the appropriately prescribed group. Regression analysis will be
conducted with each of these utilization-related variables with group status as the
independent variable. Patient characteristics that affect treatment outcomes will be
adjusted for by using the propensity score as a co-variate. Regression analysis is a better
way to compare these utilization-related variables as it allows for adjustment of multiple
patient factors compared to other methods such as analysis of variance (ANOVA).

Phase II
The purpose of phase II of the study is to determine physician-related factors that
are associated with prescribing of beta-blockers for secondary prevention of cardiac
problems after an AMI. This phase of the study will involve surveying physicians in the
specialties of cardiology, internal medicine, family practice and general practice in the
state of WV (Figure 3).
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Figure 3: Phase II
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The target physicians will be sent a survey that measures the following:
knowledge about contraindications to beta-blocker therapy, willingness to prescribe betablockers, practice characteristics and socio-demographics. One major reason for the nonprescribing of beta-blockers in patients without contraindications is that internists and
family practitioners have been shown to be less aware or less certain than cardiologists of
the cardiovascular medical advances established through clinical trails (Bradford et al,
1999). Thus, the survey will be designed to assess physicians’ knowledge about
contraindications for beta-blocker therapy post-AMI, to determine whether or not there
are differences in knowledge when compared by specialty. Specifically, they will be
compared for (1) knowledge of absolute contraindications when therapy with betablocker should not be initiated; and (2) knowledge of relative contraindications when
therapy with beta-blockers can be, and should be, initiated.
In addition to knowledge, physician willingness to prescribe beta-blocker therapy
for post AMI patients will be explored. A section will be dedicated to inquire about
physicians’ willingness to prescribe beta-blockers as post-AMI therapy in patients with
different ailments.
The last section of the survey will focus on socio-demographic and practice
characteristics. These have been reported to affect the provider’s knowledge, beliefs, and
practice (Ayanian et al., 1994). Specific characteristics reported include age, gender,
specialty of practice, year of board certification in the primary field of practice, number
of patients treated within a specific time, number of beds at practice site, and whether
practice site is associated with teaching status.
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Physician prescribing behavior for beta-blockers will be determined by asking the
respondents to recall the number of AMI patients that they prescribed long-term betablockers for secondary prevention, out of the last 10 AMI patients treated. Percent
prescribing rate will be calculated based on the response of the physicians [i.e.
(response/10)*100]. This will be used as a proxy for prescribing behavior. Though this
is not the best method of measuring prescribing behavior, questions which ask the
respondents the average number of post-AMI patients prescribed beta-blocker in the past
month or longer duration of time will involve higher recall bias and thus may be
unreliable. Also, whether the prescribing of the physicians for the last 10 patients was
appropriate or inappropriate cannot be determined through a survey. This is because
prescribing is unique for every patient and depends on patient co-morbidties. To obtain
detailed information for each individual patient would involve a very lengthy survey,
which can increase burden for the respondents for time of completion and effort to recall
each specific case. This can also result in a very low response rate. Thus, given the time
and resource constraints this method of getting a proxy for prescribing behavior appears
to be the best.
The association of this estimated prescribing rate or the proxy prescribing
behavior will be statistically investigated with knowledge of contraindications,
willingness to prescribe and physicians socio-demographic and practice characteristics,
individually and in combination. A sub-analysis will also be conducted to determine the
association of socio-demographic and practice characteristics on physicians’ knowledge
of contraindications and willingness to prescribe. Thus, this phase of the study will give
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a better understanding of the role of physician characteristics that affect their prescribing
behavior.

STUDY GOALS, AND RESEARCH QUESTIONS
Phase I
The overall goal of phase I is to study prescribing patterns of beta-blocker therapy
in Medicaid patients following an AMI and its effect on patient outcomes. Specific
research questions necessary to achieve this goal are as follows:

Research Question 1:
To what extent do physicians adhere to AHA/ACC guidelines for appropriate betablocker therapy for secondary prevention in patients who have had an AMI in the WV
Medicaid program?
Rationale: This is an exploratory question to assess the prescribing of beta-blockers in
the WV Medicaid population with regards to published guidelines and to classify them as
appropriate or inappropriate. Medicaid patients have not been studied before for such an
investigation. Thus, it would determine whether or not prescribing of beta-blockers in
post-AMI Medicaid patients is similar to those reported in other patient populations such
as the elderly (Medicare), and those in managed care.

Research Question 2:
What is the relationship between appropriate and inappropriate prescribing of betablockers following an AMI and all cause and cardiac mortality in WV Medicaid?
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Null Hypothesis A: There is no difference in all cause mortality rates between AMI
patients who receive appropriate beta-blocker therapy and those who receive
inappropriate beta-blocker therapy for secondary prevention.
Null Hypothesis B: There is no difference in cardiac mortality rates between AMI patients
who receive appropriate beta-blocker therapy and those who receive inappropriate betablocker therapy for secondary prevention.

Research Question 3:
What is the relationship between appropriate and inappropriate prescribing of betablockers following an AMI and subsequent morbidity due to the following conditions in
the WV Medicaid program (irrespective of whether they suffered from these conditions
prior to the AMI under consideration)?
-

Angina

-

Cardiogenic shock

-

Disease of endocardium, conduction disorders & cardiomyopathy

-

Essential hypertension

-

Heart failure

-

Other ischemic disease

-

Stroke

-

Successive or recurrent AMI

Null Hypothesis C: There is no difference in cardiovascular morbidity between AMI
patients who receive appropriate beta-blocker therapy and those who receive
inappropriate beta-blocker therapy for secondary prevention.
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Research Question 4:
What is the relationship between appropriate and inappropriate prescribing of betablockers following an AMI and utilization of health care services (physician services,
hospitalization services, hospital length of stay, ER visits) and expenditures due to the
following conditions in WV Medicaid (irrespective of whether they suffered from these
conditions prior to the AMI under consideration)?
-

Angina

-

Cardiogenic shock

-

Disease of endocardium, conduction disorders & cardiomyopathy

-

Essential hypertension

-

Heart failure

-

Other ischemic disease

-

Stroke

-

Successive or recurrent AMI

Null Hypothesis D: There is no difference in utilization of services due to the above listed
conditions between AMI patients who receive appropriate beta-blocker therapy and those
who receive inappropriate beta-blocker therapy for secondary prevention.
Null Hypothesis E: There is no difference in costs due to the above listed conditions
between AMI patients who receive appropriate beta-blocker therapy and those who
receive inappropriate beta-blocker therapy for secondary prevention.

Phase II
The goal of phase II is to determine how physician characteristics such as
knowledge, willingness to prescribe, demographic and practice characteristics, and
interactions of these different characteristics affect their prescribing behavior for beta-
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blockers as secondary preventive agents after an AMI. Specific research questions for
this phase are as follows:

Research Question 5:
How does WV physicians’ knowledge of absolute and relative contraindications of betablocker therapy affect their self-reported prescribing behavior of this therapy as a
secondary preventive agent following an AMI?
Null Hypothesis F: There is no relationship between knowledge of absolute and relative
contraindications of beta-blocker therapy and physician prescribing behavior of this
therapy as a secondary preventive agent.

Research Question 6:
How does WV physicians’ willingness to prescribe beta-blocker therapy affect their selfreported prescribing behavior of this therapy as a secondary preventive agent following
an AMI?
Null Hypothesis G: There is no relationship between WV physicians’ willingness to
prescribe beta-blocker therapy and their prescribing behavior of this therapy as a
secondary preventive agent following an AMI.

Research Question 7:
How does demographic (age, gender, location, year of graduation) and practice
(specialty, affiliation, size of primary practice hospital) characteristics of WV physicians
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affect their self-reported prescribing behavior of beta-blocker therapy as a secondary
preventive agent following an AMI?
Null Hypothesis H: There is no relationship between demographic and practice
characteristics of WV physicians and their prescribing behavior of beta-blocker therapy
as a secondary preventive agent following an AMI.

Research Question 8:
How does demographic (age, gender, location, year of graduation) and practice
(specialty, affiliation, size of primary practice hospital,) characteristics of WV physicians
affect their knowledge and willingness to prescribe beta-blocker therapy as a secondary
preventive agent following an AMI?
Null Hypothesis I: There is no relationship between demographic and practice
characteristics of WV physicians and their knowledge of absolute and relative
contraindications of beta-blocker therapy as a secondary preventive agent following an
AMI.
Null Hypothesis J: There is no relationship between demographic and practice
characteristics of WV physicians and their willingness to prescribe beta-blocker therapy
as a secondary preventive agent following an AMI.

Research Question 9:
Which factors among physician demographic and practice characteristics, physicians’
knowledge of beta-blocker contraindications, and willingness to prescribe them, are the
best predictors of their self-reported prescribing behavior of beta-blocker therapy as a
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secondary preventive agent following an AMI? (This simultaneously controls for all
aspects described in research question 5, 6 & 7).
Null Hypothesis K: There is no association between WV physicians’ prescribing of betablocker therapy as a secondary preventive agent following an AMI and physician factors
(demographic and practice characteristics, knowledge of beta-blocker contraindications,
and willingness to prescribe).

Research Question 10:
What are the reasons reported by physicians for not prescribing beta-blockers in postAMI patients?
Rationale: A previous study reported reasons such as adverse effects, exaggerated
concerns for relative contraindications and commercial influences of pharmaceutical
companies as reasons for under prescribing of beta-blockers as post-AMI medications
(Kennedy & Rosensen, 1995). This research question is a follow-up on this report to
determine whether the reasons for not prescribing beta-blockers in post-AMI patients are
the same or have changed over the years.

STUDY SIGNIFICANCE
In Phase I, the effect of appropriate/inappropriate prescribing of beta-blockers by
physicians on patient outcomes following an AMI will be evaluated in this study. In
Phase II, physician characteristics that affect prescribing behavior of beta-blocker therapy
post AMI will be determined. Information from Phase I will help in identifying
consequences of inappropriate prescribing if any, such as mortality, morbidity, health
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care utilization (hospitalization, ER visits, and physician visits) and health care
expenditures from a payer’s perspective. Based on past studies, it is hypothesized that
inappropriate use may increase mortality and morbidity in those patients and
consequently increase health care utilization and expenditures. This is vital information
from a payer’s perspective because it provides information about both the quality of care
provided to its members as well as cost-efficiencies within the financing of the system.
Beta-blockers are a very inexpensive way of ensuring the quality of care by reducing
mortality and morbidity received by post-AMI patients, and concurrently reducing costs
due to unnecessary health care services utilization. This is a good example in which
improving the quality of care and reducing costs are not competing interests. The above
concerns are especially important from the perspective of a Medicaid program, which is a
public health insurance program and supported by federal and state tax dollars.
Phase II will help in understanding physician related factors that are associated
with prescribing of beta-blocker therapy following an AMI. This information can be
utilized in designing active interventions to meet specific needs such as group or one-onone education, and individual outreach visits. Implementation of these active
interventions will have better results in comparison to passive interventions such as
dissemination of printed materials, reminders at the time of prescribing, and formulary
control, which do not involve physician input (Figueiras, Sastre & Gestal-Otero, 2001).
Therefore, these active interventions may be more successful in improving prescribing
behavior of physicians for secondary prevention following an AMI with beta-blockers,
and more likely to lead to better adherence of guidelines.
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Identifying the consequences of inappropriate beta-blocker use and the factors
contributing to physicians prescribing of beta-blockers are the first steps towards
improving quality of care provided to AMI patients. While quality concerns by itself is a
strong reason, reducing the avoidable health care utilization and expenditures is also vital
to a system that is facing ever-increasing costs.

STUDY LIMITATIONS
The limitations of each phase of the study are discussed below:
In Phase I, the limitations are associated with the data being used. Medicaid data
does not include utilization claims for individuals aged 65 years and over and these
patients will not be a part of the study cohort. Patients who are a part of managed care
will also be excluded due to lack of utilization claims data. Furthermore, patients who do
not have continuous eligibility during the study period will be excluded. These selection
criteria will exclude a significant portion of the Medicaid recipients. Thus, whether the
effect of inappropriate prescribing is different for the excluded group cannot be
determined and is beyond the scope of this study. Also, AMI is a condition more
predominant in the elderly. Thus, when a younger group such as Medicaid patients is
used to study this condition, the number of patients in the study will be relatively lower
when compared to previous studies that involved the elderly. This may pose problems
with power and effect size when complex statistical analyses are involved. Also, younger
patients with AMI will have better prognosis than older patients, thus results from this
study may not be extended to older patients.
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Another limitation is the fact that demographic characteristics of people from
West Virginia may not necessarily be similar to demographic characteristics of other
states. Therefore, results may not be generalized to other states. The study will use
claims data and this does not allow adjusting for all the contraindications for betablockers, as some of them do not have an ICD-9 (International classification of disease,
9th edition) code. For example, peripheral hypoperfusion, intolerance or allergies to betablockers are relative contraindications which cannot be identified. However, ICD-9 code
for peripheral vascular disease can be used as a proxy for patients with peripheral
hypoperfusion and the percentage of patients allergic to beta-blockers has been reported
to be low ranging from 7.7% to 12.5% in previous studies (Phillips et al., 2000). Some of
the attributes which classify patient risk levels can be identified only from patient charts
and are not coded in patient claims. Therefore, true risk levels of the patients cannot be
identified through claims data and thus the study will be unable to adjust for severity of
the AMI. Since claims data is being used to determine presence and absence of
conditions, errors due to billing and coding cannot be ruled out. Also, the study will not
be able to consider the effect of other possible confounding factors such as obesity,
smoking, or other life-style related conditions, which are not included in claims data.
Some of the limitations of Phase II are inherent due to the cross-sectional study
design method of data collection i.e. mail survey. Factors that affect prescribing behavior
such as disease severity, multiple co-morbidities, and patient choice will not ascertained
through the survey used, and thus cannot be included in the analysis. A major limitation
is that prescribing percent, which is the proxy for prescribing behavior, will be computed
based on last 10 patients treated and may not be representative of the physicians
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prescribing behavior in general. Also, prescribing percent calculated will not reflect
whether prescribing was appropriate or inappropriate. Thus, in reality association of
physician related factors with prescribing percent will be investigated and not their
association with appropriate and inappropriate prescribing percent.
Mail surveys usually have a response rate between 30-40 percent (Dillman, 1978).
Hence, generalization of the results obtained to those who did not respond may be
limited. There exists a lack of control over item non-response in mail surveys. Mail
surveys are insensitive to substitution of respondents, thus whether the physician
answered the survey or someone else cannot be determined. The questions in the survey
can be interpreted differently by different respondents and thus it can fail to provide
standardized understanding of survey questions among respondents. Other limitations
such as recall bias, and limitations to recall, may also exist for the section associated with
knowledge and prescribing behavior.

This chapter gave a brief introduction to the problem, the need, the research
questions, and the significance of the study. The next chapter will give a extensive
review of the existing literature associated with AMI, and beta-blocker therapy.
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CHAPTER TWO
REVIEW OF LITERATURE

This literature review will provide a background to understand – acute myocardial
infarction (AMI), beta-blocker drug therapy, their effectiveness, recommendations for
their use, variation in their use, implications of this variation in use and the physicians
role in this variation of use. The final section in the chapter will provide a brief
description of the Medicaid program and West Virginia (WV) Medicaid, the sample
frame for this study.

Acute Myocardial Infarction
Acute Myocardial Infarction (AMI) is the death of heart muscle due to the loss of
blood supply (Bellenir, 2000). This loss of blood supply is usually caused by a complete
blockage of a coronary artery by a blood clot. Coronary arteries are blood vessels, which
supply blood to the heart muscle. Coronary artery disease (CAD) is the primary
underlying process that leads to AMI (Stringer & Lopez, 1999). Cholesterol, a fatty
chemical, is a part of the outer lining of cells in the body. Cholesterol plaque is the
formation of a hard, thick substance on the artery walls, which is caused by the
deposition of cholesterol on the artery walls, a process that begins early in life. With
time, this accumulation causes thickening of the artery walls and narrowing of the
arteries, a process called as atherosclerosis. Plaque accumulation can be accelerated by
specific risk factors such as hypertension, diabetes mellitus, smoking, and
hyperlipidemia. Atherosclerosis can progress and cause significant narrowing of the
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coronary arteries. These narrowed arteries cannot increase the blood supply to meet the
increase in oxygen demand by the heart muscle during exercise or excitement. This
condition called ischemia gives rise to chest pain or angina. However, this is not the
etiology of AMI. The surface of a cholesterol plaque can become sticky due to a rupture
or fissure, precipitating thrombus formation. When a blood clot forms on top of this
plaque, the artery becomes completely blocked, causing the death of the heart muscle or
AMI.
Pain or pressure in the chest is a common symptom of AMI (Bellenir, 2000).
AMI’s most frequently occur from 4 AM to 10 AM due to high adrenaline amounts
released from the adrenal glands during the morning hours. AMI’s do not usually occur
during exercise, although exercise is commonly associated with angina. About onefourth of AMI’s are silent, without chest pain. In addition to chest pain, patients may
complain of sweating, jaw pain, heartburn, arm pain, indigestion, back pain, general
malaise, nausea and shortness of breath.

Diagnosis
Initial diagnosis is made by a combination of clinical symptoms and
electrocardiogram (EKG) changes (Bellenir, 2000). An EKG is a recording of the
electrical activity of the heart and can detect areas of muscle deprived of oxygen and /or
dead tissue in the heart. However, confirmation of an AMI can only be made hours later
through detection of elevated creatinine phosphokinase (CPK) in the blood. CPK is
muscle enzyme released into the blood by dying heart muscles when their surrounding
membranes dissolve.
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Treatment
The primary goal of the treatment is to open the blocked arteries and restore blood
flow to the heart muscles, called as reperfusion (Bellenir, 2000; Stringer & Lopez, 1999).
Once the artery is open, the patient becomes pain free. Early reperfusion minimizes the
extent of damage to the heart muscle and preserves its pumping function. Delay in
reperfusion can result in irreversible death to the heart muscle cells and may reduce the
pumping force of the remaining heart muscle. The future quality of life and longevity for
the patients depends on the amount and health of the remaining heart muscle.
The fastest method of opening a blocked artery is to perform a percutaneous
transluminal coronary angioplasty (PTCA). Here a tiny plastic catheter with a balloon at
the end is advanced over a fine guide wire to the site of blockage and inflated, under Xray guidance. This pushes the plaque and clot out of the way. PTCA can be effective in
opening up to 95% arteries within 60 minutes. Medications if given early are also
effective in opening arteries. Clot dissolving medications also called as thrombolytic
agents such as tissue plasminogen activator (t-PA) and Streptokinase are given
intravenously. These are reported to open 80% of the blocked arteries within 90 minutes.
Anti-platelet agents, such as aspirin, reduce platelet clumping and clot-formation.
This decreases the recurrent closure of artery and improves the chances of survival.
Anticoagulant agents, such as heparin, given intravenously, act as a blood-thinning agent
and prevent blood clots and maintains the artery open during the initial 24 hours.
Nitroglycerin, a vasodilator, is given either under the tongue or intravenously, to prevent
blood vessel spasm and minimize the area of the heart attack. Angiotensin-converting
enzyme (ACE) inhibitors are given orally after an AMI to improve the heart muscle
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healing process. Beta-blockers act as antiarrhythmic and are given either intravenously
or orally to decrease the magnitude of infarction and incidence of associated
complications and the rate of infarction in patients (Bellenir, 2000). Other
antiarrhythmics such as lidocaine, amiodarone, procainamide can also be used. Other
classes of drugs such as calcium channel blockers, e.g. nifedine, verampil and inotropic
agents such as digitalis may also be used [American College of Cardiology
(ACC)/American Heart Association (AHA), 1996]. When PTCA and medications fail to
achieve reperfusion or maintain open arteries, patients are subjected to coronary artery
bypass graft (CABG) surgery (Bellenir, 2000).
Patients are monitored in the hospital for 3-6 days prior to discharge. Rhythm
disturbances, shortness of breath, or recurrent pain are indications for further therapy
either through PTCA, medications, or bypass surgery (Bellenir, 2000). Patients gradually
increase their activity under observation. Before discharge, stress tests are useful for
detecting any narrowing in the coronary arteries, rhythm changes, and heart muscle
failure. These also help in prescribing discharge medications. Several weeks are needed
for the heart to heal before resuming full activity. After a small AMI, patients can resume
normal activities after 2 weeks. A moderate AMI requires gradual increase in activity
after 4 weeks while a large AMI needs up to 6 weeks for recovery. During this time
patients should avoid vigorous exertion and heavy lifting or activities which cause
shortness of breath or sweating.
After initial recovery, patients are required to take medications to prevent a
second AMI (ACC/AHA, 1996). These usually include aspirin, beta-blockers, ACE
inhibitors, lipid lowering drugs, anticoagulants, and nitroglycerine. Additionally, patients
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are required to quit smoking, reduce weight and dietary fat consumption, control blood
pressure and diabetes, reduce serum cholesterol and follow a regular prescribed exercise
regime (ACC/AHA, 1996). These measures are known to improve quality of life and
longevity after an AMI. Achievements of treatment goals can be facilitated through
participation in formal cardiac rehabilitation program or home rehabilitation if patient is
motivated (ACC/AHA, 1996). Cardiac rehabilitation combines prescriptive exercise
training with education about coronary risk factor modification techniques. Formal
rehabilitation programs have been shown to effectively improve functional capacity,
promote compliance, decrease emotional distress, improve quality of life, reduce
cardiovascular mortality, mitigate ischemic symptoms, promote reversal of
atherosclerosis, and reduce risk of future coronary events.

Beta-Blocker Therapy
Beta-blockers exert an effect by blocking beta-receptors (Khan, 2000).
Structurally they resemble catecholamines. Beta-blockers are competitive inhibitors,
their action depending on the ratio of beta-blocker concentration to catecholamine
concentration at the beta-receptor sites. Beta-receptors are sub-divided into two types:
the beta1-receptors present mainly in the heart and intestine and beta2-receptors present
mainly in the bronchial and vascular smooth muscles. Thus, beta-blockers can be divided
into cardioselective and non-cardioselective. Cardioselectivity implies that the drug
blocks chiefly the receptors on the heart muscle and therefore partially spares the
receptors on the lungs and blood vessels. However, selectivity may be lost at higher
doses precipitating bronchospasm in susceptible individuals. Beta-blockers can also be
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divided based on the presence of intrinsic sympathomimetic activity (ISA). Intrinsic
sympathomimetic activity (ISA) indicates partial agonist activity. Beta-blockers with
ISA cause a slightly lower incidence of bradycardia compared with non-ISA drugs.
However, this carries little or no advantages in angina at rest, or in angina at low exercise
levels. This could, on the other hand, produce adverse effects on ventricular fibrillation
threshold.
Physiologically, when used for AMI, beta-blockers rapidly reduce systolic blood
pressure and there is reduction in cardiac output (Plosker & Clissold, 1992). However,
several weeks of therapy are required to achieve the maximum reduction in diastolic
pressure and this reduction appears to result from a gradual decrease in total peripheral
resistance (Benfield, Clissold, & Brodgen, 1986). In addition to decreasing systemic
arterial pressure, beta-blockers also decrease heart rate and contractility (Olsson, Ablad &
Ryden, 1990). They are known to reduce myocardial oxygen demand (ACC/AHA,
1996). Prolongation of diastole due to heart rate reduction probably facilitates blood flow
through poorly perfused regions of the myocardium (Plosker & Clissold, 1992). They
delay cardiac ventricular repolarization, slow conduction velocity through the
atrioventricular (AV) node, increase sinoatrial node recovery time and decrease
automacity (Edvardsson & Olsson, 1981; Camm, Ward & Whitmarsh, 1982; Frishman &
Silverman, 1979; McDevitt, 1983). In accord with their electrophysiological effects,
beta-blockers have shown antiarrhythmic activity in post myocardial infarction patients
(Murray, Murray & Little, 1986; Olsson & Rehnqvist, 1984). They also involve
prevention of the final thrombo-embolic process and/or progression of atherosclerotic
lesions (Linden, Carmejo, Wilkund, Warnold, Olofsson & Bondjers, 1988). A decrease
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in ejection velocity reduces hydraulic stress on the arterial wall, and this action may
reduce the incidence of plaque rupture and thus protect from coronary thrombosis and
fatal or non-fatal infarction (Khan, 2000). Beta-blockers may prevent early morning
platelet aggregation induced by catecholamines, and decrease the early morning peak
incidence of an AMI (Khan, 2000). They may also cause structural changes in plasma
low density lipoprotein (LDL) resulting in a reduction of its potential for deposition in the
arterial wall (Linden, Carmejo, Wilkund, Warnold, Olofsson & Bondjers, 1988). These
additional beneficial effects are believed to decrease the incidence of cerebrovascular
complications and new myocardial infarctions, thus providing clinical efficacy.
Beta-blockers have certain side effects on the different systems it interacts with.
Thus, in the cardiovascular system it can precipitate heart failure, atrioventricular (AV)
block, hypotension, severe bradycardia, intermittent claudication, cold extremities,
Raynaud’s phenomenon and dyspnea. Dizziness, weakness, fatigue, vivid dreams,
insomnia, and rare loss of hearing are central nervous system (CNS) side effects. Other
side effects include nausea, vomiting, bronchospasm, respiratory distress, skin rashes,
decreased libido and impotence (Khan, 2000).

Effectiveness of Beta-Blockers for Post AMI
Fifteen major randomized controlled trials of beta-blocker therapy administered
after AMI were reported between 1974 and 1990 (Frishman & Cheng, 1999). The mean
follow-up time for these extended from 24 hours to six years. More than 18,000 patients
with AMI were studied to document reductions in total deaths, cardiovascular death,
coronary death, sudden death, and nonfatal re-infarction. The time between onset of AMI
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and initiation of treatment ranged from less than 24 hours to approximately 7.5 years.
Patients with low and intermediate risk were studied in 12 of these trials whereas three
trials involved patients with high risks. Results from 12 of the 15 long-term trials showed
a lower mortality rate in the beta-blocker groups than the control groups. In three of the
largest studies, the reduction in mortality rates was statistically significant, whereas in the
remaining nine trials the results were not conclusive with regard to overall deaths. By
combining the results of all 15 beta-blocker trials, a mortality rate reduction of
approximately 21% was calculated. In eight trials that evaluated sudden cardiac death,
lower rates were observed in the treatment groups. These trials yielded a trend of greater
overall reduction in sudden cardiac deaths compared to all-cause deaths. An even larger
benefit was recorded for instantaneous deaths, with an average reduction of 47%. Ten of
the 11 trials reporting the incidence of nonfatal re-infarction showed lower rates in the
treatment groups compared to the control groups, however in only one of these trials, this
was statistically significant.
In addition to these major randomized clinical trials, there have been various
reviews and reports to study effectiveness of beta-blockers. A meta-analysis of about 65
studies, including long-term and short-term treatment with beta-blocker therapy was
conducted by Yusuf et al., (Yusuf, Peto, Lewis, Collins & Sleight, 1985). The overall
results for the short-term trials demonstrated an effect on infarct size and on arrhythmias.
However, a 6% risk reduction in mortality was found in the treatment group. This small
difference did not reach statistical significance due to inadequate numbers in the
randomization process. The long-term component included results of eight randomized
trials, involving over 3,000 patients. Therapy was started orally a few days or weeks
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after myocardial infarction and continued for a period of some months or years thereafter.
A crude overview of the results of these studies suggested a risk reduction of about 20%.
After weighting the average of the relative risks reduction, a pooled relative risk estimate
of 0.77 was obtained. Though the trials had adequate numbers to demonstrate a main
effect, it was not possible to select out sub-groups (defined by age, site, or severity of
disease) of patients among whom therapy was advantageous and subgroups among whom
it was not. To elucidate the mechanism by which death was prevented, deaths were
classified as sudden and non-sudden based on time to death from the onset of pain. In
several of the studies, reductions in sudden death were statistically significant with odds
reduced by about 30%. Not all trials reported the frequency of nonfatal re-infarction.
Among those which did, treatment with long-term beta-blockers reduced the odds of reinfarction by about one-fourth and this was enormously significant (P<.0001). The metaanalysis concluded that long-term beta-blockade for perhaps a year or so following
discharge after an AMI would reduce the odds of death and re-infarction by about 25%.
Differences among benefits of different beta-blockers were not apparent and side effects
of therapy, being reversible by changing the beta-blocker or discontinuation of treatment,
were not considered to be a major problem.
Hjalmarson conducted a review of data from five clinical trials that dealt with
early and late interventions with beta-blockers following an AMI (Hjalmarson, 1988).
Two of these trials, the Norwegian (NMS- Norwegian Multicenter Study) and the
Goteborg, examined the effects of prophylactic use of beta-blocker therapy. The
Norwegian trial had a 2-year follow-up with timolol as the beta-blocker and demonstrated
a 36% reduction in mortality. The Goteborg trial also demonstrated a 36% reduction in

46

mortality with metoprolol as the beta-blocker, however it involved a 3-month follow-up
period. The American Beta-blocker Heart Attack Trial (BHAT) reported a 26%
reduction in mortality and involved propranolol as the beta-blocker. Effect of early
intervention was also assessed in the Goteborg trial, which reported a 35% greater
reduction in mortality within the first two weeks. The other two trials in this review were
Metoprolol In Acute Myocardial Infarction (MIAMI) and the First International Study of
Infarct Survival (ISIS) trial. Both of these involved large numbers of patients,
investigated early intervention and had lower differences in mortality as compared to the
Goteborg trial in the range of 13-14%. The reason mainly being that the trials included
more low-risk patients, fewer older patients and fewer patients with pre-existing cardiac
complications. The percent of patients withdrawn from these trials ranged from 19 to
29%, and the reasons for withdrawal were presence of hypotension and/or bradycardia.
The above two reviews were restricted to reports from major trials. Goldstein
reviewed 89 separate studies that addressed the effect of beta-blockers in heart disease
generally (Goldstein, 1996). In these, 19 focused specifically on outcomes following an
AMI. This review was more recent than the meta-analysis conducted by Yusuf et al., and
reported average effects for late application of beta-blockers following AMI similar to
those reported by Hjalmarson. In addition to overall mortality, this review reported
reduction in cardiovascular mortality, re-infarction rate and sudden death due to betablocker use following an AMI. Data indicated that the beneficial effects of oral betablocker therapy were maintained for at least six years after an AMI, and discontinuation
was associated with accelerated mortality. A trial involving late intervention in patients
deemed high risk indicated a 48% decrease in overall mortality and a 58% decrease in
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vascular mortality. Analysis on subgroups identified by increasing mortality risk
revealed mortality benefits from a low 2% to a high 23%. Subgroup analysis was also
conducted on data from trials, for high-risk patients such as those with congestive heart
failure (CHF), elderly patients and patients with diabetes. Beta-blockers had a more
marked effect in decreasing sudden death in those with CHF. It clearly illustrated that
absolute benefits of treatment in older patients were greater than those achieved in
younger patients. Additionally, for patients with diabetes the reduction in mortality was
greater, (22-48%) compared to patients without diabetes, (4-29%). Thus, higher benefits
accrue to patients who are at higher risk of mortality. It is important to consider the fact
that in all of these studies the proportion of the AMI population determined to be eligible
for beta-blocker therapy varied significantly in every study. Hjalmarson reported that 1418% of patients were excluded from treatment in the Norwegian, Goteburg and the
American trials because of contraindications. However, the specific contraindications
were not mentioned in this review. Agusti et al., reported that 23% of the patients in their
study had contraindications and these were history of chronic obstructive bronchitis,
intermittent claudication, heart failure and permanent AV block (Agusti, Arnau &
Laporte, 1994). Another study, which mentioned specific contraindications, was by
Whitford and Southern (Whitford & Southern, 1994). The contraindications specified
were ‘active reversible airway disease, heart block, and heart failure’. This deemed 45%
of the patients ineligible for therapy.
An examination of the data from BHAT was done by Furberg and Byinton
(Furberg & Byinton, 1983) wherein they examined the difference in outcomes between
patients in the tails of the distribution of expected mortality risk. They found a relative
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risk reduction of 40% in the group receiving beta-blocker agents in this limited set.
Olsson et al., took a different approach (Olsson, et al, 1992). They collected individual
patient level data from five randomized trials and analyzed the pooled data. They found a
relative risk of mortality reduction of 19% overall. A higher benefit to women (23%)
was observed compared to men (16%). The reduction in total mortality was mainly due
to reduced sudden cardiac deaths. Additionally, beneficial effect of drug was not
influenced by risk factors such as age, sex, and smoking habits. Thus, treatment effects
were observed both in high and low risk patients. However, pooling data from different
studies involves limitations, as each study involved different treatment protocols,
dosages, treatment initiation and treatment duration time frames.
Beta-blockers have four potentially important ancillary properties: intrinsic
sympathomimetic activity (ISA), beta1- selectivity, membrane stabilizing activity and
lipophilicity (White, 1999). A meta-analysis of 73 trials was conducted to determine if
these properties could help predict the degree of mortality benefit in the peri- and postAMI periods (Soriano, Meems, & Grobbee, 1997). The results were divided among
drugs with or without each of these properties. This meta-analysis suggested that the
absence of intrinsic sympathomimetic effect and membrane stabilizing effect, and the
presence of beta1- selectivity and lipophilicity were most efficacious at reducing oneweek mortality, long-term mortality, re-infarction and sudden death. However, when the
Cooperative Cardiovascular Project (CCP) data was investigated to compare effects of
three beta-blockers- atenolol, metoprolol and propranolol, the study suggested that the
specific beta-blocker selected has little influence on mortality (Gottlieb & McCareter,
2001). The mortality rates of the lipophilic agent metoprolol and the nonlipophilic agent
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atenolol were virtually identical. When comparison was made between the nonselective
agent propranolol with the selective agents- atenolol and metoprolol, propranolol had
slightly negative outcomes in patients. However, patients receiving propranolol were
sicker, compared to the other two agents, and after adjusting for the confounding
variables, the difference between the selective and nonselective agents decreased.
Furthermore, outcomes in patients who received propranolol was much better than
patients not receiving any beta-blocker.
Observational studies involving retrospective database studies investigating betablocker efficacy have also been previously reported. A retrospective analysis was
conducted to determine the effectiveness of metoprolol (a beta-blocker) for secondary
prevention of AMI in Japan (Iskkawa et al, 2000). All AMI patients who were admitted
or received regular outpatient treatment for AMI during an 11-year period from 1986 to
1996 were included. The primary endpoints were recurrent AMI (fatal and non-fatal),
sudden death, or death from CHF. The metoprolol group had a 3% incidence of cardiac
events compared to the 6.8% of the non beta-blocker group, which represents a 56%
reduction. Multivariate analysis revealed that metoprolol was significant in reducing
cardiac events and in reducing the incidence of sudden death. Sub-group analysis by
heart rate (> 65 and <65 beats/min) revealed that the effect of metoprolol on lower
incidence of cardiac events remained unchanged.
Chen et al., investigated the data from the CCP, to determine whether betablockers were effective in reducing mortality after an AMI in patients who undergo
coronary re-vascularization (Cheng, Radford, Wang, Marchiniak & Krumholz, 2000).
The CCP collected data on over 200,000 patients in 45 states over an eight-month period
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from 1994 to 1995. The study was initiated due to the lack of inclusion of patients who
undergo coronary re-vascularization such as PTCA or CABG in randomized clinical
trials. Mortality at the end of one year between patients who underwent revascularization procedures such as CABG and PTCA and patients who did not undergo
re-vascularization procedures were compared. The findings suggested that beta-blocker
therapy was as effective in reducing-one year mortality for patients who undergo revascularization (CABG Vs. PTCA) as for patients not undergoing re-vascularization.
Bisoprolol, a beta-blocker, has been shown to reduce cardiac death and myocardial
infarction when used long-term in high-risk patients after major vascular surgery, further
establishing the effectiveness of beta-blockers in this cohort of patients (Poldermans et al,
2001).
Due to their negative inotropic and chronotropic effects, beta-blockers are
contraindicated in patients with pre-existing decompensated heart failure and acute
pulmonary edema. However, they can be used in patients with large AMI that may result
in left ventricular dysfunction (White, 1999). In a subgroup of Survival And
Enlargement Ventricular (SAVE) trial, which evaluated patients with left-ventricular
dysfunction after AMI, beta-blockers reduced the risk of cardiovascular death and the
risk of developing severe heart failure (Vantrimpont, Rouleau, & Wun, 1997). Thus, data
suggests that patients with more severe AMI’s and reduced ejection fraction after an AMI
have greater benefits than those with less severe AMI’s. In a subgroup analysis of the
BHAT, patients with stable heart failure before receiving propranolol (a beta-blocker)
achieved a mortality reduction similar to that of propranolol-treated patients without heart
failure (Chadda, Goldstein, Byinton, & Curb, 1986). Propranolol also reduced the
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occurrence of sudden death more frequently in patients with heart failure. Also,
propranolol therapy did not increase the overall incidence of heart failure exacerbation,
nor did it increase the incidence of heart failure exacerbation in patients with a prior
history of heart failure.
Beta-blockers have shown to induce broncho-constriction in some patients with
chronic obstructive pulmonary disease (COPD), hence COPD is a relative
contraindication (White, 1999; ACC/AHA, 1996). However, it is usually patients with
reversible obstructive lung disease (bronchial asthma, asthmatic bronchitis) who are at
risk for bronchospasm. Additionally, beta1 selective agents such as esmolol have shown
not to alter pulmonary function in patients with non-reversible obstruction (Gold, Dee,
Cocca-Spofford & Thompson, 1991). However, caution is required when used in such
patients, as increase in dose may increase risk of worsening pulmonary function.
Treating patients with fixed COPD with a beta1 selective agent poses great benefits. A
retrospective trial using beta-blocker in patients with COPD revealed mortality risk
reduction of 40% (Gottleib, McCarter & Vogel, 1998).
Beta-blockers are also relatively contraindicated in the patients with diabetes as
they increase the risk for hypoglycemia (White, 1999). However, when used in diabetic
patients during the post-AMI period, they have been associated with a 36% mortality risk
reduction (Gottleib et al, 1998). This is important because patients with diabetes are
historically known to have the worse outcomes compared to patients without diabetes,
after an AMI. Thus, there is ample evidence that there are absolute benefits from betablocker therapy among patients with relative contraindications. Additionally, esmolol, a
short-acting beta-blocker, has been demonstrated to be relatively safe in AMI patients
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with relative contraindications (Mooss, Hilleman, Mohiuddin & Hunter, 1994). Thus,
this drug can be replaced for conventional beta-blockers such as propranolol or
metoprolol in such patients.
There has been debate about use of beta-blockers in patients with low-risk of
complications associated with AMI (ACC/AHA, 1996). The risks of drug use could be
greater than the benefits in these relatively healthy patients. However, a study including
low-risk patients and beta-blocker therapy revealed a 40% decrease in mortality (Gottleib
et al., 1998). Due to their better long-term prognosis, the absolute benefit in low-risk
patients was not as great as high-risk patients, but there is a substantial improvement in
survival.

Recommendation for Beta-Blocker Use for Post AMI
Due to their effectiveness, beta-blocker therapy has been included in the guidelines
for management of patients with AMI by the ACC and AHA (ACC/AHA, 1996). The
guidelines recommend their use both in hospital and for long-term prevention. The
guidelines divide patients into three classes with respect to beta-blocker therapy - Class I,
Class II and Class III. Class I include those patients with conditions for which there is
evidence and/or general agreement that the therapy is beneficial, useful, and effective.
Class II is sub-divided into IIa and IIb. Class IIa includes patients with conditions for
which the weight of evidence/opinion is in favor of usefulness/efficacy of therapy and
Class IIb includes patients with conditions for which usefulness/efficacy of therapy is less
well established by evidence/opinion. And finally, Class III includes patients with
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conditions in the presence of which there is evidence and/or general agreement that a
therapy is not useful/effective, and in some cases may be harmful.
For long-term therapy with beta-blockers, all patients accept those who are low-risk
and without a clear contraindication to beta-blockers were included in Class I. Treatment
for these patients should begin within a few days of the event and continue indefinitely.
Low-risk patients without a clear contraindication to beta-blocker were in Class IIa.
Class IIb did not include anyone. And Class III included patients with a contraindication
to beta-blocker therapy. However, due to the increasing evidence of effectiveness of
beta-blockers in patients with relative contraindications and low-risk patients, these
guidelines were updated in 1999. According to the updated guidelines, Class I still
includes patients who are not low-risk and have no clear contraindication to beta-blocker
therapy. Class IIa includes low-risk patients without a clear contraindication to betablocker therapy and survivors of non-ST elevation AMI. There was an addition of Class
IIb patients that included patients with moderate to severe left ventricular (LV) failure or
other relative contraindications to beta-blockers, provided the patients were monitored
closely. The updated guidelines did not include any patients in Class III.
In addition to being recommended by ACC/AHA, use of these agents long-term for
secondary prevention after AMI has also been endorsed by other organizations such as
the HEDIS (Health Plan Employer Data and Information Set). This organization has
included long-term beta-blocker therapy as a quality of care indicator to evaluate
performance of managed care plans (Bradford et al, 1999).
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Utilization of Beta-blockers at Post AMI
Although clinical trails have revealed impressive results, a large population of
patients who could benefit from this therapy do not receive it in actual practice. Overall,
40% of all patients with AMI could be safely treated in the short-term with beta-blockers
and at least 70% of patients could receive long-term therapy with beta-blockers (White,
1999). Surveys indicate that intravenous (IV) beta-blockers are used in <15% of patients
and oral beta-blockers are used in <40% of patients without specific contraindications.
Furthermore, 52-89% of patients in clinical practice receive beta-blocker doses that are
<50% of those studied in clinical trials.
The National Registry of Myocardial Infarction (NRMI) reported a 17 to 36%
beta-blocker use in patients treated with thrombolytics and a 30 to 42% beta-blocker use
in patients not receiving thrombolytics (Rogers et al, 1994). NRMI is a phase IV (post
marketing), observational, collaborative endeavor sponsored by Genetec Inc, in which
contributing hospitals throughout the United States record demographic, procedural, and
outcomes data on patients with AMI. Even in 1996, in the quarterly report, the registry
indicated that fewer than 50% of patients post AMI were taking beta-blockers (NRMI,
1996). However, a follow-up of this study in 1999 revealed a significant increase in betablocker usage at hospital discharge. This follow-up revealed that beta-blocker use
increased from 42% in 1994 to over 60% in 1999 (Rogers et al., 2000).
McCormik et al., examined utilization of beta-blockers in a different manner.
They examined receipt of beta-blockers before hospitalization for recurrent AMI during
1986, 1988, 1990, 1991, 1993 and 1995 in all hospitals in Worcester, MA. (McCormik,
Gurwitz, Lessard, Yarzebski, Gore & Goldberg, 1999). They reported a moderate
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increase of beta-blocker use from 33.2% in 1986 to 44.4% in 1995. Age and white race
were negatively associated with beta-blocker use, whereas history of angina,
hypertension, concurrent use of other cardiovascular medications such as aspirin and
lipid-lowering drugs were positively associated with receiving beta-blocker agents.
Two recent studies that examined the consequences of beta-blocker under-use
were conducted by Soumerai et al., and Krumholz et al. (Soumerai, McLaughin,
Spielgelman, Hertzmark, Thibault & Goldman, 1997; Krumholz, Radford, Wang, Chen,
Heiat, & Marciniak, 1998). The first study linked Medicare claims data to two databases
covering pharmaceutical usage in New Jersey for these Medicare patients. Since the data
utilized was for administrative claims, they were unable to identify all potential
contraindications for beta-blocker therapy. Instead they defined eligibility as the absence
of a diagnosis or medication reported prior to the AMI that would be suggestive of a
contraindication. Thus, they excluded patients with CHF, asthma, COPD, as well as
those with a prescription consistent with these diagnosis or a prescription for insulin.
They found that 30% of the patients with AMI had 1 or more contraindications to betablocker treatment, thus 70% were eligible for therapy. However, only 21% of the eligible
subjects received a prescription for beta-blockers. Also, among patients not receiving
beta-blocker treatment before AMI, only 15% were started on therapy after the AMI.
The second study collected data through an intensive chart review of Medicare AMI
patients. These were selected from the CCP. For this study, Krumholz et al., excluded
patients who died, were transferred, and who had contraindications for therapy. The
contraindications included were: bradycardia, low blood pressure, high grade AV block,
asthma, chronic lung disease, heart failure during hospitalizations or chart documented
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intolerance to beta-blocker. This study reported an eligible population of about 39%. Of
this, only 50% had a prescription for a beta-blocker at discharge.
Variation in beta-blocker usage has also been reported geographically. A
significant variation in utilization by state and region was present in the CCP (Krumholz
et al, 1998). Connecticut (77.1%), Massachusetts (74.2%), Maine (68.3%), New
Hampshire (68.9%), and Vermont (66.7%) had the highest utilization rates, whereas
Mississippi (30.2%), Puerto Rico (32.1%), Oklahoma (33.5%), Arkansas (33.5%), and
Nevada (36.4%) had the lowest utilization rates. Also, among the different regions, New
England had the highest utilization rates of 72.6%. Variations within small areas were
observed while examining data from six hospitals in Connecticut (Meehan, Hennen,
Radford, Petrillo, Elstein, & Ballard, 1995). Overall utilization rate was 41%, however, it
varied from 39% and 54% for the low-mortality hospitals to 29% and 33% for the high
mortality hospitals.
Pilote et al., reported regional variation within the United States, when data from
the Global Utilization of Streptokinase and Tissue plasminogen activator for Occluded
coronary arteries trial (GUSTO-1) was explored (Pilote et al, 1995). Generally, they
found that New England had the highest utilization of therapy with 71% of patients
receiving a beta-blocker at discharge. Compared to this the Mountain and South Central
regions had the lowest utilization at 47% and 49%, respectively. The average age of
patients in this study was between 59 and 62 for the various regions. An investigation of
treatment and outcomes of AMI in Quebec from 1988-1995 revealed similar results
(Pilote, Lavoie, Ho & Eisenberg, 2000). Increasing beta-blocker utilization was found
for the duration of the study, with the 50% rate in 1995 being the highest. Analysis of
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patient treatment data in 11 geographically defined European regions revealed rates from
25% to 85% from center to center (Woods et al, 1998). About 48% of patients had at
least one contraindication to beta-blocker on admission. In the patient group not admitted
on a beta-blocker and without perceived contraindications, only 58% of patients actually
received therapy at discharge. Variation in beta-blocker use has also been reported by
urban-rural location. An examination of the CCP data in Kansas by rural, semi-rural and
urban locations revealed utilization rates of 30.7%, 30.2% and 36.4%, respectively,
among ideal patients (patients who should definitely receive the agents). The trend was
repeated even among the less than ideal patients (patients in whom use was controversial
due to contraindications) with utilization rates of 22.5%, 25.0%, and 31.3% in rural,
semi-rural and urban locations (Sheikh & Bullock, 2001).
Underutilization of beta-blockers, following AMI, has also been established in
specific patient sub-groups. Fishkind et al., studied elderly patients (mean age =81) and
found that utilization of beta-blockers following an AMI was quite low at 19% (Fishkind,
Paris, & Aronow, 1997). This number is lower than the average usage in the overall AMI
population. This suggests that physicians are reluctant to use this therapy in older
patients, despite age not being a contraindication. Although age is not a contraindication,
older patients are more likely to have conditions that will make them ineligible for
therapy. Also, the authors included patients without consideration to contraindications.
A recent study in the rural state of WV revealed similar results (Schade, Behm, Stephens
& Rezek, 2002). Around 59.4 % of patients received beta-blockers at discharge over a
span of six quarters with no detectable trend of improvement over time. Additionally,
beta-blocker use declined with patient age. Gurwitz et al., extracted data from patient
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charts from 16 hospitals in a single Metropolitan Statistical Area for six years (Gurwitz,
Goldberg, Chen, Gore, & Alpert, 1992). They demonstrated a consistent trend toward
reduced beta-blocker therapy in older patients. After adjusting for demographic and
clinical variables (gender, prior history of angina, hypertension, or diabetes mellitus;
myocardial infarction characteristics; complications including CHF and shock; and use of
digoxin), odds ratio for receipt of beta blocker therapy relative to patients less than 55
years of age were 0.61 for those 55 to 64, 0.52 for those 65 to 74, 0.36 for those 75 to 84,
and 0.26 for those 85 or older. Utilization of therapy was 39.8% for the overall study
population. Male patients and those with a prior history of angina or hypertension were
more likely to receive therapy than those with diabetes mellitus.
Utilization differences have also been reported by gender and race. Pashos et al.,
conducted a retrospective analysis of administrative data (Pashos, Normand, Garfinkle,
Newhouse, Epenstein, & McNeil, 1994). This demonstrated odds ratios of 0.93 for
women relative to men and 0.81 for blacks relative to non-blacks for receiving betablockers. Similar findings were reported while examining patient charts in two large
urban hospitals (Sial, Malone, Freeman, Battiola, Nachodsky, & Goodwin, 1994). A
utilization of 38% was reported in patients with no potential contraindications. It
reported a variety of conditions to be associated with under utilization of therapy. These
include female gender (OR=0.52), health insurance (OR=0.34), presence of COPD
(OR=0.21), development of CHF (OR=0.46), and AV block (OR=0.28). CHF has been
reported to be the reason for underutilization in a number of other studies. Also, presence
of contraindications did not determine prescribing behavior. Up to 24% utilization was
reported in patients with potential contraindications. Beta-blockers have certain adverse
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effects, which may also be responsible for it’s under use. These include fatigue,
depression, sexual dysfunction, nightmares and difficulty to detect hypoglycemia and
diabetics.
The CCP data has also demonstrated association of socio-demographic
characteristics with the use of beta-blockers (Rathore, et al., 2000). Beta-blockers were
underused as discharge medications in the treatment of black, female and poor patients
with AMI. This variation in treatment was not explained by severity of illness, physician
specialty, hospital and geographic characteristics. Variation in beta-blocker use at
discharge by gender was also reported by Wilkinson et al., in an observational follow-up
study for 5 years from 1988 to 1992, with fewer women receiving therapy compared to
men (Wilkinson, Laji, Ranjadayaln, Parson, & Timmis, 1994).
Though there are reports of under utilization of these agents for the post AMI
population, there has been a steady rise in average use of these agents over recent years.
A recent study examined changes in post-AMI beta-blocker use occurring between 1994
and 1997 (Heller, Ahern, & Kozak, 2000). It included patients >65 years of age who
were enrolled in Pennsylvania’s pharmaceutical assistance contract for the elderly
(PACE) and who survived AMI between 1994 and 1997. The results presented an
increase of beta-blocker use from 39.6% in 1994 to 58.6% in 1997. Those patients who
did not use beta-blockers tended to have greater severity of illness, and co-morbidities
such as CHF, COPD, and asthma. Other researchers have also pointed out strong time
trends in the utilization of beta-blocker therapy. Paschos et al., (1994) documented a rise
from 29 % to 38% from 1988 to 1992. Similarly Pilote et al., (2000) reported an increase
from 33% to 50% from 1991 to 1995. This may be due to publication of results of
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rigorous clinical trials. Recent survey indicates that beta-blockers are prescribed to as
few as 40% of eligible patients in some health plans, however, there are some plans that
report 96% prescribing rates (NCQA, 1999; NCQA, 2000).
Most of the investigations associated with beta-blocker use have excluded patients
with contraindications. However, a study which did examine utilization of beta-blockers
in patients with contraindications revealed that 11% of patients with contraindications
were receiving beta-blockers at discharge after an AMI (Brand et al., 1995). Some of
these patients had absolute contraindications such as AV block, whereas some had
relative contraindications such as diabetes mellitus, heart failure, and asthma. Another
study, reported a 24% utilization in patients with potential contraindications such as CHF,
hypotension, cardiogenic shock, COPD, asthma, AV block and diabetes (Sial et al.,1994).
Despite established guidelines there is ample evidence to establish under use of betablockers in patients with no contraindications and a few reports of misuse in patients with
absolute contraindications. All these reports establish inappropriate utilization of betablockers in AMI patients for secondary prevention, and thus non-adherence to guidelines.

Implications of Inappropriate Utilization of Beta-Blocker Therapy
The inappropriate utilization of beta-blocker therapy raises the primary question
“What are the consequences of this pattern of care?” There is very little information that
addresses this aspect directly. There can be higher morbidity and mortality due to
inappropriate care and there is a cost that can be attributed to these effects. Whenever
effective treatment is withheld from a patient, or given to a patient not eligible, it can
result in death or lower quality of life than anticipated. Each life lost or day of sub
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optimal health quality increases societal costs. In addition to having intrinsic value,
every life saved also contributes to economic productivity. Second, there is the increase
in medical resources utilized due to inappropriate care. This can be in the form of
increased hospital readmission, frequent physician visits, increase in number of bed days
and increase in emergency visits.
Lower mortality rates have been previously reported when there is utilization of
beta-blockers. For example, Krumholz et al., reported a 14% lower risk of mortality at
one year after discharge, among eligible patients who received a prescription for betablockers at discharge, when compared to eligible patients who did not receive a
prescription (Krumholz et al., 1998). Similarly, Soumerai et al., reported a 43% lower
mortality rate among beta-blocker recipients compared to non-recipients (Soumerai et al.,
1997). Additionally, this study also reported that beta-blocker recipients were rehospitalized 22% less often than non-recipients were.
The costs associated with mortality has been addressed to some extent through
simulation and modeling techniques for underutilization. One such study analyzed the
cost effectiveness of routine use of beta-blockers in three specific ages of 45, 55 and 65
(Goldman, Sia, Cook, Rutherford & Weinstein, 1988). Additionally, for each age group
three prognostic categories were considered - high risk, medium risk and low risk. The
estimated cost of six years of therapy to save an additional year of life was $23,400 in
low-risk patients, $5,900 in medium-risk patients, and $3,600 in high-risk patients for all
the three age categories. This was assuming that the entire benefit of earlier treatment is
lost immediately after six years. With a more likely assumption that the benefit of six
years of treatment wears off gradually over the subsequent nine years, the results
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differed. Here the estimated cost of therapy per year of life saved was $13,000 in lowrisk patients, $3,600 in medium-risk patients, and $2,400 in high-risk patients. The study
disregarded costs savings generated in follow-up medical utilization or potential costs of
any side effects.
Another study investigated health and economic benefits of increased betablocker use following an AMI. A computer simulated Markov-model of the coronary
heart disease policy (CHDP) model was used in the US population (Philips et al., 2000).
The aim of the study was to estimate the epidemiological impact and cost-effectiveness
of increased beta-blocker use from current to target levels among survivors of AMI aged
35 to 84 years. Simulations included one cohort of AMI survivors in 2000 followed up
for 20 years and 20 annual successive cohorts of all first-AMI survivors in 2000-2020. In
the first group, this resulted in 4,300 fewer coronary heart disease (CHD) deaths, 3,500
fewer AMIs, and 45,000 life-years gained when utilization of therapy was compared to
current use. The incremental cost per QALY (quality adjusted life years) gained was
estimated to be $4,500. For the second simulation, increase in use resulted in savings of
$18 million and 72,000 fewer CHD deaths, 62,000 fewer AMIs and 447,000 life years
gained. Restricting the therapy to ideal patients however, would reduce the impact of
beta-blocker therapy by about 60%.
Thus, there has been some attempt to model effect of underutilization on patient
outcomes. However, effect on utilization related variables such as physician visits,
emergency room visits, length of stay and expenditures have not been investigated.
Additionally, implications of use of beta-blocker therapy in patients with
contraindications (misuse) has been ignored. Similar investigations in other chronic
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disease management suggests adverse patient outcomes due to misuse of therapy. For
example, in asthma the National Heart, Lung and Blood Institute (NHLBI) developed
guidelines for diagnosing and managing asthma (Podell, 1992). According to these
guidelines, a short course of systemic corticosteroids is the most cost-effective way of
reducing asthma excaberations. Long term B2 agonists and methylxanthines are
recommended to be used as adjuvant therapy. Short-term B2 agonists should be used
only on an as-needed basis. When drug therapy patterns and effect of these patterns on
patient outcomes was investigated, the results demonstrated patterns outside of the
guidelines (Shireman et al., 2002). Less than one-half of the population under study
received sub-optimal dose per day of inhaled corticosteroid. A large percent (44%) of the
population received high or very high levels of short–acting B2 agonists. Additionally,
patients with high doses of short-acting B2 agonists had the worst asthma outcomes.
Their odds of receiving an oral steroid burst, an indicator of ambulatory asthma
excaberations, were more than doubled. They were also more likely to be hospitalized
and had significantly more emergency department visits. Another study which
investigated effect of inappropriate medication use and outcomes in asthma was
conducted by Anis et al. (Anis et al., 2001). This defined inappropriate medication use as
use of nine or more canisters of short-acting B2 agonists, combined with no more than
100 ug/day of corticosteroid in a year. Appropriate medication use was defined as four or
fewer canisters of short-acting B2 agonists and at least 400 ug/day of corticosteroid. A
greater proportion of those patients with inappropriate medication use were admitted to
hospital on an urgent basis at least once during the year. Additionally, these patients
were admitted or admitted on an urgent basis more frequently compared to the
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appropriate medication use group. The appropriate medication use groups had fewer
physician visits overall and also fewer physician visits per physician. Thus, the
inappropriately prescribed patients used more health care services, suggesting greater
morbidity and greater health care costs.
Another class of drugs that have been investigated for inappropriate prescribing is
antibiotics. An investigation of inappropriate antibiotic use in pyelonephritis revealed an
association between inappropriate prescribing and length of stay (LOS) (Knapp, Knapp,
Speedie, Yaeger, & Naker, 1979). Inappropriate prescribing was associated with a twoday or 50% longer LOS than appropriate prescribing. This was regardless of disease
severity. When a sub-analysis was conducted with the youngest cohort in this study, the
inappropriately prescribed group still had a longer LOS, indicating that patient age did
not affect inappropriate prescribing.
In addition to specific drug classes there have been investigations of multiple drug
classes and inappropriate prescribing. Such investigations have examined inappropriate
prescribing using criteria’s such as indication, effectiveness, dosage, correct directions,
practical directions, drug-drug interactions, drug-disease interactions, therapeutic
duplication, duration and cost (Schmader et al., 1997). One such investigation revealed
that patients with inappropriate prescribing were more likely to be admitted to the
hospital or have an unscheduled physician visit during the subsequent 12 months.
Lindely et al., identified inappropriate prescriptions, defined as unnecessary drugs and
those with absolute contraindication, and adverse drug reactions (ADRs), defined as
presenting symptoms that were known adverse effects of admission drugs, in 429 patients
aged 65 years or over (Lindley, Tulley, Paramsothy, & Tallis, 1992). Of the total ADRs
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presented, 72.8% were attributable to inappropriate prescriptions. Similarly, in a study of
patients over 65 years, readmitted to the hospital, 17 of the 48 problems in 40 patients
were drug-related (Bero, Lipton, & Bird, 1991). These were overdose, under-dose,
inappropriate choice, allergy and drug-drug interaction. Stroupe et al., investigated under
and over supply of required medications using medication possession ratio in a network
of community based ambulatory care centers (Stoupe et al., 2000). This revealed that
patients with over supply had higher average inpatient and outpatient costs compared to
patients with normal supply. Both under and over supply of medication were
independently associated with significantly higher probabilities of hospital admission and
emergency department visits.
Thus, there is evidence of inappropriate prescribing of various drugs and their
consequent adverse health outcomes among patients. However, such investigations with
beta-blocker use for post AMI patients for long-term prevention is non-existent, and
needs to be undertaken.

Physician’s Role in Inappropriate Utilization
A number of researchers have gone beyond the issue of beta-blocker utilization
and attempted to understand the physician’s role in beta-blocker therapy. As most of the
research associated with beta-blocker utilization has investigated under-utilization, the
physician’s role has also been investigated in under-utilization more than inappropriate
utilization. One of the primary findings is the association between beta-blocker
prescribing and physician specialty. Fehrenbach et al. investigated an administrative
managed care data retrospectively (Fehrenbach, Budnitz, Gazmararian, & Krumholz,
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2001). The results revealed that 43.4% of family practice physicians, and 40% of other
physicians prescribed beta-blockers compared to 67.7% by cardiologists. Others have
documented prescribing rates of 77.5% for cardiologists, 63.0 % for internists, and 53.1%
for family practitioners of beta-blockers as post AMI therapy (Ayanian et al. 1994). The
CCP data revealed prescription rates of 52.4% for cardiologists which was much higher
than 39.7%, 35.4%, 36.1% & 39.4% for internal medicine, family medicine, general
practice and other specialty, respectively. In elderly patients, individuals who had
prescriptions written by cardiologists were more likely to use a beta-blocker than
individuals who received prescriptions from non-cardiologists (OR=1.52) ( Heller,
Ahern, & Kozak, 2000). A recent study in WV revealed similar results (Schade, Behm,
Stephens & Rezek, 2002). Around 59.4 % of patients received beta-blockers at discharge
over a span of six quarters with no detectable trend of improvement over time. However,
there was a significant difference in beta-blocker use by physician specialty with
prescribing rates of 60.8% by cardiologists, 49.7% by primary care practitioners and
45.8% by other specialties. All these suggest that physicians in different specialties are
not equally aware of information and that this information difference may be a reason for
differential prescribing rates by these physicians. Though cardiologists are more likely to
prescribe beta-blockers at discharge, this does not necessarily imply that their prescribing
behavior is adherent to guidelines. For example, a study measuring cardiologists’
adherence to guidelines revealed a low level of compliance (Brand et al., 1995). About
31% of the cases had an error of omission (beta-blocker not given in the absence of a
contraindication) and 11% of the cases had an error of commission (beta–blocker given
in the presence of a contraindication).
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In addition to physician specialty there are other characteristics which have been
shown to affect beta-blocker prescribing. For example Fehrenbach et al, revealed that
52.6% of physicians trained before 1980 prescribed beta-blocking agents as compared to
63.2% physicians trained since 1980 (Fehrenbach et al, 2001). Additionally, region of
practice was also associated with use of beta-blockers in this study, with the physicians in
the northeast being more likely to prescribe beta-blocking agents than physicians in other
regions. One other factor that affects prescribing is affiliation with university. Mitra et
al., reported that patients at a government, university affiliated teaching hospital had high
prescribing rates for beta-blocker therapy and this was in accordance with the ACC/AHA
guidelines (Mitra, Findley, Frohnapple & Mehta, 2002). This study examined the
frequency with which cardiologists prescribed post AMI medications at discharges and
evaluated medical management at the end of 24 months after discharge from the acute
event. The study reported that over 90% patients were given beta-blockers at discharge,
this utilization however decreased to 71% at the end of 2 years. These prescribing rates
however, were much higher than the national registry rates of 48%. Similar results were
found when beta-blocker use was compared in two centers of Perth and Newcastle of
world health organization (WHO). The study revealed that more patients were
discharged from hospital on beta-blockers in Perth (68%) than in Newcastle (45%). The
reason attributed to this difference was the fact that higher proportion of patients in Perth
were treated by cardiologists in large teaching hospitals compared to the more rural
nature of New-Castle (Nicholls, McElduff, Dobson, Jambrozik, Hobbs, & Leitch, 2001).
While the above studies have dealt with association between physician and
physician practice characteristics and prescribing of beta-blockers, there are also reports
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of association between physician knowledge and beliefs with prescribing behavior. For
example, cardiologists believed more strongly that beta-blockers improve survival as
long-term therapy after an AMI and they were also more likely to prescribe this therapy
compared to internists and family practitioners (Ayanian et al., 1994). In a critical look at
literature regarding physician under-utilization of beta-blocker therapy, three primary
reasons were revealed (Kennedy & Rosensen, 1995). These include exaggerated
concerns of adverse effects of beta-blockers, undue importance of contraindications, and
skepticism of drug therapies due to competitive practice of pharmaceutical industry.

Medicaid Program
The present study will be undertaken in a Medicaid population. Thus, it is
necessary to understand the structure and functioning of this health care system.
Medicaid is a federal and state jointly funded health insurance program for the indigent,
disabled, and members of families with dependent children (NPC, 1995). This program
was started in 1965. In managing Medicaid, the federal and the state governments have
separate responsibilities (NPC, 1995). The federal government provides fiscal assistance
and a framework with regulations, guidelines, and policies for operation to state
governments. State governments are responsible for administration of the Medicaid
program which include - determining eligibility, determining services, claims processing
and monitoring. Benefits provided by Medicaid include coverage for physician visits,
inpatient and outpatient hospitalizations, laboratory tests, nursing home care, family
planning services and supplies, and home health care. These benefits are mandated by
the federal government. Additionally, there are optional services that are left to the
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discretion of each state. Some of these are coverage for pharmaceuticals, eyeglasses, and
dental services for person 21 and older. Although optional, all states provide
pharmaceutical coverage as a part of Medicaid benefits.
From the time of its initiation, Medicaid has had a tremendous impact on the US
health care system. It has made healthcare accessible to individuals who are not
financially well off. However, health care spending through Medicaid programs has
grown tremendously. Total federal and state Medicaid expenditures, including
administrative costs and dis-proportionate share hospital payments, increased from $58
billion in 1989 to $194.7 billion in 2000 (Coughlin, Ku, & Holahan, 1994; Medicaid
Consumer Information, 2003). One of the major reasons for this increase in expenditures
is the increase in size of the Medicaid-covered populations. In 1990, there were 25.3
million recipients which increased to 36.3 million in 1995 and in 2000 there were more
than 44 million (NPC, 1995; Medicaid Consumer Information, 2003).
This national trend for Medicaid growth is also evident in WV. This growth has
been witnessed by both increase in enrollment and expenditures. In WV, the Bureau for
Medical Services of the WV Department of Health and Human Resources has been
responsible for the management of the Medicaid program (West Virginia Medicaid
Program -WVMP). The total number of recipients in the WVMP has increased from
178,254 in 1982 to 354,326 in 2000 (NPC, 1998; Medicaid Consumer Information,
2003). This growth in number of recipients has resulted in a dramatic increase in
expenditures from $121 million in 1982 to over $1.391 billion in 2000 (NPC, 1998;
Medicaid Consumer Information, 2003). This can be interpreted as an increase in
average spending per recipient from $678.84 to approximately $3,900 (NPC, 1998;
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Medicaid Consumer Information, 2003). Thus, it becomes important to identify areas
that incur unnecessary costs - appropriate use of medication can be one such area.
Investigation undertaken to study consequences of inappropriate care will help in
developing and implementing strategies for minimizing expenditures for this health care
system.

Thus, this chapter presented a review of literature associated with AMI, betablocker drug therapy, their effectiveness, recommendation for their use, variation in their
use, implications of this variation in use and physicians role in this variation of use. It
also provided a brief introduction to Medicaid, the health system in the study. The next
chapter will discuss the methodology employed to fulfill the goals of this study.
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CHAPTER THREE
METHODOLOGY

This study had two phases. In phase I, the study evaluated the impact of
appropriate and inappropriate prescribing of beta-blocker therapy by physicians,
following an acute myocardial infarction (AMI), on patient outcomes and utilization of
health services. In Phase II, the study determined physician-related factors that were
related to beta-blocker prescribing in post-AMI patients. The methodologies required to
accomplish the two phases were different. Phase I involved analysis of secondary data
from paid claims of West Virginia (WV) Medicaid. Phase II was completed using
primary data collected from physicians involved in post AMI care in the state of WV.

Phase I
The following sections describe the data source, data extraction, modification of
raw data, and the analytical methods that were utilized for this phase of the study.

Data Source
The WV Bureau for Medical Services (WVBMS) contracts with Consultec Inc.
(Atlanta, Georgia), to serve as its claims processor. Consultec maintains and operates the
Medicaid Management Information Systems (MMIS), which process provider claims and
payments. MMIS data comprises of 3 files- provider, recipient, and claims files
(Momani, 1999).
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The provider file contains specific information regarding various types of
providers eligible to deliver services to Medicaid recipients. This includes a provider
number, the provider’s name, address, specialty, Medicaid eligibility, and tax related
information. The recipient file contains information about Medicaid recipients, such as
name, Medicaid number, eligibility begin date, end date, Social Security Number (SSN),
aid category, gender, race and address. The claim files store detailed information specific
to processed claims. For each medical claim information, such as invoice type, provider
number, recipient number, International Classification of Disease 9th edition (ICD-9)
code of diagnosis for which service was provided, Common Procedural Terminology 4th
edition (CPT-4) code for procedures and services provided, Diagnosis Related Group
(DRG) codes, date claims are submitted, date of adjudication through-date of service, coordination of benefit code, total primary carrier code, and total amount paid. For
pharmaceutical products, the file contains fields such as name of the drug, begin date,
number of days supply, metric quantity, National Drug Classification (NDC) code,
generic code, therapeutic class code, refill number, pharmacy provider number, and the
amount paid.
Paid claims data relevant for the study were obtained from Consultec, Inc.
Consultec stores data going back several years. However, not all of this data were
pertinent to this study and so relevant data between January 1, 1996 to June 30th, 2001
were extracted to conduct the analysis.
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Data Extraction
The data obtained from Consultec was loaded on a computer in access files.
These were extracted through the software BrioIntelligence and converted into statistical
analysis software (SAS® version 8.2) data sets. The extraction process involved defining
selection criteria, defining the time period of the study, inclusion of specific fields
required, defining exclusion criteria, and classification of groups.

Selection Criteria
The main selection criteria for patients was recipient numbers who were
discharged from a hospital with the primary or secondary diagnosis of AMI, ICD-9 codes
410.0 to 410.9, during January 1, 1997 to June 30, 2000. These recipient numbers were
unduplicated to make sure that each recipient number occurred only once. Social security
numbers (SSNs) for these recipients were identified. This is because SSN is the only
unique identifier for Medicaid recipients since each recipient can have multiple Medicaid
ID numbers.

Time Period
The total period of study was from January 1, 1997 to June 30, 2000 (42 months).
From the database, every patient with AMI identified was categorized into two groups.
The first group consisted of Class I & II patients, who are eligible to receive beta-blocker
therapy post-AMI and second group consisted of Class III patients, who are not eligible
to receive beta-blocker therapy post-AMI. However, in order to do this, in addition to the
data from the time period of the study, patient information from the previous year was
also needed. Therefore, additional patient data for the time period of January 1, 1996 to
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December 31, 1996 was additionally extracted from the database. Also, since the study
involved investigating outcomes for these AMI patients in the following one-year period
after the AMI, additional data from July 1, 2000 to June 30, 2001 was extracted. Thus,
the history file (hospital, ER, and physician), demographic file, managed care file,
prescription or drug file were obtained for the identified AMI patients from January 1,
1996 to June 30, 2001.

Specific Fields
Appendix A provides the lists of the fields chosen that were essential for the
study. From the demographic file, the fields selected were recipient number, recipient
social security number (SSN), date of birth, sex, race, eligibility begin date and eligibility
end date. From the hospital/ER file, the fields selected were recipient number, recipient
SSN, first date of service, last date of service, billed amount, paid amount, procedure
code, diagnosis codes and hospital extract indicator. From the physician file, the fields
requested were recipient number, recipient SSN, first date of service, last date of service,
billed amount, paid amount, procedure code, diagnosis codes and physician extract
indicator. From the pharmacy file, the fields requested were recipient number, recipient
SSN, date of prescription filled, billed amount, paid amount, NDC code, generic code,
and days supply. From the managed care file, the fields requested were recipient SSN,
managed care begin date and managed care end date. The drug file had the NDC code,
drug name and generic code. The DRG file had DRG code and DRG name. The
procedure file had procedure (CPT-4) codes and code description. And finally, the
diagnosis file had the diagnosis (ICD-9) codes and code description.
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Exclusion Criteria
The following exclusion criteria were applied to the selected SSNs with a
diagnosis of an AMI during the time specified;
• The first restriction was to include only those patients who were continuously
eligible in the Medicaid system for a period of one year before the hospitalized
AMI under study.
• From these, managed care recipients were excluded as managed care recipients
do not have all their utilization information in the Medicaid claims.
• Patients who were 65 years or older were excluded to avoid the issues of
incomplete information as they have Medicare as their primary payer for health
services. The age limit was set to 64 to avoid including those patients who would
become eligible for Medicare during the period of follow-up after being initially
present.
• Patient who have length of hospital stay less than 3 days were excluded to avoid
error due to misdiagnosis of AMI.
• Patients with the primary ICD-9 code of 410.x2 were excluded as this code is
utilized for subsequent episodes of care for AMI where the initial treatment was
received less than 8 weeks ago.
• When patients who had recurrent AMI within the time period of the study were
present, only the first AMI was considered.
• Beta-blocker receipt in the study was defined as presence of beta-blocker
prescription in the claims within 90 days of discharge. Thus, those patients who did
not receive a prescription for beta-blockers in the first 90 days after the AMI but
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received it sometime within the year were excluded to prevent potential bias due to
misclassification.
• Patients who died during the AMI or within 30 days of the incident AMI were
excluded.
The resultant group of patients was investigated to see the effect of appropriate and
inappropriate prescribing on mortality
• Patients who died due to non-cardiac causes in the follow-up period were
excluded.
The resultant group of patients was investigated to see the effect of appropriate and
inappropriate prescribing on cardiac mortality
• Patients who were not continuously eligible for Medicaid in the follow-up oneyear period after the AMI were excluded.
The resultant group of patients was investigated to see the effect of appropriate and
inappropriate prescribing on health care utilization and expenditures. This process of
applying inclusion and exclusion criteria is outlined in Figure 4.
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Figure 4: Data Extraction

Extracted paid claims
data for the period
from January 1, 1997
to June 30, 2000

ICD-9 codes for AMI

+

Continuously eligible
for one year before the
incident AMI,
N = 1,940

Extracted all files
associated with the
identified SSNs

Managed Care, N = 3
&
Medicare and Age >64,
N = 748
1,940-(3+748) = 1,189

Length of stay <3 days
& ICD-9 of 410.x2
N = 590
1,189-590 = 599

Cohort for mortality
N = 488

Cohort for cardiac
mortality, N = 470

Cohort for morbidity
and utilization,
N = 412

Identified recipient
numbers that received
claims for AMI

Unduplicated the list of
recipient numbers and
identified
corresponding SSNs
Duplicate AMIs and
beta-blockers after 90
days of discharge, N =
91

Death during or within
30 days of incident
AMI, N = 20
508-20 = 488

Death due to noncardiac causes, N = 18
488-18 = 470

Not continuously
eligible for one year
after AMI, N = 58
470-58 = 412

AMI: Acute myocardial infarction, ICD-9: International classification of disease-9th edition, SSN: Social security
numbers
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Classification of groups
Information about procedures, services, medications and medical history were
extracted during the incident AMI, one year prior to the incident AMI and one year after
the incident AMI for every patient identified who satisfied all the inclusion and exclusion
criteria. Based on their medical history, patients were divided into those with absolute
contraindications, and those with relative contraindications, using ICD-9, CPT-4 codes
and DRG-codes (see Appendix B). For example, a person with the ICD-9 code of 458.x
was considered to have hypotension, an absolute contraindication. It is important to point
out that certain relative contraindications such as a heart rate less than 60 bpm, systolic
arterial pressure less than 100 Hg, signs of peripheral hypoperfusion, and beta-blocker
intolerance were not recognized and constitute a limitation of this study.
Based on presence of the contraindications, patients were classified as Class I, II
and III for beta-blocker use after AMI. Prescription claims within 90 days of AMI were
obtained. Patients were classified into two groups based on presence of absolute
contraindications and beta-blocker receipt. Those who did not have absolute
contraindications and received therapy and those who had absolute contraindications and
did not receive therapy constituted the appropriately prescribed group. Similarly, those
who did not have absolute contraindications and did not receive therapy and those who
had absolute contraindications and received therapy constituted the inappropriately
prescribed group. Additionally, a sub-classification within the inappropriately prescribed
group was created to differentiate between patients with under use (those who did not
have absolute contraindications and were not prescribed) and misuse (those who had
absolute contraindications and were prescribed) of beta-blocker therapy.
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Modification of Raw Data
The raw data obtained from the hospital, physician and prescription claims data
was modified to obtain all the relevant variables that were required for the analysis, using
SAS® version 8.2. For the pre-phase (before the incident AMI) and during the incident
AMI, information about various medical conditions, such as left ventricular (LV) failure,
1st and/or 2nd and /or 3rd degree atrioventicular (AV) block, chronic obstructive
pulmonary disease (COPD), asthma, insulin dependent diabetes mellitus (IDDM),
hypotension, bradycardia, non-insulin diabetes mellitus (NIDDM), hypertension,
previous AMI, previous coronary artery bypass graft (CABG), previous percutaneous
transluminal coronary angioplasty (PTCA), congestive heart failure (CHF), stroke and
renal dysfunction was obtained. The presence of these were determined by presence of
either ICD-9 codes or CPT-4 codes in either the hospital or the physician claims during
the year before the incident AMI or as secondary diagnosis during the incident AMI. In
some cases DRG-codes were used (only CABG and PTCA). These are listed in
Appendix B.
The hospital claims had both hospitalization and ER claims in one file and the
physician file contained claims for clinic, department of health screening, lab tests,
transportation, family planning, special services and practitioner. Thus, the
hospitalization file required to be separated into hospitalizations and ER visits and the
physician file had to be limited to only outpatient physician visits. There was a variable
called hospitalization extract indicator in the hospital claims data, which classified the
claims as hospitalizations or ER visit. This variable and the following criteria were
utilized to separate the hospital claims data into hospitalization or ER visits. Those
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claims that had the variable as 1 (indicating hospital claim), had length of stay greater
than 1 day, and had a specific DRG code were classified as hospitalizations. Those
events which had length of stay as zero, had the indicator variable as 2 (indicating ER
extraction) and CPT-4 codes between 99281 to 99285 (CPT-4 codes for emergency
department visits) were classified as ER visits. There were claims that did not fit into
both these categories. An inspection of the procedure codes of these claims revealed that
these were claims associated with laboratory, radiology, & pathology during either
hospital admissions or ER admissions. Since the only information needed from these
claims were billed and paid amounts, they were classified as hospital/ER laboratory
claims. Similarly, in the physician claims files there was an extract indicator variable,
which was utilized to classify the physician visits as outpatient physician visits and
outpatient laboratory claims. All claims were converted to one observation per visit.
However, the billed and paid values for these observations were a sum of all the billed
and paid values of all the claims associated with that visit.
The total number of admissions for any cardiac condition in the pre-phase was
determined by summing the number of hospitalizations in the pre-phase with ICD-9
codes for cardiac conditions (Appendix B). Similarly, those hospitalizations that were
not related to cardiac conditions were summed to get total number of admissions due to
non-cardiac conditions in the pre-phase.
The pharmacy claims data was combined with the drug file to get drug names in
the database. Based on drug names, the total number of different unique drug claims per
person in the six months before the incident AMI was utilized to get total number of
drugs in the pre-phase. Similarly, any use of drugs such as digoxin, Angiotensin
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converting enzyme (ACE) inhibitors, anti-arrhythmic agents, beta-blockers, and calcium
channel blockers in the pre-phase was determined. Use of these agents in the 90-day
period after the incident AMI was also determined. Medication possession ratio and total
days supply of beta-blockers in the post-AMI period was determined. Medication
possession ratio is defined as
Total days supply of medication during study period
Total number of days between fill date of first and last prescription + days supply on last
claim
Total days supply was the sum of the days for which the patient filled a prescription
during the year after the incident AMI. In the post-AMI period, the total number of
hospitalizations, ER visits, physician visits and total length of stay for those who had
hospitalizations for the cardiac conditions under study were estimated by addition of each
visit for the specific ICD-9 codes (See Appendix B-outcomes conditions).
Expenditures were defined as direct costs incurred to Medicaid. Thus, reimbursed
amount was obtained by summing the paid amounts for the specific ICD-9 codes from
the hospitalizations, ER visits, hospital/ER laboratory, physician visits and physician
laboratory files for each patient. Similarly, total charges was obtained by adding the
billed amounts for the specific ICD-9 codes from the hospitalizations, ER visits,
hospital/ER laboratory, physician visits and physician laboratory files for each patient.

Research Design
The research design used for this phase of the study was a quasi-experimental
longitudinal design. There was an experimental group and a comparison group, i.e. the
appropriately prescribed group and the inappropriately prescribed group. However, since
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the allocation to group was not randomized it was a quasi-experimental design. Both the
groups were followed for a period of 12-months to determine the effect of prescribing on
outcomes, thus it is also longitudinal. Additionally, since the study involved following a
cohort of patients, determining their exposure to inappropriate/appropriate beta-blocker
use and determining the effect of this exposure on outcomes, it can also be classified as a
cohort design.
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Figure 5: Quasi-experimental Longitudinal Research Design

NR O1 X -------O1`
NR O2

-------O2`

NR: Non randomized, X: Exposure, O1: Experimental group, O2: Control group
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Data Analysis for Phase I
The data analysis used for this phase is presented by research questions proposed.
The Statistical Package for Social Sciences® (SPSS) version 10) was used for data
analysis:

Research Question 1: Prescribing Patterns for Beta-blocker Therapy in WV Medicaid
Frequencies were calculated to identify what proportion of patients received betablocker therapy, appropriately and inappropriately, as per AHA/ACC guidelines. There
were four classes of patients; those who should be prescribed and received a prescription
– appropriate use, those who should be prescribed and did not receive a prescription –
under use, those who should not be prescribed and received a prescription – misuse and
those who should not be prescribed and did not receive a prescription – appropriate use.
The percentage of patients in the misuse category was low, and hence was pooled with
the under use category to get an inappropriately prescribed group which was utilized for
analysis purposes. Similarly, the two appropriate use groups were pooled into one.
These two groups (appropriate and inappropriate) were compared on demographic
and patient history (co-morbidities and drug use) characteristics with t-tests and chisquares depending on whether the variable was dichotomous or categorical. The
different characteristics compared were: age, gender, presence of diabetes, hypertension,
peripheral vascular disease, renal dysfunction, previous AMI, previous CHF, previous
stroke, previous CABG, presence of relative contraindications, presence of absolute
contraindications, number of cardiac admissions in the year prior to AMI, number of noncardiac admissions in the year prior to AMI, number of different drugs in the six months
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before AMI, CABG during incident AMI, PTCA during incident AMI, length of stay
during incident AMI, number of secondary diagnosis during incident AMI, use of
digoxin, ACE inhibitors, anti-arrhythmics, beta-blockers and calcium channel blockers
before the incident AMI.
Of these, age, hypertension, presence of absolute contraindications, number of
non-cardiac admissions, use of digoxin and use of beta-blockers in the pre-period were
significantly different between the two groups. These variables were used in a logistic
regression to predict group status. Group 1 was for appropriately prescribed patients and
0 for inappropriately prescribed patients. The predicted value of this logistic regression
was used as propensity score for further analysis. Propensity scores calculated from
observational characteristics of patients are used to reduce selection bias in observational
studies. This is because in observational studies, investigators have no control over
inherent risks that patients bring into the study. Thus, large differences on observed covariates in the selected groups, may lead to biased estimates of outcomes. Propensity
score calculated from these observed co-variates can thus be used to reduce bias and
increase precision.
The equation for the logistic regression can be represented as:
Appropriate assignment (Y)=
to treatment with beta-blockers

X1 (age)
+X2 (hypertension)
+X3 (presence of absolute contraindications)
+X4 (number of previous non-cardiac admissions)
+X5 (previous use of digoxin)
+X6 (previous use of beta-blockers)
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Research Question 2: Effect of Appropriate and Inappropriate Prescribing on Mortality
Patients who did not have follow-up information and were confirmed to have died
from death certificate records in the 12-month period after the AMI were utilized to study
the relationship between appropriate and inappropriate prescribing of beta-blockers and
mortality. This relationship was investigated by Kaplan-Meier survival curves where the
dependent variable was time to death and the independent variables were appropriate and
inappropriate use. A duplicate analysis was conducted with time to cardiac death as the
dependent variable. Significant survival analysis is usually followed by Cox-proportional
hazards regression model, where the effect of the main independent variable on survival
time is examined after adjusting for other covariates. However, since the survival time
for cardiac death was not significant, a follow-up Cox-proportional hazards model was
not conducted.
The equations for the survival analysis can be represented as follows;
Survival Analysis:
Time to death (Y) = Xi (appropriate use) +Xii (inappropriate use)
Where, Xi, was 1 for those patients in the appropriate group and Xii was 1 for those
patients in the inappropriate group.

Research Question 3: Effect of Appropriate and Inappropriate Prescribing on Morbidity
Patients who had follow-up data and were continuously eligible for the follow-up
period were utilized to investigate the relationship between beta-blocker prescribing and
morbidity. As in the case of mortality, Kaplan-Meier survival curves were utilized to
examine the relationship between cardiovascular (CV) morbidity and prescribing of beta-

87

blockers following an AMI. However, the dependent variable was time to event during
the follow-up period where event was first hospitalization due to any of the following: a
successive AMI, heart failure, stroke, angina, other ischemic disease, essential
hypertension, cardiogenic shock, disease of endocardium, conduction disorders and/or
cardiomyopathy, in the follow-up period after the incident AMI. Since survival analysis
was found to be significant it was followed by a Cox-proportional regression model to
adjust for the various co-variates. Thus the equations were;
Survival Analysis:
Time to event (Y) = Xi (appropriate use) +Xii (inappropriate use)

Cox-Proportional Hazards Regression Model:
Time to event (Y) =

X1 (demographics- age, gender)
+X2 (appropriate/inappropriate use)
+X3 (predictors of appropriate beta-blocker assignment or
propensity score)
+X4 (presence of absolute contraindications)
+X5 (current procedures CABG, PTCA, length of stay)
+X6 (other discharge medications – aspirin, calcium channel
blockers, ACE inhibitors, loop diuretics)
+X7 (medication possession ratio)
+X8 (days supply)

Where X1, represented demographic characteristics such as age and gender.
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X2, was 1 for those patients who were in the appropriately prescribed group and 0 for
those who were inappropriately prescribed group.
X3, was propensity score estimated through the logistic regression with group status as
the predictor, estimated in research question 1. An alternative analysis was done where
this included a list of variables that were significant predictors of appropriate betablocker receipt in the logistic regression for predicting group status in research question
1.
X4, was 1 if any of the absolute contraindications such as Bradycardia, Hypotension,
and/or AV block were present and 0 if none of them were present.
X5, and X6, were variables associated with procedures undertaken during the incident
AMI and discharge medications after the incident AMI, respectively.
X7, was medication possession ratio. Medication possession ratio is proxy for patient
compliance calculated as days of supply of the medication divided by the total days
elapsed between 1st fill and last fill of the medication, which was obtained from the
prescription data.
X8, was days supply a total of number of days for which the patient had beta-blockers
filled.

Research Question 4: Effect of Appropriate and Inappropriate Prescribing on Utilization
and Expenditure
Patients who had follow-up data and were continuously eligible for the follow-up
period were utilized to investigate the relationship between beta-blocker prescribing and
health care utilization and expenditure. To examine the relationship between prescribing
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of beta-blockers and utilization of health care services, multiple regression analyses were
conducted. The utilization variables investigated were:
Y1 = Number of physician visits due to cardiac conditions
Y2 = Number of hospitalizations due to cardiac conditions
Y3 = Total hospital length of stay due to cardiac conditions
Y4 = Number of ER visits due to cardiac conditions
Cardiac conditions included the following: a successive AMI, heart failure, stroke,
angina, other ischemic disease, essential hypertension, cardiogenic shock, disease of
endocardium, conduction disorders and/or cardiomyopathy, in the follow-up period after
the incident AMI. To examine the relationship between prescribing of beta-blockers and
expenditures, two multiple regression analyses were conducted. The dependent variables
were:
Y5 = Log total charges associated with physician visits, hospitalizations, and ER
visits due to cardiac conditions
Y6 = Log total reimbursed amounts associated with physician visits,
hospitalizations, and ER visits due to cardiac conditions
Here, cardiac conditions were the same as defined earlier. Reimbursed amount and
charges were transformed into log form to decrease effect of skewness associated with
the cost data. The independent variables were similar to the regression models for
morbidity analysis. Thus, the generic equation can be represented as;
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Dependent variable (Y) =

X1 (demographics- age, gender)
+X2 (appropriate/inappropriate use)
+X3 (predictors of appropriate beta-blocker
assignment or propensity score)
+X4 (presence of absolute contraindications)
+X5 (current procedures CABG, PTCA, length of
stay)
+X6 (other discharge medications – aspirin, calcium
channel blockers, ACE inhibitors, Loop diuretics)
+X7 (medication possession ratio)
+X8 (days supply)

Phase II
The goal of the second phase was to determine association between physician
characteristics and prescribing behavior for beta-blockers for secondary prevention
following an AMI. For this, knowledge of contraindications, willingness to prescribe,
socio-demographic, and practice characteristics of prescribers in the state were obtained.
Primary data was collected for this phase using a survey instrument. The following
section describes the research design, methodology for identifying the study population,
development of the survey instrument, the data collection process, and data analytical
techniques that were used for this phase of the study.
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Research Design
The research design employed for this phase of the study was a cross-sectional
design. The assumption made for this phase is that the knowledge, willingness to
prescribe and socio-demographic and practice characteristics of physicians would affect
their prescribing behavior. In this phase of the study, the dependent variable was
prescribing rate of beta-blocker therapy by physicians, which was obtained from the
survey.

Study Population and Sample Selection
The population of interest for this phase was physicians who were care-providers
for AMI patients in WV. A mailing list of all WV board certified physicians in the
specialties of cardiology, internal medicine, primary practice and general practice was
obtained from the West Virginia Medical Board (WVMB). The total number of
physicians in the state obtained from the WVMB in these specialties was 1151. Since
physician surveys are associated with low response rates, all of the listed physicians were
surveyed.

Instrument Development and Content
A self-administered survey was used for this phase. Mail surveys offer many
advantages such as the ability to collect data from a larger geographical area at a
relatively low cost, greater versatility, and absence of interviewer bias. For respondents,
it offers the flexibility of replying at their convenience and offers respondent anonymity.
In developing the survey instrument, attention should be given to the kind of information
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needed to measure both the independent and dependent variables of interest, length of
questionnaire, cost, comprehension level of prospective respondents, complexity of the
questionnaire and the time required to complete it (Dillman, 1978). All these factors
collectively can have a significant impact on the kind of data collected and the response
rate.
The survey in this study was designed to assess the WV physicians’ knowledge of
contraindications according to the guidelines associated with post AMI care and use of
beta-blockers, and their willingness to prescribe beta-blocker therapy in patients with
various co-morbidities. To avoid leading the respondents to desirable responses,
questions for other post-AMI medications were included in the survey. Thus, section one
of the survey was designed to be more general for post-AMI medications. The first
question asked the respondents to mark those medications which were important
secondary preventive agents following an AMI. The response set included those
medications which are present in the AHA/ACC guidelines. A follow-up question
required the respondents to rate their willingness to prescribe these medications for
patients after an AMI, on a 1 to 5 Likert scale where 1 was least likely and 5 was most
likely. The next two questions in this section asked respondents to indicate how many of
the last 10 AMI patients they had treated, they had prescribed beta-blockers and ACE
inhibitors. Those respondents whose response was less than 10 were instructed to list the
specific reasons for not prescribing these medications in those patients not prescribed
beta-blockers or ACE-inhibitors.
The second section of the survey was primarily designed to measure willingness
to prescribe beta-blockers in patients with other co-morbidities, on a 1 to 5 Likert scale
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where 1 was least likely and 5 was most likely. The respondents were also asked to list
their willingness to prescribe ACE-inhibitors in these patients with other co-morbidties.
However, this was done to prevent leading the respondents into giving desirable
responses to questions with regards to beta-blocker use. The co-morbidities included a
list of conditions that were either relative or absolute contraindications for beta-blocker
use, or conditions that are associated with higher or lower risk of complications, during
an AMI. A few other conditions associated with CV disease, but not associated with
beta-blocker use, were also added to give a better mix of co-morbidities.
The third section of the questionnaire focused on knowledge of contraindications.
The respondents were asked to classify a list of conditions into relative and absolute
contraindications and conditions that were neither relative nor absolute contraindications,
for use of beta-blockers after an AMI. The response set consisted of a list of conditions,
which are either relative or absolute contraindications for beta-blocker use. A few
conditions, which were neither relative nor absolute contraindications, were also listed to
give a good mixture of disease conditions. These conditions were listed randomly in the
response set.
Socio-demographic and practice information were obtained in the last section of
the survey. Data obtained included age, gender, specialty, year of board certification in
this specialty, the average number of patients with AMI they treat per month (both new
and repeat), the number of beds in the hospital which is their primary practice site, and
information about their primary practice site. The demographic questions were asked on
a dichotomous or an interval scale. Open-ended questions were used for obtaining
information about practice characteristics.
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Instrument Validation
The instrument was submitted to experts for face and content validation. Experts
in the area of health services research at West Virginia University were approached to
assess clarity and appropriateness. Content validity is defined as “ the extent to which
test exercises reflect and fully cover the curriculum which the test was designed to
measure” (Mussio, 1987). Feedback from the experts was incorporated into the survey.
Institutional review board (IRB) permission was obtained from West Virginia University
on the validated survey. The final survey is represented in Appendix F.

Instrument Pilot Testing
The survey instrument was pre-tested to assess clarity, readability, and time for
completion. This process helps determine whether any important variable is being
omitted, any information is redundant, and if any changes are required in the
questionnaire wording and formatting, determine the ease of use and comprehension of
the instrument, and helps obtain a mean completion time. Pilot testing was conducted in
a convenience sample of cardiology, and internal medicine residents at the West Virginia
School of Medicine. A total of six internal medicine residents and two cardiology
residents responded to the survey. Seven of these surveys had complete responses to all
the questions indicating ease of comprehension. The residents were asked to rate the
questionnaire for clarity and readability on a 1 to 5 scale where 1 was unacceptable and 5
was acceptable. A total of 5 residents responded to this question, and the mean was 5 for
both the clarity and readability. The residents were also asked to state the time taken for
completing the survey. Five residents responded to this question and the mean time for
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completion was 11.4 minutes. No changes were made to the survey and the pilot testing
suggested that the survey was suitable for the study.

Data Collection
The data collection process included survey implementation, and non-response
assessment.

Survey Implementation
Physicians’ from the mailing list were mailed an individualized cover letter, the
survey instrument and a business reply envelope. The cover letter explained the purpose
of the study, and assured confidentiality of response (Appendix C). Respondents were
asked to return the completed questionnaire in the self-addressed business reply envelope
provided in the package. The surveys were coded for follow-up purposes. All completed
and returned questionnaires were checked off the mailing list. A second mailing was
made two weeks after the first one. This consisted of the questionnaire survey, the
second cover letter, and the self-addressed business reply envelope. The second mailing
was done only to those physicians who did not respond to the first mailing. This was
possible due to the coding procedure utilized during the first mailing. The second cover
letter was designed to stress the importance of participating in the study (Appendix D).
Similar to the first mailing, completed responses were checked off the coding list. The
physicians who did not respond to the second mailing were sent a third mailing to boost
the response rate. This package contained the third cover letter (Appendix E), which
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stressed the importance of the physicians’ response, the survey instrument and the selfaddressed envelope. All three cover letters were pre-approved by the IRB.

Non-Response Survey
Bias can be introduced into the study due to possible differences between
respondents and non-respondents. Therefore a non-response analysis was conducted to
determine if those physicians, who chose not to respond to any of the surveys, were in
any way different from those physicians who did respond. The non-respondents were
mailed a brief, half-page questionnaire to ascertain their reason for not responding to the
survey. Several options were presented including: no time, did not receive the survey,
forgot, survey misplaced, lost the survey, topic irrelevant, no incentive, don’t like to
respond to survey, too long, not enough information and not interested. A few critical
items from the study survey instrument were also included. These were utilized to
compare the demographic and practice characteristics of the non-respondents with the
respondents of the study survey, thus determine if there were significant differences
between the two groups on key variables that prevent generalization of the study findings.
Appendix G represents the non-response survey. This was also approved by the IRB

Data Handling
Each questionnaire received was checked for completeness. The Statistical
Package for Social Sciences® (SPSS) version 10 was used for data entry and statistical
analysis. The data was checked for appropriate entry and to assure that data was free of
errors. A total of 20 surveys were not included in the analysis as they had more than 50%
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of the questions incomplete. Thus, the data file contained 261 cases that represent usable
responses.

Data Analysis for Phase II
The data analysis used for this phase is presented by research questions proposed:

Research Question 5: Knowledge of Contraindications and Prescribing Behavior
Descriptive statistics were performed to summarize the correct classification of
the different conditions listed in the knowledge section (Section C) of the survey
instrument. The absolute contraindications were hypotension, bradycardia, second and
third degree AV block. The relative contraindications were systolic blood
pressure<100Hg, heart rate <60bpm, peripheral vascular disease, peripheral
hypoperfusion, ejection fraction (EF)<40%, first degree AV block, COPD, asthma,
insulin dependent diabetes mellitus (IDDM), PR interval on ECG>0.24 second, and betablocker intolerance. The conditions which were neither absolute nor relative
contraindication, were hypertension, non-insulin dependent diabetes mellitus (NIDDM),
stroke, and ACE inhibitor intolerance. Three scores were calculated based on their
correct classification (number of correct responses) - the absolute contraindication score,
the relative contraindication score, and the not a contraindication score.
Prescribing rate for beta-blocker therapy was calculated by dividing the number
of patients, of the last 10 AMI patients, the respondents prescribed beta-blockers, divided
by 10. This was multiplied by 100 to get the prescribing percent, which was used as a
proxy for prescribing behavior. The correlation of this prescribing behavior with the

98

three computed scores was estimated to determine the association of prescribing behavior
for beta-blockers as a secondary preventive agent after an AMI and knowledge of
contraindication of beta-blockers.

Research Question 6: Willingness to Prescribe and Prescribing Behavior
Descriptive statistics were performed to get the mean of willingness to prescribe,
for each of the conditions listed in the Section B of the survey. These were divided into
those conditions where beta-blockers should definitely be prescribed, as they definitely
provide benefits, conditions where they may be prescribed, as there is uncertainty about
their benefits to patients with these conditions, and conditions where they definitely
should not be prescribed as they do not provide benefits and can be harmful.
The conditions in the definitely prescribe category were: age greater than 50
years, large or anterior AMI, previous infarction, angioplasty, by-pass surgery, stroke,
hypertension, and complex ventricular ectopy. The conditions in the maybe prescribe
category were: age less than or equal to 50 years, small infarction, EF<40%, history of
CHF, systolic blood pressure <100Hg, heart rate <60bpm, LV failure, first degree AV
block, peripheral vascular disease, COPD, asthma, and IDDM. The conditions in the
definitely not prescribe category were: hypotension, bradycardia, second and third degree
AV block. Three scores were calculated by summations of the answers to the conditions
in each of these categories-the definitely prescribe score, the maybe prescribe score and
the definitely not prescribe score. The correlation of prescribing behavior calculated in
research question 5 with these three computed scores were estimated to determine the

99

association of prescribing behavior for beta-blockers as a secondary preventive agent
after an AMI and willingness to prescribe.

Research Question 7: Demographic and Practice Characteristics and Prescribing
Behavior
The association of prescribing percent/behavior calculated in research question 5
with demographic and practice characteristics such as age, gender, specialty, year of
board certification, location, type of primary practice site, number of beds (size of
hospital) and number of patients (both new and repeat) was investigated. Association of
prescribing percent with categorical variables such as gender, specialty, location, year of
board certification and type of primary practice site were evaluated using t-tests and Ftests. Association of prescribing percent with continuous variables such as age, size of
hospital, and number of patients (both new and repeat) was investigated using Pearson’s
correlations.

Research Question 8: Knowledge of Contraindications, Willingness to Prescribe and
Demographic and Practice Characteristics
The association of the three knowledge scores estimated in research question 5
and the three willingness to prescribe scores estimated in research question 6 with
demographic and practice characteristics such as age, gender, specialty, year of board
certification, location, type of primary practice site, number of beds (size of hospital) and
number of patients (both new and repeat) was investigated. Association of each
individual score with categorical variables such as gender, specialty, year of board
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certification, location, and type of primary practice site was evaluated using t-tests and Ftests. Association of each individual score with continuous variables such as age, size of
hospital, and number of patients (both new and repeat) was investigated using Pearson’s
correlations.

Research Question 9: Physician Characteristics and Prescribing Behavior
Association of all physician characteristics with prescribing behavior was
investigated using multiple regression analysis. The dependent variable was prescribing
percent calculated in research question 5. The independent variables were age, gender,
specialty, primary practice site, the three knowledge scores estimated in research question
5, the three willingness to prescribe scores estimated in research question 6, and number
of AMI patients treated (both new and repeat). Size of hospital, and location were not
investigated in this analysis as this question was answered by only those physicians who
reported their primary practice site as hospitals. Year of board certification was
excluded, as more than 33% of the respondents did not answer this question and inclusion
of this variable would decrease the number of cases in the analysis below the required
minimum for adequate power.

Research Question 10: Reasons for Not Prescribing Beta-Blockers
The reasons for not prescribing beta-blockers in post-AMI patients for secondary
prevention given by respondents were combined and enlisted.
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This chapter discussed in detail the methodology employed to fulfill the goals and
research questions of both phases I and II. In the next chapter, results of the analysis
conducted for accomplishing these will be presented.
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CHAPTER FOUR
RESULTS AND DISCUSSION

Earlier chapters of this text provided an overview of the effect of beta-blockers on
outcomes, the effect of physician knowledge on prescribing, need for study, and study
objectives. The methods employed to achieve these objectives were also outlined. This
chapter presents the findings of the study and discussion for the results obtained. Results
of phase I are presented first, followed by phase II in the second half of the chapter.

Phase I
Phase I of the study involved analyzing claims data for those patients who
suffered from an acute myocardial infarction (AMI) from January 1, 1997 to June 30,
2000. The purpose was to determine prescribing of beta-blockers as long-term therapy
following an AMI and effect of this prescribing on patient outcomes such as mortality,
morbidity, health care utilization, and costs.
Paid claims data relevant for the study were obtained from Consultec, Inc.
Consultec, Inc. stores data going back to several years. However, not all of this data was
pertinent to this study and so relevant data between January 1, 1996 to June 30, 2001 was
obtained to conduct the analysis. Table 1 outlines the extraction process from the raw
data. A total of 1,940 patients had a hospital claim for AMI and were continuously
eligible for one year before the AMI. Of these, 3 patients were excluded as they were
part of managed care. The next criterion was age limit. A total of 748 patients were
excluded, as they were older than 64 years of age. This also excluded the Medicare
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eligible patients. Those patients who had length of stay less than 3 days (indicating a
possible misdiagnosis) and those with ICD-9 (International Classification of Disease 9th
edition) codes of 410.x2 were excluded in the next step. This gave a cohort of 599
patients.
In this cohort there were some patients who had a recurrent AMI. In such
situations only the first AMI during the selected time frame was included. Additionally,
those patients who did not receive beta-blockers in the first 90 days after discharge from
the incident AMI but received a prescription after the first 90 days were excluded. The
reason being the objective of the study, which was to evaluate the effect of beta-blockers
when given long-term after an AMI according to American College of Cardiology
(ACC)/American Heart Association (AHA) guidelines. These patients did receive the
drug, but this was not according to the guidelines and inclusion of these patients would
lead to misclassification bias. A total of 20 patients were excluded because they died
during the incident AMI or within 30 days of the incident AMI. Thus, a total of 488
patients satisfied the inclusion criteria and were further investigated for beta-blocker use
and its effect on mortality. A total of 18 patients died due to causes not related to AMI.
These were excluded from the analysis that investigated effect of
appropriate/inappropriate beta-blocker use on cardiac deaths. From this cohort, 58
patients were excluded for investigating beta-blocker use and morbidity and health care
utilization, as they were not continuously eligible during the 12-month period after the
incident AMI. Thus, 412 patients satisfied all the inclusion criteria for evaluating betablocker use and its effect on morbidity and health care utilization following an AMI.
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Table 1: Cohort Selection
Inclusion Criteria

Patients Excluded

First extraction- patients
with AMI and
continuously eligible for
one year before AMI
Managed care recipients

Selected Cohort

1,940

3

1,937

Age > 64 years and
Medicare eligible patients

748

1,189

Length of Stay <3 days
and/or ICD-9 of 410.x2

590

599

Duplicates and received
beta-blockers after the
initial 90 days of discharge

91

508

Death during incident AMI
or within 30 days of
incident AMI

20

488 => final cohort for all
cause mortality

Death due to non-cardiac
causes

18

470 => final cohort for
death due to cardiac
mortality

58

412 => final cohort for
morbidity and utilization
related objectives

Continuously eligible for
one year after AMI
excluding those who died
within the year

AMI: Acute myocardial infarction, ICD-9: International classification of disease 9th edition
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Demographic and Medical History of Patients in Phase I
The demographic characteristics of the selected cohort is presented in Table 2.
The mean age of the cohort at incident AMI was 53.76 (S.D. + 8.14) years. More than
half (68.2%) were over the age of 50 years with majority between the age of 50 to 60
years. About one-third (31.7%) were below the age of 50, with 22.3% in the age group
of 40 to 50 years. This positive skewness in the age distribution confirms that AMI is an
elderly condition and is more prevalent in higher age groups. The study cohort consisted
of 246 males (50.4%), 238 females (48.8%) and 0.8% who did not report their gender and
were excluded. This is not consistent with the gender distribution of the Medicaid
population which is predominantly female (In the year 1999, the distribution of WV
Medicaid was 43:56, M:F). This could be due to the fact that AMI is more common
among males in this age group (below 65 years) compared to females. The majority of
the cohort (91.6%) was white, 4.1% were black and the remaining 4.3 % belonged to
other ethnic groups. This is characteristic of the West Virginia Medicaid population
which consists of a white majority (In the year 1999, 92% of the Medicaid recipients
were white).
Medical history and other characteristics of the selected cohort are represented in
Table 3. About 45% of the patients had hypertension, 37% were diabetic, and about 7%
had peripheral vascular disease. Approximately 20% of the patients had suffered from
congestive heart failure (CHF) in the year before the incident AMI and 28% had suffered
a previous AMI. A very small percent of patients had a previous coronary artery bypass
graft (CABG) (1.2%) and none had a previous percutaneous transluminal coronary
angioplasty (PTCA). Around 6% of the patients had suffered a stroke, and less than 1
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percent had renal dysfunction. Over 11% had some absolute contraindications and over
60% had some relative contraindications for beta-blocker use following an AMI. The
mean number of cardiac admissions and non-cardiac admissions in the previous year was
less than 1. However, the range was broader for non-cardiac admissions (0-5). The mean
number of different prescription drugs the patients were on was 10.49. Less than onethird of the patients were on medications associated with AMI such as calcium channel
blockers (31.6%), Angiotensin converting enzyme (ACE) inhibitors (29.1%), betablockers (22.7%), digoxin (12.3%), and anti-arrhythmics (2.5%), and in the six months
prior to the incident AMI. A very small number of the patients underwent a CABG
(10%) or PTCA (about 16%) during the incident AMI. The mean length of stay during
the incident AMI was 7 and the patients had an average of 4 secondary diagnoses at index
AMI. Among the discharge medications, about 64% were prescribed beta-blockers, 40%
were prescribed ACE-inhibitors, 38% were prescribed loop diuretics, 27% were
prescribed calcium channel blockers, and 12% were prescribed aspirin.
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Table 2: Demographic Characteristics of the Final Phase I Study Patients
Demographic
Characteristics

N

Percent

< 30 years

4

0.8

30 < to < 40 years

42

8.6

40 < to < 50 years

109

22.3

50 < to < 60 years

212

43.5

60 < to < 64 years

121

24.8

488

100.0

Age

Total
Average Age + S.D.

53.76 + 8.14

Gender
Males

246

50.4

Females

238

48.8

Unknown

4

0.8

Total

488

100.0

White

447

91.6

Black

20

4.1

Others

21

4.3

Total

488

100.0

Race

N: Number of patients, S.D: Standard deviation
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Table 3: Medical History and Other Characteristics
Characteristics*

N

Percent

Hypertension

221

45.3

Diabetes

179

36.7

Previous AMI

138

28.3

Previous CHF

97

19.9

Peripheral vascular disease

33

6.8

Previous stroke

30

6.1

Previous CABG

6

1.2

Renal dysfunction

4

0.8

Previous PTCA

0

0.0

Presence of relative contraindications

295

60.5

Presence of absolute contraindications

55

11.3

Calcium channel blockers

154

31.6

ACE inhibitors

142

29.1

Beta-blockers

111

22.7

Digoxin

60

12.3

Anti-arhythymics

12

2.5

77

15.8

Pre-AMI medications received

Procedures during the incident AMI
PTCA
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Table 3: Medical History and Other Characteristics (contd.)

Characteristics*

N

Percent

50

10.2

Beta-blockers

310

63.5

ACE-inhibitors

193

39.5

Loop diuretics

183

37.5

Calcium channel blockers

132

27.0

Aspirin

58

11.9

Mean (S.D.)

Min-Max

Number of cardiac admissions in the prior year

0.26 (0.44)

0-1

Number of non-cardiac admissions in the prior year

0.30 (0.68)

0-5

Number of different drugs in the prior six months

10.49 (7.18)

0-42

Length of stay during incident AMI

7.36 (4.49)

4-38

Number of secondary diagnosis at index AMI

4.17 (2.88)

1-9

CABG
Discharge Medications

N: Number of patients, AMI: Acute myocardial infarction, CHF: Congestive heart failure, CABG:
Coronary artery bypass graft surgery, PTCA: Percutaneous transluminal coronary angioplasty, ACE:
Angiotensin converting enzyme S.D: Standard deviation, Min: Minimum value, Max: Maximum value
*Medical history and presence of various conditions were determined using International classification of
disease-9th edition (ICD-9) codes, Common procedural terminology (CPT) codes and Diagnosis related
group (DRG) codes. Medication use was determined by using generic and National drug classification
(NDC) codes
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Results for Research Question 1
The first research question of the study was to determine prescribing patterns of betablocker therapy for secondary prevention following an AMI and to see whether it was
consistent with recommendations by AHA/ACC.
A total of 310 (63.5%) patients received beta-blocker prescription within 90 days
of discharge. When beta-blocker use was determined at the end of 30 days and 60 days
from discharge, the number of patients was lower with 282 (57.8%) receiving betablocker prescription at both occasions. For study purposes, beta-blocker use was defined
as a prescription of beta-blocker within 90 days of discharge from the incident AMI.
This allowed sufficient time to pass, after discharge, in case the patients received an
initial supply of medications with refill orders from the hospital during discharge for
which there would be no prescription record. Based on the presence or absence of
absolute contraindications to beta-blocker and presence of beta-blocker usage, the
patients were classified to those who received beta-blocker appropriately and those who
received beta-blocker inappropriately (See Figure 6). Thus, those who had the absolute
contraindications and received therapy were classified in the misuse category, and those
who did not have absolute contraindications and did not received therapy were classified
in the underuse category. Both misuse (5.7%) and underuse (30.9%) formed the
inappropriately prescribed category (36.7%). Similarly, those patients who did not have
absolute contraindications and received therapy (57.8%) and those who did have absolute
contraindications and did not receive therapy (5.5%) were classified as appropriately
prescribed (63.3%) (See Table 4).
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Univariate Analysis was conducted to see if the groups (appropriately prescribed
and inappropriately prescribed) were different from each other (Table 5). The two groups
were compared on the following variables: Age, gender, presence of diabetes, presence of
hypertension, presence of peripheral vascular disease, presence of renal dysfunction,
presence of previous AMI, CHF, stroke, previous CABG, presence of relative and
absolute contraindications, number of cardiac and non-cardiac admissions in the preperiod, number of drugs in the 6 months before AMI, procedures during incident AMI
(CABG, PTCA), length of stay during incident AMI, number of secondary diagnosis at
incident AMI and pre-AMI medication use (ACE inhibitors, anti-arrhythmic agents, betablockers, calcium channel blockers & digoxin,). T-tests were done for continuous
variables and chi-square analysis was performed for categorical variables. Among these
different variables, age, presence of hypertension, presence of absolute
contradindications, number of non-cardiac admissions in the pre period, and use of
digoxin, and beta-blockers in the pre-period were significantly different between the two
groups. The appropriate group was slightly younger, had more hypertensive patients, had
fewer patients with absolute contraindications, and fewer patients who had fewer noncardiac admissions in the pre-period as compared to the inappropriate group.
Additionally, the appropriate group had more patients who received prescriptions of betablockers but fewer patients who received prescriptions for digoxin in the pre-period
compared to the inappropriate group. Though not significant the appropriate group had
higher percentage of patients with stroke and previous CABG compared to the
inappropriate group.
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A logistic regression analysis was conducted to predict assignment of patients to
the appropriate and inappropriate group. Those variables that were significant in the
univariate analysis were used as independent variables. Thus, the independent variables
included were age, presence of hypertension, presence of absolute contraindications,
number of non-cardiac admissions in the pre-period, use of digoxin, and beta-blockers in
the pre-period. Table 6 represents results of this analysis. The model was significant (χ2
= 58.003, p = 0.000, n = 488) with an R2 of 15.3% and 67.42% correct classification.
Five of the six independent variables were significant predictors of group status. These
were age, hypertension, presence of absolute contraindications, number of non-cardiac
admissions in the pre-period, and use of beta-blockers in the pre-period. Those who were
hypertensive were almost twice as likely to belong to the appropriate group, whereas
those who received beta-blockers in the pre-period were 2.6 times more likely to belong
to the appropriate group. Older patients, those with absolute contraindications and those
with more non-cardiac admissions in the pre-period were more likely to belong to the
inappropriate group. The predicted value of this regression or propensity score, was
utilized in future analysis as a co-variate to reduce bias due to the differences between the
two groups.
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Figure 6: Appropriate/Inappropriate Use of Beta-blockers

Presence of
Absolute Contraindications
Yes

No

Beta-blocker
Use
Yes

Misuse

Appropriate use I

No

Appropriate use II

Under use
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Table 4: Prescription Patterns for Beta-blocker Use
Category

N

Percent

309

63.3

Appropriate use I

282

57.8

Appropriate use II

27

5.5

179

36.7

Under use

151

30.9

Misuse

28

5.7

488

100.0

Appropriate use

Inappropriate Use

Total

N: Number of patients
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Table 5: Univariate Comparisons between the Two Groups
Variables

Appropriate
Group %

Inappropriate
Group %

Test
Statistic

Significance
(p)

Age Mean (S.D.)

52.72 (8.58)

55.56 (7.00)

t = 3.975

0.000*

χ2 = 0.215

0.643

Gender
Males

51.6

49.4

Females

48.4

50.6

Diabetes

35.3

39.1

χ2 = 0.716

0.397

Hypertension

50.5

36.3

χ2 = 9.188

0.002*

Peripheral vascular
disease

6.8

6.7

χ2 = 0.002

0.969

Renal dysfunction

1.0

0.6

χ2 = 0.237

0.626

Previous AMI

29.1

26.8

χ2 = 0.298

0.585

Previous CHF

19.1

21.2

χ2 = 0.324

0.569

Previous Stroke

7.1

4.5

χ2 = 1.380

0.240

Previous CABG

1.6

0.6

χ2 = 1.048

0.306

Presence of relative
contraindications

59.2

62.6

χ2 = 0.531

0.466

Presence of absolute
contraindications

8.7

15.6

χ2 = 5.403

0.020*

Number of cardiac
admissions Mean
(S.D.)

0.28 (0.45)

0.23 (0.42)

t = 1.215

0.225

Number of noncardiac admissions
Mean (S.D.)

0.24 (0.61)

0.40 (0.78)

t = 2.454

0.015*
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Table 5: Univariate Comparisons between the Two Groups (contd.)

Variables

Appropriate
Group %

Inappropriate
Group %

Test
Statistic

Significance
(p)

Number of different
drugs in the prior six
months Mean (S.D.)

10.66 (7.51)

10.20 (6.56)

t = 0.694

0.488

CABG

10.0

10.6

χ2 = 0.046

0.838

PTCA

17.2

13.4

χ2 = 1.196

0.274

Length of stay Mean
(S.D.)

7.20 (4.63)

7.65 (4.23)

t = 1.083

0.280

Number of secondary
diagnosis Mean
(S.D.)

4.30 (2.89)

3.95 (2.85)

t = 1.299

0.194

ACE inhibitors

28.2

30.7

χ2 = 0.363

0.547

Anti-arhythymics

2.9

1.7

χ2 = 0.723

0.395

Beta-blockers

28.8

12.3

χ2 = 17.586

0.000*

Calcium channel
blockers

31.7

31.3

χ2 = 0.010

0.921

Digoxin

10.0

16.2

χ2 = 4.000

0.046*

Pre-AMI medications
received:

* Significant at p < 0.05, S.D: Standard deviation, AMI: Acute myocardial infarction, CHF: Congestive
heart failure, CABG: Coronary artery bypass graft, PTCA: Percutaneous transluminal coronary
angioplasty, ACE: Angiotensin converting enzyme

117

Table 6: Predictors for Appropriate/Inappropriate Group
Predictor

Estimate

S.E.

Odds Ratio

Significance

Age

-0.0529

0.0135

0.9484

0.000*

Hypertension

0.6420

0.2074

1.9002

0.002*

Presence of absolute
contraindications

-0.7914

0.3056

0.4532

0.009*

Number of non-cardiac
admissions

-0.4317

0.1478

0.6494

0.003*

Digoxin

-0.3000

0.3010

0.7408

0.318

Beta-blockers

0.9916

0.2723

2.6956

0.003*

Pre-AMI medications:

R2 = 15.3% (χ2 = 58.003, p = 0.000), n = 488
* Significant at p < 0.05, S.E: Standard error, AMI: Acute myocardial infarction
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Discussion for Research Question 1
An analysis of the data revealed that there was inappropriate utilization of betablockers as secondary preventive agents following an AMI. Compared to previous
studies where the utilization among eligible patients ranged from 30-40%, this study
revealed a utilization of almost 64% (Rogers et al., 2000; Krumholz et al., 1998 &
Soumerai et al., 1997). This was also higher compared to the utilization levels reported
recently in a Medicare population in the state of West Virginia, the same state as the
study state, where only 59.4% received therapy at discharge (Schade et al., 2002). Thus,
there appears to be an increase in utilization of beta-blockers among eligible patients over
time. This confirms previous reports of steady rise in average use over years reported by
Heller et al., (39.6% to 58.6%, 2000) and Pilote et al., (33% to 50%, 2000). Thus,
physicians are responding to the increase in awareness about the beneficial effects of
beta-blockers for AMI patients. The results also demonstrated a 5.7% use among patients
with absolute contraindications. This proportion is smaller than that reported in previous
studies, where it was 11% (Brand et al., 1995) and 24% (Sial et al., 1994). A subanalysis was conducted to investigate the distribution of age in the misuse, under use and
appropriate use categories. This study confirmed the association of age with beta-blocker
use as reported in previous studies (Fishkind et al., 1997 ;Gurwitz et al., 1992). Even in
this younger population, the under use group was older (56.1 years) than the appropriate
use (52.7 years) and misuse groups (52.7 years) and this was statistically significant (F =
9.29, p < 0.0001). Thus, though this study revealed an increase in use of beta-blocker
therapy in post AMI patients, there is still room for improvement in patients in whom it
would maximize benefits.
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A comparison of the two groups classified for study purposes revealed that they
were different from each other on a few variables. However, this could not help identify
which group was more severely ill between the appropriate and inappropriate. A
multivariate comparison revealed that five of these variables were significant predictors
of group status. These include- age, hypertension, presence of absolute contraindications,
number of non-cardiac admission in pre-period, and use of beta-blockers in the preperiod. Patients who were older, had presence of absolute contraindications, and had a
greater number of non-cardiac admissions were in the inappropriate group, whereas
patients with hypertension and pre-beta-blocker use were in the appropriate group.

Results for Research Question 2
Kaplan-Meier survival curves were constructed to investigate effect of
appropriate and inappropriate prescribing of beta-blocker therapy on mortality for the
selected patients in the first-year after the incident AMI. Two separate analyses were
conducted. The first included death due to all causes and the second included death due
to cardiac causes. Figure 7 illustrates the all-cause death curves and Figure 8 illustrates
the cardiac-cause death curves. The two groups (appropriate and inappropriate) differed
significantly for survival at the end of the one-year period (Log Rank Statistic = 4.44, p =
0.0351). The appropriate group had a better survival distribution compared to the
inappropriate group. An investigation of only cardiac deaths revealed better survival
distribution for the appropriate group too (Figure 8), however this was not statistically
significant (Log Rank Statistic = 1.35, p = 0.245).
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The different causes of deaths are displayed in Table 7. The non-cardiac deaths
were not related to AMI and were mostly due to cancer or diabetes. A majority of the
cardiac deaths were due to coronary artery disease (CAD) and acute myocardial
infarction (AMI). A frequency of cardiac deaths by group is represented in Table 8. This
shows that there were more deaths due to AMI in the inappropriate group. Power
analysis revealed that time to all cause death analysis had a power of 88% whereas time
to cardiac death had a power of 46%. The numbers of deaths in the two groups were
investigated by chi-square analysis. The results were similar to the survival analysis,
with the difference between the two groups being significant for all cause deaths and not
significant for cardiac-cause deaths (Table 9). Additionally, the groups were compared
for deaths due to an AMI. Even though the percentage was higher in the inappropriate
group this was not statistically significant. When analysis was repeated using betablocker prescribing at 30 and 60 days after the AMI to categorize appropriate and
inappropriate prescribing, the results for both all-cause and cardiac mortality did not
change.
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Figure 7: Kaplan-Meier Survival Curves (all-cause deaths) for
Appropriate/Inappropriate Use of Beta-blockers
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Figure 8: Kaplan-Meier Survival Curves (cardiac deaths) for
Appropriate/Inappropriate Use of Beta-blockers
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Table 7: Causes of Death
Non-cardiac Causes (n = 15)

Cardiac Causes (n = 16)

Accident (1)

Coronary arteriosclerosis (5)

AIDS (1)

Dysrhythmia (1)

Cancer of trachea, lung, and bronchi (4)

Heart disease, unspecified (1)

Chronic obstructive pulmonary disease (1)

Ischemia (1)

Diabetes (4)

Acute myocardial infarction (8)

End stage renal disease (1)
Injury to peripheral nerves (1)
Kidney disorder (1)
Pulmonary embolism (1)
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Table 8: Cardiac Deaths by Group
Appropriate Use (8)

Inappropriate Use (8)

Coronary arteriosclerosis (3)

Coronary arteriosclerosis (2)

Dysrhythmia (1)

Heart disease (1)

Ischemia (1)

Acute myocardial infarction (5)

Acute myocardial infarction (3)
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Table 9: Patient Deaths by Group Status
Mortality

Percent

All Cause Death
Appropriate use

4.5

Inappropriate use

9.5

Cardiac Death
Appropriate use

2.7

Inappropriate use

4.7

Death due to AMI
Appropriate use

1.0

Inappropriate use

2.9

* Significant at p < 0.05, AMI: Acute myocardial infarction
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χ2 Statistic

Significance

4.699

0.030*

1.370

0.241

2.444

0.118

Discussion for Research Question 2
There was a significant relationship between beta-blocker receipt among eligible
patients for secondary prevention after an AMI and all cause mortality. Thus, null
hypothesis A is rejected. The appropriate group had a significantly better distribution of
survival in the year after the AMI. This is consistent with the information associated with
both clinical trials and observational studies in this area (Soumerai et al., 1997; Bradford
et al., 1999). However, beta-blockers have been reported to reduce cardiac mortality by
reduction in re-infarction rates and sudden death (Goldsetin, 1996). The chi-square test
that investigated this relationship between cardiac mortality and beta-blocker use was not
significant. Though the numbers were in favor of appropriate use of beta-blocker
therapy, statistical significance was not observed. Thus, the null hypothesis B is not
rejected. There could be two reasons for this observation. First, the number of patients
in this cohort is small, thus the analysis did not have sufficient power to achieve
statistical significance compared to previous studies that involved large numbers of
patients. Soumerai et al., (1997) had a cohort of almost 4,000 patients and Krumholz et
al., (1998) involved greater than 45,000 patients. The second more important reason is
the fact that this study was conducted in a relatively younger population, in which the
average age was less than 54 years compared to previous retrospective studies. Thus,
intuitively, the probability of death in a younger patient due to AMI would be smaller
compared to an older patient greater than 65 years old, and thus this population probably
had lower death rates, which did not achieve significance. However, even in this younger
population, appropriate use of beta-blocker had a lower proportion of cardiac deaths,
compared to the inappropriate group.
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An important fact to consider is that some of the deaths that were excluded when
cardiac mortality was investigated were associated with diabetes. Diabetes can be an
underlying cause for death but not the actual cause of death, unless it is type I diabetes
where acute coma is the leading cause of death (NIH, 1995). The majority of deaths in
type II diabetics is due to heart disease (NIH, 1995). Additionally, one of the excluded
death was due to an accident. A patient with a previous AMI is more likely to die of an
AMI during an accident compared to other causes. Also, another death excluded was due
to pulmonary embolism. Pulmonary embolism is one of the complications associated
with an AMI (Ahdout, Damani, & Ultan, 1989). However, a pulmonary embolism can be
due to other causes too (Carson et al., 1992). Hence, this death had to be excluded. The
information obtained from vital statistics for death is for record purposes and not research
purposes. More detailed information about death would probably be helpful in getting
the true cause of death. Thus, this identifies using death information from Vital Statistics
as a limitation for determining true cause of death.

Results for Research Question 3
Morbidity between the two groups was compared via Kaplan-Meier survival
curves too. However, the dependent variable was time to first hospitalization due to a
cardiovascular event from the date of discharge. Here cardiovascular event was defined
as first hospitalization due to various conditions related to AMI (See Table 10). This
revealed a statistical significant difference in the distribution for the dependent variable
by group. The inappropriate group had a better distribution with fewer events compared
to the appropriate group (Long rank statistic = 5.42, p = 0.0199, Figure 9). This analysis
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had a power of 75.5%. When the number of patients was compared, this was also
statistically significant (Table 11). However, when similar analysis was repeated for
recurrent AMI, both distribution and number were not significant (Figure 10, Table 11).
The significant survival analysis of time to event was followed with Coxproportional hazard’s regression model to adjust for patient conditions in the form of covariates. Two models were run, the first one used those variables which were significant
predictors of group status (appropriate/inappropriate) as co-variates in addition to some
of the identified variables associated with the incident AMI and post-AMI care. The
second model used the propensity score calculated as the predicted probability for group
status in analysis of research question 1 and the identified variables associated with the
incident AMI and post-AMI care.
The first model revealed that survival distribution was significant by group status
even after adjusting for the various co-variates. The hazards ratio (HR) for the group was
2.00, implying that the hazard for the appropriate group was almost two times the hazard
for the inappropriate group to suffer from the defined cardiovascular event (Table 12).
Some of the other co-variates which were significant in this model were number of noncardiac admissions in the pre-period (HR = 1.44), use of beta-blockers in the pre-period
(HR = 1.47), CABG during incident AMI (HR = 0.39), and length of stay during incident
AMI (HR = 1.04). Days supply of beta-blockers in the follow-up period was almost
significant (HR = 0.99, p = 0.06). Thus, those with greater length of stay during incident
AMI, pre-period beta-blocker use, and greater number of hospitalization in the pre-period
were more likely to suffer from a cardiac event, whereas those who underwent CABG
during incident AMI were less likely to suffer from a cardiac event. Also, days supply
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though not statistically significant was associated with lower morbidity. The second
model also revealed that survival distribution was significant by group (Table 13). Here
the HR for group was 1.98, and two other variables CABG during incident AMI and
length of stay during incident AMI were significant. Thus, results did not change much
using propensity score analysis. When analysis was repeated using beta-blocker
prescribing at 30 and 60 days after the AMI to categorize appropriate and inappropriate
prescribing, the results for morbidity did not change.
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Table 10: Cardiovascular Events for Morbidity
Conditions for Morbidity

Angina
Cardiogenic shock
Cardiomyopathy
Conduction disorders
Disease of endocardium
Essential hypertension
Heart failure
Ischemia
Ischemic heart disease
Acute myocardial infarction
Stroke
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Figure 9: Kaplan-Meier Survival Morbidity Curves (time to first cardiovascular
hospitalization) for Appropriate/Inappropriate Use of Beta-blockers
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Figure 10: Kaplan-Meier Survival Morbidity Curves (time to recurrent AMI) for
Appropriate/Inappropriate Use of Beta-blockers
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Table 11: Cardiac Events by Group Status
Events

Percent

All Cardiac Events
Appropriate use

47.3

Inappropriate use

37.2

Recurrent Myocardial Infarction
Appropriate use

18.4

Inappropriate use

14.1

* Significant at p < 0.05
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χ2 Statistic

Significance

4.013

0.045*

1.260

0.262

Table 12: Cox-Proportional Regression Model for Time to First Cardiac Event
Predictor

Estimate

S.E.

Hazard’s Ratio Significance

Age

0.0076

0.0105

1.0079

0.449

Sex

0.0857

0.1621

1.0895

0.597

Appropriate/Inappropriate use
of Beta-blockers at post-AMI

0.6931

0.2454

2.000

0.004*

Hypertension

-0.1201

0.1658

0.8869

0.469

Presence of absolute
contraindications

-0.0591

0.2630

0.9426

0.822

Number of non-cardiac
admissions

0.3675

0.0979

1.4441

0.000*

0.3856

0.1927

1.4705

0.045*

CABG

-0.9253

0.3275

0.3964

0.004*

PTCA

-0.2361

0.2293

0.7897

0.303

Length of stay

0.0362

0.0171

1.0369

0.034*

Aspirin

0.0716

0.2397

1.0742

0.765

ACE-inhibitors

0.1498

0.1614

1.1617

0.353

Calcium channel
blockers

0.0639

0.1684

1.0660

0.704

Loop diuretics

0.1531

0.1695

1.1654

0.366

0.0252

0.3099

1.0256

0.935

Pre-AMI medications:
Beta-blockers
Procedures during the
incident AMI

Discharge Medications

Medication Possession Ratio
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Table 12: Cox-Proportional Regression Model for Time to First Cardiac Event
(contd.)

Predictor

Estimate

S.E.

Hazard’s Ratio Significance

Day supply

-0.0014

0.0007

0.9987

0.061+

-2LL = 1989.8 (χ2 = 47.89, p = 0.000*), n = 408
* Significant at p < 0.05, + Significant at p < 0.01, S.E: Standard error, AMI: Acute myocardial infarction,
CABG: Coronary artery bypass graft, PTCA: Percutaneous transluminal coronary angioplasty, ACE:
Angiotensin converting enzyme inhibitor
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Table 13: Cox-Proportional Regression Model for Time to First Cardiac Event
using Propensity Score
Predictor

Estimate

S.E.

Hazard’s Ratio Significance

Age

-0.0063

0.0124

0.9937

0.609

Sex

-0.0110

0.1587

0.9890

0.944

Appropriate/Inappropriate use
of Beta-blockers at post-AMI

0.6844

0.2455

1.9826

0.005*

Propensity score

-0.8823

0.6585

0.4138

0.180

Presence of absolute
contraindications

-0.2401

0.2774

0.7866

0.386

CABG

-0.9348

0.3239

0.3927

0.003*

PTCA

-0.3421

0.2261

0.7102

0.130

Length of stay

0.0333

0.0168

1.0339

0.047*

Aspirin

0.0420

0.2374

1.0429

0.859

ACE-inhibitors

0.1529

0.1605

1.1652

0.340

Calcium channel
blockers

0.1497

0.1671

1.1615

0.370

Loop diuretics

0.2045

0.1681

1.2269

0.223

Medication Possession Ratio

0.0239

0.3094

1.0241

0.938

Day supply

-0.0011

0.0006

0.9989

0.126

Procedures during the
incident AMI

Discharge Medications

-2LL = 2003.3 (χ2 = 34.704, p = 0.001*), n = 408
* Significant at p < 0.05, S.E: Standard error, AMI: Acute myocardial infarction, CABG: Coronary artery
bypass graft, PTCA: Percutaneous transluminal coronary angioplasty, ACE: Angiotensin converting
enzyme inhibitor
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Discussion for Research Question 3
The above analysis rejected the null hypothesis C that there was no significant
relationship between appropriate use and inappropriate prescribing of beta-blockers and
morbidity (time to first hospitalization due to a cardiovascular event). Thus, there was an
association, but unlike mortality this association revealed that appropriate use was
associated with a higher probability of a cardiovascular event in the post AMI 12-month
period as compared to the inappropriate group. When the event was restricted to
recurrent AMI, though the distribution was not significant, the survival curves illustrated
that the association was similar to when all cardiac events were considered. The Coxproportional hazards model confirmed this association even after adjusting for all covariates. Appropriate beta-blocker use was still associated with greater morbidity.
Additionally, the first model, where the co-variates included predictors of
appropriate/inappropriate group, days supply was almost significant and was negatively
associated with morbidity. This illustrates a conflict (appropriate use is associated with
greater morbidity, but higher days supply is associated with lower morbidity). Thus,
although there is a definite association between appropriate/inappropriate prescribing and
morbidity, the above results do not clearly help interpret this association.

Results for Research Question 4
Utilization of services between the two groups was compared by exploring
whether there was any difference in the number of hospitalizations, number of ER visits,
number of physician visits, total length of stay, total charges and total reimbursed
amounts in the follow-up period due to cardiac conditions. The descriptive statistics for
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these are listed in Table 14. The cardiac conditions were the same as those specified in
Table 10. Two multiple regression models were performed for each of the utilization
variables. The first model included those co-variates that were significant in predicting
group status for appropriate/inappropriate beta-blocker receipt in addition to other covariates. The second model included propensity score instead of these predicting
variables with other co-variates. The total charges and total reimbursed amounts
variables were log transformed to decrease skewness of the data. The following
utilization models were significant: number of hospital visits (both models), number of
ER visits (both models), number of physicians visits (only the first model), length of stay
(both models), log total charges (both models), and log total reimbursed amounts (both
models) (Tables 15-26). The R2 values for the significant models ranged between 6 to
14%. Thus, there was a lot of variance in the utilization variables that could not be
explained by the independent variables. For interpretation of semilogarithmic models,
the correction of Halverson and Palmquist with a modification by Kennedy was
employed (Halverson, & Palmquist, 1980; Kennedy, 1981). All models were checked for
violation of assumptions associated with linear regression. The models had no problems
with multicollinearity, heteroskedasticity and autocorrelation. The power of analysis for
the models was 100%. For these models, the variables that were significant in predicting
the utilization variables are listed below:

Number of Hospital visits due to Cardiac Conditions (Group when significant is in bold):
First Model (Table 15): Appropriate/Inappropriate group of beta-blocker at
post AMI, Number of non-cardiac admissions, Use of beta-blockers in the preperiod, CABG during incident AMI, and Length of stay during incident AMI.
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Propensity Score Model (Table 16): Appropriate/Inappropriate group of betablocker at post AMI, CABG during incident AMI, and Length of stay during
incident AMI.

Number of ER visits due to Cardiac Conditions:
First Model (Table 17): Appropriate/Inappropriate group of beta-blocker at
post AMI, Presence of absolute contraindications, Number of non-cardiac
admissions, Use of beta-blockers in the pre-period, and Medication possession
ratio (MPR).

Propensity Score Model (Table 18): Appropriate/Inappropriate group of betablocker at post AMI, Presence of absolute contraindications, and MPR.

Number of Physician visits due to Cardiac Conditions:
First Model (Table 19): Presence of hypertension, Number of non-cardiac
admissions, and Use of beta-blockers in the pre-period.

Propensity Score Model (Table 20, model not significant): Presence of absolute
contraindications during or before incident AMI.

Length of Stay due to Cardiac Conditions:
First Model (Table 21): Appropriate/Inappropriate group of beta-blocker at
post AMI, Number of non-cardiac admissions, Use of beta-blockers in the preperiod, CABG during incident AMI, Length of stay during incident AMI, and
Days supply.

Propensity Score Model (Table 22): Appropriate/Inappropriate group of betablocker at post AMI, CABG during incident AMI, Length of stay during
incident AMI, and Days supply.
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Log Total Charges due to Cardiac Conditions:
First Model (Table 23): CABG during incident AMI.

Propensity Score Model (Table 24): CABG during incident AMI.

Log Total Reimbursed Amounts due to Cardiac Conditions:
First Model (Table 25): CABG during incident AMI and Length of stay during
incident AMI.

Propensity Score Model (Table 26): CABG during incident AMI and Length of
stay during incident AMI.

Appropriate/inappropriate use of beta-blockers post AMI was a significant predictor in
some of the utilization variable models. It was a significant predictor for number of
hospitalizations in the follow-up period, number of ER visits in the follow-up period, and
length of stay in the follow-up period due to cardiac conditions. It did not affect the
number of physician visits, charges and reimbursed amounts. Additionally, for the
variables where it was significant, the beta coefficients in the models were positive,
suggesting increased utilization of health care services for the appropriate group. Among
the other significant predictors, higher number of non-cardiac admissions in the preperiod were associated with higher utilization, use of beta-blockers in the pre-period was
associated with higher utilization, presence of any absolute contraindication was
associated with higher utilization except for physicians visits where it was associated
with lower utilization. Presence of hypertension was associated with fewer physician
visits, CABG during incident AMI was associated with lower utilization but higher
expenditures, longer length of stay during incident AMI was associated with lower
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utilization but higher expenditures, compliance variable (MPR) was associated with
lower utilization and days supply was also associated with lower utilization. Propensity
score was not significant in any of the models and use of propensity score did not affect
significance of other variables. When analysis was repeated using beta-blocker
prescribing at 30 and 60 days after the AMI to categorize appropriate and inappropriate
prescribing, the results for utilization and expenditures did not change.
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Table 14: Utilization Variables
Mean +S.D.

Range

Number of Hospital Visits

0.86+1.54

0-11

Number of ER Visits

0.23+0.88

0-12

Number of Physicians Visits

6.63+9.62

0-64

Length of Stay

4.65+9.77

0-70

Total Charges

$17,258.50+33,146.57

0-3,14,066.70

Total Reimbursed Amounts

$15,609.00+30,573.02

0-2,77,218.00

Variables

ER: Emergency room, S.D: Standard deviation
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Table 15: Predictors for Number of Hospital Visits due to Cardiac Conditions
Predictor

Estimate

S.E.

t-Statistic

Significance

Age

-0.003

0.010

0.368

0.713

Sex

-0.013

0.152

-0.087

0.931

Appropriate/Inappropriate use
of beta-blockers at post-AMI

0.829

0.228

3.627

0.000*

Hypertension

-0.180

0.155

-1.162

0.246

Presence of absolute
contraindications

0.127

0.242

0.525

0.600

Number of non-cardiac
admissions

0.500

0.118

4.244

0.000*

0.486

0.189

2.575

0.010*

CABG

-0.647

0.260

-2.489

0.013*

PTCA

0.0007

0.205

0.004

0.997

Length of stay

-0.043

0.020

2.224

0.027*

Aspirin

-0.168

0.231

-0.725

0.469

ACE-inhibitors

0.128

0.157

0.816

0.415

Calcium channel
blockers

0.075

0.167

0.456

0.649

Loop diuretics

0.225

0.165

1.366

0.173

-0.129

0.309

-0.419

0.676

Pre-AMI medications:
Beta-blockers
Procedures during the incident
AMI

Discharge Medications

Medication Possession Ratio
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Table 15: Predictors for Number of Hospital Visits due to Cardiac Conditions
(contd.)

Predictor

Estimate

S.E.

t-Statistic

Significance

Days supply

-0.001

0.001

-1.503

0.134

R2 = 13.5 %(F = 3.798, p = 0.000*), n = 407
* Significant at p < 0.05, S.E: Standard error, AMI: Acute myocardial infarction, CABG: Coronary artery
bypass graft, PTCA: Percutaneous transluminal coronary angioplasty, ACE: Angiotensin converting
enzyme inhibitor
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Table 16: Predictors for Number of Hospital Visits due to Cardiac Conditions using
Propensity Score
Predictor

Estimate

S.E.

t-Statistic

Significance

Age

-0.007

0.012

-0.611

0.542

Sex

-0.096

0.156

-0.622

0.534

Appropriate/Inappropriate use of
beta-blockers at post-AMI

0.799

0.232

3.437

0.001*

Propensity score

-0.650

0.625

-1.039

0.299

Presence of absolute
contraindications

-0.026

0.267

-0.101

0.920

CABG

-0.679

0.267

-2.548

0.011*

PTCA

-0.111

0.209

-0.532

0.595

Length of stay

-0.045

0.020

2.268

0.024*

Aspirin

-0.215

0.237

-0.909

0.364

ACE-inhibitors

0.093

0.160

0.588

0.557

Calcium channel blockers

0.177

0.169

1.047

0.296

Loop diuretics

0.270

0.169

1.593

0.112

Medication Possession Ratio

-0.143

0.317

-0.450

0.653

Days supply

-0.0008

0.001

-1.114

0.266

Procedures during the incident
AMI

Discharge Medications

R2 = 8.3 %(F = 2.529, p = 0.002*), n = 407
* Significant at p < 0.05, S.E: Standard error, AMI: Acute myocardial infarction, CABG: Coronary artery
bypass graft, PTCA: Percutaneous transluminal coronary angioplasty, ACE: Angiotensin converting
enzyme inhibitor

146

Table 17: Predictors for Number of ER Visits due to Cardiac Conditions
Predictor

Estimate

S.E.

t-Statistic

Significance

Age

-0.006

0.006

-1.188

0.236

Sex

-0.096

0.090

-1.071

0.285

Appropriate/Inappropriate use
of beta-blockers at post-AMI

0.470

0.135

3.484

0.001*

Hypertension

-0.037

0.091

-0.414

0.679

Presence of absolute
contraindications

0.320

0.143

2.242

0.026*

Number of non-cardiac
admissions

0.155

0.070

2.233

0.026*

0.220

0.111

1.977

0.049*

CABG

-0.057

0.153

-0.376

0.707

PTCA

0.095

0.121

0.794

0.427

Length of stay

-0.003

0.012

-0.271

0.786

Aspirin

-0.049

0.137

-0.361

0.718

ACE-inhibitors

-0.064

0.093

-0.693

0.489

Calcium channel
blockers

-0.0006

0.098

-0.007

0.994

Loop diuretics

0.165

0.097

1.697

0.090

-0.474

0.182

-2.598

.010*

Pre-AMI medications:
Beta-blockers
Procedures during the incident
AMI

Discharge Medications

Medication Possession Ratio
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Table 17: Predictors for Number of ER Visits due to Cardiac Conditions (contd.)

Predictor

Estimate

S.E.

t-Statistic

Significance

Days supply

-0.00004

0.000

0.095

0.924

R2 = 8.5 %(F = 2.276, p = 0.003*), n = 407

* Significant at p < 0.05, ER: Emergency room, S.E: Standard error, AMI: Acute myocardial infarction,
CABG: Coronary artery bypass graft, PTCA: Percutaneous transluminal coronary angioplasty, ACE:
Angiotensin converting enzyme inhibitor
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Table 18: Predictors for Number of ER Visits due to Cardiac Conditions using
Propensity Score
Predictor

Estimate

S.E.

t-Statistic

Significance

Age

0.008

0.007

-1.197

0.232

Sex

-0.125

0.090

-1.380

0.168

Appropriate/Inappropriate use of
beta-blockers at post-AMI

0.460

0.135

3.417

0.001*

Propensity score

-0.006

0.363

-0.017

0.987

Presence of absolute
contraindications

0.306

0.155

1.980

0.048*

CABG

-0.071

0.155

-0.464

0.643

PTCA

0.055

0.121

0.462

0.644

Length of stay

-0.002

0.012

-0.200

0.842

Aspirin

-0.067

0.137

-0.494

0.621

ACE-inhibitors

-0.076

0.093

-0.827

0.408

Calcium channel blockers

0.035

0.098

0.367

0.714

Loop diuretics

0.184

0.098

1.869

0.062

Medication Possession Ratio

-0.481

0.184

-2.619

0.009*

Days supply

0.0001

0.000

0.332

0.740

Procedures during the incident
AMI

Discharge Medications

R2 = 6.4 %(F = 1.935, p = 0.022*), n = 407
* Significant at p < 0.05, ER: Emergency room, S.E: Standard error, AMI: Acute myocardial infarction,
CABG: Coronary artery bypass graft, PTCA: Percutaneous transluminal coronary angioplasty, ACE:
Angiotensin converting enzyme inhibitor
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Table 19: Predictors for Number of Physician Visits due to Cardiac Conditions
Predictor

Estimate

S.E.

t-Statistic

Significance

Age

0.008

0.062

-0.136

0.892

Sex

-0.603

0.980

-0.615

0.539

Appropriate/Inappropriate use
of beta-blockers at post-AMI

2.406

1.469

1.639

0.102

Hypertension

-1.995

0.995

-2.004

0.046*

Presence of absolute
contraindications

-2.984

1.554

-1.920

0.056

Number of non-cardiac
admissions

2.248

0.757

2.968

0.003*

2.885

1.213

2.379

0.018*

CABG

-3.061

1.671

-1.831

0.068

PTCA

-1.560

1.313

-1.186

0.236

Length of stay

0.061

0.127

0.489

0.625

Aspirin

-1.837

1.487

-1.235

0.217

ACE-inhibitors

0.570

1.010

0.564

0.573

Calcium channel
Blockers

0.250

1.071

0.234

0.815

Loop diuretics

0.070

1.060

-0.066

0.947

1.999

1.987

1.006

0.315

Pre-AMI medications:
Beta-blockers
Procedures during the
incident AMI

Discharge Medications

Medication Possession Ratio
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Table 19: Predictors for Number of Physician Visits due to Cardiac Conditions
(contd.)

Predictor

Estimate

S.E.

t-Statistic

Significance

Days supply

-0.008

0.005

-1.924

0.055

R2 = 8.6 %(F = 2.299, p = 0.003*), n = 407
* Significant at p < 0.05, S.E: Standard error, AMI: Acute myocardial infarction, CABG: Coronary artery
bypass graft, PTCA: Percutaneous transluminal coronary angioplasty, ACE: Angiotensin converting
enzyme inhibitor
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Table 20: Predictors for Number of Physician Visits due to Cardiac Conditions
using Propensity Score
Predictor

Estimate

S.E.

t-Statistic

Significance

Age

-0.052

0.074

-0.706

0.480

Sex

-0.883

0.991

-0.891

0.374

Appropriate/Inappropriate use of
beta-blockers at post-AMI

1.977

1.481

1.335

0.183

Propensity score

-1.941

3.984

-0.487

0.626

Presence of absolute
contraindications

-3.571

1.698

-2.103

0.036*

CABG

-3.139

1.699

-1.848

0.065

PTCA

-2.140

1.330

-1.609

0.108

Length of stay

0.071

0.129

0.552

0.581

Aspirin

-2.044

1.510

-1.353

0.177

ACE-inhibitors

0.194

1.017

0.191

0.849

Calcium channel blockers

0.641

1.078

0.594

0.553

Loop diuretics

0.231

1.079

0.214

0.831

Medication Possession Ratio

2.027

2.020

1.003

0.316

Days supply

-0.007

0.005

-1.554

0.121

Procedures during the incident
AMI

Discharge Medications

R2 = 4.9 %(F = 1.441, p = 0.131), n = 407
* Significant at p < 0.05, S.E: Standard error, AMI: Acute myocardial infarction, CABG: Coronary artery
bypass graft, PTCA: Percutaneous transluminal coronary angioplasty, ACE: Angiotensin converting
enzyme inhibitor
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Table 21: Predictors for Length of Stay due to Cardiac Conditions
Predictor

Estimate

S.E.

t-Statistic

Significance

Age

0.055

0.062

0.890

0.374

Sex

-0.173

0.977

-0.177

0.859

Appropriate/Inappropriate use
of beta-blockers at post-AMI

3.417

1.464

2.334

0.020*

Hypertension

-0.427

0.992

-0.430

0.667

Presence of absolute
contraindications

0.785

1.549

0.506

0.613

Number of non-cardiac
admissions

1.695

0.755

2.245

0.025*

2.343

1.209

1.939

0.053*

CABG

-5.510

1.666

-3.307

0.001*

PTCA

-1.200

1.311

-0.915

0.361

Length of stay

0.425

0.126

3.368

0.001*

Aspirin

0.316

1.483

0.213

0.831

ACE-inhibitors

0.293

1.007

0.291

0.771

Calcium channel
Blockers

-0.020

1.068

-0.019

0.985

Loop diuretics

1.561

1.057

1.476

0.141

1.142

1.981

0.576

0.565

Pre-AMI medications:
Beta-blockers
Procedures during the incident
AMI

Discharge Medications

Medication Possession Ratio
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Table 21: Predictors for Length of Stay due to Cardiac Conditions (contd.)

Predictor

Estimate

S.E.

t-Statistic

Significance

Days supply

-0.012

0.005

-2.617

0.009*

R2 = 12.0 %(F = 3.335, p = 0.000*), n = 407

* Significant at p < 0.05, S.E: Standard error, AMI: Acute myocardial infarction, CABG: Coronary
artery bypass graft, PTCA: Percutaneous transluminal coronary angioplasty, ACE: Angiotensin
converting enzyme inhibitor
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Table 22: Predictors for Length of Stay due to Cardiac Conditions using Propensity
Score
Predictor

Estimate

S.E.

t-Statistic

Significance

Age

0.033

0.073

0.455

0.649

Sex

-0.492

0.979

-0.503

0.615

Appropriate/Inappropriate use of
beta-blockers at post-AMI

3.341

1.463

2.284

0.023*

Propensity score

-0.818

3.936

-0.208

0.835

Presence of absolute
contraindications

0.512

1.678

0.305

0.760

CABG

-5.652

1.678

-3.368

0.001*

PTCA

-1.624

1.314

-1.236

0.217

Length of stay

0.433

0.127

3.404

0.001*

Aspirin

0.105

1.492

0.071

0.944

ACE-inhibitors

0.174

1.005

0.173

0.863

Calcium channel blockers

0.376

1.065

0.353

0.724

Loop diuretics

1.742

1.066

1.634

0.103

Medication Possession Ratio

1.070

1.996

0.536

0.592

Days supply

-0.010

0.005

-2.372

0.018*

Procedures during the incident
AMI

Discharge Medications

R2 = 10.0 %(F = 3.136, p = 0.000*), n = 407
* Significant at p < 0.05, S.E: Standard error, AMI: Acute myocardial infarction, CABG: Coronary
artery bypass graft, PTCA: Percutaneous transluminal coronary angioplasty, ACE: Angiotensin
converting enzyme inhibitor
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Table 23: Predictors for Log Charges due to Cardiac Conditions
Predictor

Estimate

S.E.

t-Statistic

Significance

Age

-0.035

0.039

-0.893

0.372

Sex

2.311

0.618

1.664

0.097

Appropriate/Inappropriate use
of beta-blockers at post-AMI

1.096

0.926

0.562

0.574

Hypertension

1.138

0.628

0.521

0.603

Presence of absolute
contraindications

0.139

0.980

-1.521

0.129

Number of non-cardiac
admissions

0.748

0.478

1.566

0.118

1.899

0.765

1.222

0.223

CABG

0.011

1.054

-3.715

0.000*

PTCA

0.806

0.829

0.154

0.878

Length of stay

0.144

0.080

1.808

0.071

Aspirin

1.629

0.938

0.990

0.323

ACE-inhibitors

0.854

0.637

0.072

0.942

Calcium channel
blockers

1.798

0.675

1.206

0.228

Loop diuretics

1.539

0.669

0.980

0.328

1.311

1.253

1.046

0.296

Pre-AMI medications:
Beta-blockers
Procedures during the
incident AMI

Discharge Medications

Medication Possession Ratio
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Table 23: Predictors for Log Charges due to Cardiac Conditions (contd.)

Predictor

Estimate

S.E.

t-Statistic

Significance

Days supply

-0.003

0.003

-1.215

0.225

R2 = 7.7 %(F = 2.050, p = 0.010*), n = 407
* Significant at p < 0.05, S.E: Standard error, AMI: Acute myocardial infarction, CABG: Coronary
artery bypass graft, PTCA: Percutaneous transluminal coronary angioplasty, ACE: Angiotensin
converting enzyme inhibitor
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Table 24: Predictors for Log Charges due to Cardiac Conditions Using Propensity
Score
Predictor

Estimate

S.E.

t-Statistic

Significance

Age

-0.029

0.046

-0.631

0.528

Sex

2.186

0.616

1.415

0.158

Appropriate/Inappropriate use of
beta-blockers at post-AMI

1.136

0.921

0.600

0.549

Propensity score

0.955

2.477

0.386

0.700

Presence of absolute
contraindications

0.144

1.056

-1.303

0.193

CABG

0.010

1.056

-3.818

0.000*

PTCA

0.669

0.827

-0.072

0.943

Length of stay

0.150

0.080

1.868

0.062

Aspirin

1.495

0.939

0.898

0.370

ACE-inhibitors

0.779

0.632

0.078

0.938

Calcium channel blockers

2.233

0.670

1.534

0.126

Loop diuretics

1.668

0.671

1.099

0.272

Medication Possession Ratio

1.219

1.256

0.970

0.332

Days supply

-0.003

.003

-1.126

0.261

Procedures during the incident
AMI

Discharge Medications

R2 = 6.7 %(F = 2.003, p = 0.017*), n = 407
* Significant at p < 0.05, S.E: Standard error, AMI: Acute myocardial infarction, CABG: Coronary
artery bypass graft, PTCA: Percutaneous transluminal coronary angioplasty, ACE: Angiotensin
converting enzyme inhibitor
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Table 25: Predictors for Log Reimbursed Amounts due to Cardiac Conditions
Predictor

Estimate

S.E.

t-Statistic

Significance

Age

-0.041

0.039

-1.044

0.297

Sex

2.406

0.621

1.725

0.085

Appropriate/Inappropriate use
of beta-blockers at post-AMI

1.380

0.930

0.812

0.418

Hypertension

1.110

0.630

0.481

0.631

Presence of absolute
contraindications

0.164

0.984

-1.343

0.180

Number of non-cardiac
admissions

0.846

0.480

1.763

0.079

2.032

0.768

1.307

0.192

CABG

0.011

1.059

-3.708

0.000*

PTCA

0.763

0.833

0.093

0.926

Length of stay

0.159

0.080

1.981

0.048*

Aspirin

1.152

0.942

0.622

0.534

ACE-inhibitors

0.816

0.640

0.004

0.997

Calcium channel
blockers

1.639

0.678

1.067

0.287

Loop diuretics

1.403

0.672

0.841

0.401

1.415

1.258

1.124

0.262

Pre-AMI medications:
Beta-blockers
Procedures during the
incident AMI

Discharge Medications

Medication Possession Ratio
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Table 25: Predictors for Log Reimbursed Amounts due to Cardiac Conditions
(contd.)

Predictor

Estimate

S.E.

t-Statistic

Significance

Days supply

-0.003

0.003

-1.268

0.206

R2 = 8.0 %(F = 2.134, p = 0.007*), n = 407
* Significant at p < 0.05, S.E: Standard error, AMI: Acute myocardial infarction, CABG: Coronary artery
bypass graft, PTCA: Percutaneous transluminal coronary angioplasty, ACE: Angiotensin converting
enzyme inhibitor
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Table 26: Predictors for Log Reimbursed Amounts due to Cardiac Conditions using
Propensity Score
Predictor

Estimate

S.E.

t-Statistic

Significance

Age

-0.003

0.046

-0.795

0.427

Sex

2.027

0.620

1.451

0.148

Appropriate/Inappropriate use of
beta-blockers at post-AMI

1.422

0.926

0.843

0.400

Propensity score

0.863

2.490

0.346

0.729

Presence of absolute
contraindications

0.165

1.062

-1.160

0.247

CABG

0.009

1.062

-3.813

0.000*

PTCA

0.621

0.831

-0.158

0.875

Length of stay

0.164

0.080

2.044

0.042*

Aspirin

1.049

0.944

0.523

0.601

ACE-inhibitors

0.816

0.636

0.000

1.000

Calcium channel blockers

2.072

0.674

1.419

0.157

Loop diuretics

1.534

0.675

0.973

0.331

Medication Possession Ratio

1.318

1.263

1.044

0.297

Days supply

-0.003

0.003

-1.166

0.244

Procedures during the incident
AMI

Discharge Medications

R2 = 6.7 %(F = 2.031, p = 0.015*), n = 407
* Significant at p < 0.05, S.E: Standard error, AMI: Acute myocardial infarction, CABG: Coronary
artery bypass graft, PTCA: Percutaneous transluminal coronary angioplasty, ACE: Angiotensin
converting enzyme inhibitor
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Discussion for Research Question 4
The null hypothesis D is rejected and appropriate/inappropriate use of betablockers does affect utilization and null hypothesis E is not rejected and
appropriate/inappropriate use of beta-blockers does not affect expenditures.
Appropriate/Inappropriate prescribing of beta-blockers following an AMI, did affect
utilization such as hospital visits, ER visits and length of stay in the follow-up duration.
This relationship was similar to the morbidity results, which demonstrated that
appropriate use was associated with greater hazards for cardiac hospitalization. In other
words, appropriate use was associated with increased utilization and longer length of stay
due to cardiac visits. Physician visits and expenditures were not affected by
appropriate/inappropriate use.
A further investigation to explain this association was undertaken. This revealed
that the appropriate group had a significantly higher percentage (p = 0.003, n = 412) of
patients with hypertension (50.4%) - one of the important risk factors for cardiac
problems, compared to the inappropriate group (35.3%). A recent study has revealed that
during the 6-month period after a successful PTCA, patients with hypertension have
significantly higher adverse event rates that those without hypertension (Tsang,
Sheppard, Mak, Brown, Huynh et al., 2002). Hence, it is possible that the patients in the
appropriate group had worse outcomes (higher utilization-hospitalization, ER visits and
length of stay and lesser time to first cardiac event in research question 3) due to a higher
percentage of hypertensive patients.
Additionally, the two groups were compared for other anti-anginal drug use such
as nitroglycerin and calcium channel blocker. Due to the unavailability of other
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information such as Killip class, ejection fraction (EF), and creatinine phosphokinase
levels (available in patient charts but not available in patient claims data) this was
considered to be a proxy for severity of incident AMI. This revealed that the appropriate
group had a significantly higher (p = 0.001) percentage (74.4%) of patients on other antianginals compared to the inappropriate group (60.3%). Both the above characteristics
(hypertension and anti-anginal use) insinuate that the appropriate group was probably in a
worse health state during the incident AMI compared to the inappropriate group. Hence,
higher utilization in the appropriate group could be because of their more severe illness
rather than beta-blocker use.
An important observation is that beta-blockers did have significantly lower allcause mortality and a non-significantly lower cardiac mortality. It is possible that therapy
actually postponed death in severe patients. This however, resulted in them being alive
and utilizing more resources which resulted in higher morbidity and utilization.
Among the other significant predictors for utilization, higher non-cardiac
admissions before the incident AMI, presence of absolute contraindications, and use of
beta-blockers in the pre-period were associated with higher utilization. These variables
suggest that patients with more co-morbidities, and thus worse health states, had more
utilization after the AMI. In other words, presence of certain co-morbidties can increase
the risk for the patient to suffer from more cardiac illness. Presence of hypertension was
a significant predictor in the number of physician visits model and was negatively
associated with number of physician visits. Similarly, CABG during incident AMI and
higher length of stay during incident AMI was associated with lower utilization. These
findings are difficult to interpret. Logically, a person with hypertension would have more
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physician visits, compared to a non-hypertensive patient. Also, a patient with higher
length of stay and/or CABG during incident AMI would have higher utilization due to
higher severity of the incident AMI. Thus, these results identify more gaps due to
unavailability of other information that would be present on patient charts. MPR or
compliance and days supply, were both associated with lower utilization. Thus, for those
patients who received beta-blockers, treatment did have a protective effect and thus they
had lower utilization.
The above analyses indicated that there was a definite association between
appropriate/inappropriate use and utilization of health care services. There was higher
utilization in the appropriately prescribed group and this could be due to higher severity
of the patients with AMI in this group compared to the inappropriate group. This phase
also identified inability of claims data to recognize severity levels of patients’ conditions
as a limitation for studying utilization of health care services due to cardiac conditions in
the follow-up period after an AMI.

Phase II
Phase II of the study involved assessing effects of physicians’ knowledge of
contraindications and willingness to prescribe on their prescribing behavior for post-AMI
beta-blocker therapy. It involved surveying physicians associated with post-AMI care. A
mailing list was obtained from West Virginia Medical Board. The mailing list had a total
of 1,151 physicians from the specialties of cardiology, internal medicine, family practice
and general practice. A survey instrument developed for this project was mailed to each
physician. Table 27 illustrates the response rate analysis. Of the 1,151 surveys mailed,
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132 questionnaires were returned because of incomplete or wrong addresses, and death or
retirement of the physician. Thus, 1,019 surveys were assumed to have reached the
respondents. A total of 281 responses were obtained giving a response rate of 27.57%.
Twenty surveys were excluded because they had more than 50% incomplete item
responses, thereby reducing the response rate to 25.61%. A higher response rate is
always desirable, but this response rate is comparable to other studies involving physician
population surveys. For example a recent survey by Zeiler et al., had a response rate of
20% and Chao had a response rate of 17.6%. (Zierler, Meissner, Cain & Strandness, 2002
; Chao, 2002).
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Table 27: Response Rate Calculations
Initial survey population

1,151

Wrong addresses/dead/retired

132

Effective population reached

1,019

Incomplete responses

20

Response rate

261/1,019 = 25.61%
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Non-response Analysis
The non-response survey (Appendix G) was mailed to 738 physicians who did not
respond to one of the three survey mailings. A total of 121 completed surveys were
returned, thus giving a response rate of approximately 16.40%. Table 28 depicts the
reasons the respondents gave for not responding to the main survey. The most common
reasons were: not enough time to complete the survey (30.6%), followed by “don’t like to
respond to survey” (17.4%), and survey was too long (14.9%). Among other reasons,
survey was misplaced (9.9%), and forgot about survey (7.4%) were more common. A
few reported topic irrelevant (5.0%), not interested (4.1%), not enough incentive (3.3%),
did not receive survey (2.5%), and not enough information (2.5%).
Table 29 presents demographic and practice characteristics of the respondents to
the non-response survey. Of the 89 respondents, who responded to the question, 65 were
males and 24 were females. Also, 17.9% were less than 40 years of age, 34.5% were 4049, 28.6% were 50-59, and 19.0% were 60 or older. The mean age was 50.55 (SD =
11.80) years. The distribution of the respondents in the different specialty were; 2.2%
cardiology, 30.3% internal medicine, 39.3% family practice, 5.6% general practice and
22.5% others. Of the 63 respondents who answered the question on year of board
certification, 52.4% were certified before or during 1990, and 47.6% were certified after
1990. A total of 43.9% described their primary practice place as solo, 32.9% as groupbased, 11.0% as hospital-based, 11.0% as university-affiliated hospital, and 1.2% as
other. The mean number of new AMI patients visiting every month was 2.02 and the
mean number of repeat AMI patients visiting every month was 2.63.
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The respondents and non-respondents were compared on the basis of their
demographic and practice characteristics. The variables compared were age, gender,
specialty, year of board certification, practice site, number of new and repeat AMI
patients treated. Chi-squares and t-tests were used for comparison of these variables.
The result of this analysis is reported in Table 30. The respondents were not different
from the non-respondents on age, year of board certification, practice site and average
number of new AMI patients treated per month. The respondents and non-respondents
were significantly different on gender, specialty, and average number of repeat AMI
patients treated per month. A higher percent of non-respondents were females compared
to the respondents. There were more physicians among the non-respondents who
reported to belong to other specialty compared to respondents. The respondents reported
a higher average number of repeat AMI patients treated per month compared to nonrespondents. Thus, results of the study should be interpreted with caution.
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Table 28: Reasons for Not Responding to the Study Survey
Reasons

N (121)

Percent (%)

Not enough time to complete survey

37

30.6

Don’t like to respond to survey

21

17.4

Survey was too long

18

14.9

Survey was misplaced

12

9.9

Forgot about survey

9

7.4

Topic was irrelevant

6

5.0

Not interested in such studies

5

4.1

Not enough incentive to complete survey

4

3.3

Did not receive the survey

3

2.5

Not enough information about study

3

2.5

Other (retired, don’t treat AMI, leave, sick)

46

38.0

N: Number of physicians, AMI: Acute myocardial infarction
Multiple responses were checked by the responders of the non-response survey, hence total greater than
100%
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Table 29: Demographic and Practice Characteristics of Respondents of the Nonresponse Survey
Characteristics

N

Percent

Less than 40 years

15

17.9

40-49 years

29

34.5

50-59 years

24

28.6

60 years or older

16

19.0

Age

Average age +S.D.

50.55+11.80

Gender
Males

65

73.0

Females

24

27.0

Cardiology

2

2.2

Internal Medicine

27

30.3

Family Practice

35

39.3

General Practice

5

5.6

Other

20

22.5

<1990

33

52.4

>1990

30

47.6

36

43.9

Specialty

Year of Board Certification

Primary Practice site
Solo, office-based
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Table 29: Demographic and Practice Characteristics of Respondents of the Nonresponse Survey (contd.)

Characteristics

N

Percent

Group, office-based

27

32.9

Hospital-based

9

11.0

University-affiliated hospital based

9

11.0

Other

1

1.2

Average number of new AMI patients
Mean (S.D.), Min-Max

2.02+3.53

0-20

Average number of repeat AMI patients
Mean (S.D.), Min-Max

2.63+4.99

0-30

N: Number of physicians, S.D: Standard deviation, AMI: Acute myocardial infarction, Min: Minimum
value, Max: Maximum value
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Table 30: Analysis of Non-response Bias for Demographic and Practice
Characteristics
Characteristics

Respondents

Nonrespondents

Test
Statistic

Significance
p

Age Mean (S.D.)

49.23+10.96

50.55+11.80

t = -0.938

0.349

χ2 = 3.84

0.050*

χ2 = 22.23

0.000*

χ2 = 0.018

0.892

χ2 = 5.334

0.255

Gender
Males

82.6

73.0

Females

17.4

27.0

Specialty
Cardiology

9.7

2.2

Internal Medicine

32.6

30.3

Family Practice

47.7

39.3

General Practice

3.5

5.6

Other

6.6

22.5

Year of Board
Certification
53.4

52.4

46.6

47.6

<1990
>1990
Practice site
Solo, office-based

35.1

43.9

Group, officebased

33.6

32.9

Hospital-based

14.7

11.0

Universityaffiliated
hospital-based

10.0

11.0
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Table 30: Analysis of Non-response Bias for Demographic and Practice
Characteristics (contd.)

Characteristics

Respondents

Nonrespondents

6.6

1.2

Average number of new
AMI patients
Mean (S.D.)

3.36+5.40

Average number of
repeat AMI patients
Mean (S.D.)

9.64+33.92

Other

Test
Statistic

Significance
p

2.02+3.53

t = 1.894

0.059

2.63+4.99

t = 3.005

0.003*

* Significant at p < 0.05, S.D: Standard deviation, AMI: Acute myocardial infarction
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Demographic and Practice Characteristics of Physicians in Phase II
Demographic and practice characteristics of the respondents are presented in
Table 31. Of the respondents, 214 (82.6%) were males and 45 (17.4%) were females.
The average age was 49.23 years (SD = 10.96). Approximately 10% belonged to the
specialty of cardiology, 33% belonged to internal medicine, 48% belonged to family
practice, 4% belonged to general practice, and 7% reported other specialties. The year of
board certification was divided into two categories, those who received their board
certification before or during 1990 and those who received their board certification after
1990. Among those who responded to the question on year of board certification, a total
of 95 physicians received board certification before or during 1990 and 83 physicians
received board certification after the year 1990.
The distribution of practice site among the respondents was as follows: 35.1%
were solo office-based, 33.6% were group office-based, 14.7% were hospital-based,
10.0% were university-affiliated hospital based, and 6.6% reported other practice sites.
Among those who reported the primary practice site as hospital, 22 described it as rural, 9
described it as sub-urban and 12 described it as urban. Also, 6 worked in
governmental/nonfederal settings, 12 worked in government/federal settings, 24 worked
in private-not-for-profit settings, and 3 worked in private investor owned settings. A total
of 23 respondents reported provision of tertiary care at their hospital and the average
number of beds in the hospital was 266.56. The average number of new AMI patients
treated by the respondents was 3.36 and the average number of repeat AMI patients
treated was 9.64.
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Table 31: Demographic and Practice Characteristics of Respondents
Characteristics

N

Percent

Less than 40 years

57

22.4

40 to 49 years

73

28.7

50 to 59 years

80

31.5

60 or older

44

17.3

Age

Average Age+ S.D.

49.23+10.96

Gender
Males

214

82.6

Females

45

17.4

Cardiology

25

9.7

Internal Medicine

84

32.6

Family Practice

123

47.7

General Practice

9

3.5

Others

17

6.6

<1990

95

53.4

>1990

83

46.6

Solo, office-based

91

35.1

Group, office-based

87

33.6

Specialty

Year of Board Certification

Primary Practice Site
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Table 31: Demographic and Practice Characteristics of Respondents (contd.)

Characteristics

N

Percent

Hospital based

38

14.7

University-affiliated Hospital based

26

10.0

Others

17

6.6

Rural

22

31.4

Sub-urban

9

12.9

Urban

12

17.1

Government/Non-federal

6

8.6

Government/Federal

12

17.1

Private Not-for-Profit

24

34.3

Private Investor Owned

3

4.3

Provides Tertiary Care

23

32.9

Number of beds Mean (S.D.), Min-Max

266.56 (208.40)

18-900

Number of new AMI patients Mean (S.D.), Min-Max

3.36 (5.40)

0-50

Number of repeat AMI patients Mean (S.D.), Min-Max

9.64 (33.92)

0-450

Hospital Characteristics

N: Number of physicians, S.D: Standard deviation, AMI: Acute myocardial infarction, Min: Minimum
value, Max: Maximum value
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Results for Research Question 5
The guidelines classify three conditions as absolute contraindications:
hypotension, bradycardia and atrioventricular (AV) block. The guidelines also classify
second and third degree AV block as relative contraindications. Hence, there is
uncertainty whether AV block is an absolute contraindication or a relative
contraindication. For study purposes, first degree AV block was considered to be a
relative contraindication and second and third degree AV blocks were considered to be
absolute contraindications.
Hence, four absolute contraindications used in the questionnaire were
hypotension, bradycardia, second degree and third degree AV blocks (Table 32). About
35% of the respondents classified hypotension as an absolute contraindication and almost
61% classified bradycardia as an absolute contraindication. Exactly 50% of the
respondents classified second degree AV block and greater than 85% classified third
degree AV block as absolute contraindications.
The relative contraindications in the questionnaire were systolic blood pressure
greater than 100Hg, heart rate less than 60bpm, peripheral vascular disease, peripheral
hypoperfusion, EF<40%, first degree AV block, COPD, asthma, insulin dependent
diabetes mellitus (IDDM), PR-interval greater than 0.24 second, and beta-blocker
intolerance. A high percent of respondents classified systolic blood pressure <100hg
(about 78%), heart rate<60bpm(75%), COPD (about 83%) and asthma (about 76%) as
relative contraindications. Greater than 50% of the respondents classified peripheral
vascular disease (58%), peripheral hypoperfusion (55%), first degree AV block (53%),
IDDM (about 60%) and PR>0.24 second (about 64%) as relative contraindications. A
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relatively lower percent of respondents classified EF<40% (34%) and beta-blocker
intolerance (41%) as a relative contraindication.
There were four conditions in the questionnaire, which were neither absolute nor
relative contraindications for beta-blockers. These include hypertension, non-insulin
diabetes mellitus (NIDDM), stroke and ACE-inhibitor intolerance. A very high
percentage of respondents classified three of these conditions - hypertension (98%),
stroke (about 88%), and ACE-inhibitor intolerance (about 91%) as not a contraindication
for beta-blocker therapy. However, NIDDM was classified almost equally as a relative
contraindication (49%) and not a contraindication (50%).
Three aggregate scores were computed based on correct classification of each of
the conditions in the questionnaire in the three groups – absolute contraindication,
relative contraindication, and not a contraindication (Table 33). The mean absolute
contraindication score was 2.29 (SD = 1.20) out of a total of 4 responses. The mean
relative contraindication score was 6.73 (SD = 2.10) out of a total of 11 correct responses.
And the mean not a contraindication score was 3.17 (SD = 0.84) out of a total of 4
responses.
The number of patients prescribed beta-blockers by the respondent among the last
10 was obtained from the survey question 3, in Section A. Prescribing percent was
calculated by dividing the response with 10 and multiplying it by 100. Thus, the mean
number of patients prescribed beta-blocker among the last 10 individuals treated by the
physician was 9.01 (SD = 1.35) and the mean prescribing percent of beta-blockers was
90.10 (SD = 13.5). This prescribing percent was a proxy for prescribing behavior.
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A correlation matrix was developed for the prescribing percent/behavior with
absolute contraindication score, relative contraindication score and not a contraindication
score (Table 34). The only correlation that was significant was the not a contraindication
score and it was positively related to prescribing percent. Thus, those respondents who
classified the conditions which were not contraindications correctly, were more likely to
prescribe beta-blockers among the post-AMI patients.
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Table 32: Knowledge of Contraindications
Patient conditions

Absolute
contraindication

Relative
contraindication

Not a
contraindication

N

%

N

%

N

%

Hypotension (systolic
pressure <90hg)

90

34.75

164

63.32

5

1.93

Bradycardia (heart
rate<50bpm)

158

61.00

98

37.84

3

1.16

Second degree AV block

129

50.00

119

46.12

10

3.88

Third degree AV block

220

85.27

29

11.24

9

3.49

Systolic blood pressure
<100hg

13

5.00

203

77.80

45

17.20

Heart rate <60 bpm

15

5.79

196

75.68

48

18.53

Peripheral vascular
disease

7

2.71

150

58.14

101

39.15

Peripheral hypoperfusion

56

22.22

139

55.16

57

22.62

EF<40%

13

5.06

88

34.24

156

60.70

First degree AV block

15

5.84

138

53.70

104

40.47

COPD

10

3.85

217

83.46

33

12.69

Asthma

49

18.80

197

75.50

15

5.70

IDDM

14

5.43

156

60.47

88

34.11

Absolute
contraindications

Relative
contraindications
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Table 32: Knowledge of Contraindications (contd.)
Patient conditions

Absolute
contraindication

Relative
contraindication

Not a
contraindication

N

%

N

%

N

%

PR >0.24 second

38

15.02

165

65.22

50

19.76

Beta-blocker intolerance

149

57.53

108

41.70

2

0.77

Hypertension (systolic
pressure >140hg)

0

0

6

2.31

254

97.69

NIDDM

3

1.16

126

48.65

130

50.19

Stroke

1

0.04

31

12.11

224

87.50

ACE-inhibitor
Intolerance

8

3.29

15

6.17

220

90.53

Not a contraindication

N: Number of physicians, AV: Atrioventricular, EF: Ejection fraction, COPD: Chronic obstructive
pulmonary disease, IDDM: Insulin dependent diabetes mellitus, NIDDM: Non insulin dependent diabetes
mellitus, ACE: Angiotensin converting enzyme

181

Table 33: Knowledge Scores
Mean +S.D.

Range

Absolute contraindication score

2.29+1.20

0-4

Relative contraindication score

6.73+2.10

0-11

Not a contraindication score

3.17+0.84

0-4

Number of patients prescribed betablockers

9.01+1.35

2-10

90.10+13.50

20-100

Variables

Prescribing percent/behavior
S.D: Standard deviation
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Table 34: Correlation Matrix for Knowledge of Contraindications
Variables

Prescribing
percent/
behavior

Absolute
contraindication score

Relative
contraindication score

Not a
contraindication score

Prescribing
1.000
percent/ behavior
Absolute
contraindication
score

-0.032

1.000

Relative
contraindication
score

0.050

0.114

1.000

Not a
contraindication
score

0.229*

-0.053

-0.098

* Significant at p < 0.05
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1.000

Discussion for Research Question 5
Greater than 50% of the respondents classified three of the four listed absolute
contraindications correctly. The one condition that had a lower percent of physicians
classifying it as a contraindication was hypotension. Similarly, except for beta-blocker
intolerance and EF<40% all the other relative contraindications were also classified
correctly by greater than 50% of the physicians. Of the 4 conditions, which were neither
absolute nor relative contraindications, three- hypertension, stroke and ACE-inhibitor
intolerance were classified correctly as not a contraindication by greater than 85% of the
physicians. However, a relatively high percent of physicians classified NIDDM as a
relative contraindication. Thus, there appears to be higher than average awareness about
the relative and absolute contraindications for beta-blocker therapy in post AMI patients.
Based on the correct classification of these conditions three scores were computed, the
absolute contraindication score, the relative contraindication sore and the not a
contraindication score. Of these, two scores - the absolute contraindication score and the
relative contraindication score were not significantly correlated with prescribing percent.
Thus, the null hypothesis F that there is no association between knowledge of absolute
and relative contraindications and prescribing behavior is not rejected. The not a
contraindication score was significantly correlated with prescribing percent. Thus,
correct knowledge of conditions that are not contraindications for use does result in
positive prescribing behavior.

Results for Research Question 6
The questionnaire asked the respondents to give their willingness to prescribe
beta-blockers in patients with different conditions on a Likert scale from 1 to 5 where 1
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was least likely and 5 was most likely. These conditions could be divided into three
categories: those conditions where beta-blockers definitely provide benefits, hence
therapy should be definitely prescribed to the patient; those conditions where therapy
may be prescribed as there is uncertainty about benefits to the patient either because of
lower risk or because of presence of relative contraindications; and those conditions in
the presence of which beta-blockers should definitely not be prescribed as these are
absolute contraindications and in the presence of these conditions beta-blockers do not
provide benefit and may be harmful.
The conditions in the definitely prescribe category were: age>50 years (Mean =
4.76), large or anterior AMI (Mean = 4.55), previous AMI (Mean = 4.77), patient who
had an angioplasty (Mean = 4.64), or by-pass surgery (Mean = 4.67), patients with stroke
(Mean = 4.23), hypertension (Mean = 4.84) and complex ventricular ectopy (Mean =
4.19) (Table 35). The conditions in the maybe prescribe category were: age<50years
(Mean = 4.74), small infarction (Mean = 4.75), EF<40% (Mean = 4.16), history of CHF
(Mean = 3.95), systolic blood pressure<100Hg (Mean = 2.97), heart rate<60bpm (Mean =
2.75), LV failure (Mean = 3.76), first degree AV block (Mean = 3.20), peripheral
vascular disease (Mean = 3.26), COPD (Mean = 2.89), asthma (Mean = 2.36), and IDDM
(Mean = 3.58). The conditions in the definitely not prescribe category were: hypotension
(Mean = 2.30), bradycardia (Mean = 1.72), second degree AV block (Mean = 1.69) and
third degree AV block (Mean = 1.31).
A score was computed for each of the three categories by adding the individual
answers for each condition within the category (Table 36). Thus, the definitely prescribe
score had a mean of 36.75 (SD = 4.28) and ranged from 8 to 40. The maybe prescribe
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score had a mean of 42.36 (SD = 8.26) and ranged from 17 to 60. And the mean for
definitely not prescribe score was 7.01 (SD = 2.91) and ranged from 2.5 to 18. The mean
for prescribing percent/behavior was 90.10 (SD = 13.50).
A correlation matrix was developed for the prescribing percent with definitely
prescribe score, maybe prescribe score and the definitely not prescribe score (Table 37).
All the three scores had significant correlations with prescribing percent. The correlation
coefficient was approximately 0.47 for definitely prescribe score, and 0.41 for maybe
prescribe score, and was 0.13 for the definitely not prescribe score. Thus, those with
higher scores in all the three categories were more likely to prescribe beta-blockers
among the post-AMI patients.
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Table 35: Willingness to Prescribe Beta-blockers
Patient Characteristics

Mean

S.D.

Age >50 years

4.76

0.56

Large or anterior MI

4.55

0.87

Previous infarction

4.77

0.66

Angioplasty

4.64

0.80

By-pass surgery

4.67

0.75

Stroke

4.23

1.07

Hypertension

4.84

0.53

Complex ventricular ectopy

4.19

1.17

Age < 50 years

4.74

0.63

Small infarction

4.75

0.58

EF<40%

4.16

1.06

History of CHF

3.95

1.13

Systolic blood pressure <100Hg

2.97

1.27

Heart rate<60bpm

2.75

1.28

LV failure

3.76

1.21

First degree AV block

3.20

1.36

Peripheral vascular disease

3.26

1.38

COPD

2.89

1.20

Asthma

2.36

1.17

Definitely prescribe

Maybe prescribe
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Table 35: Willingness to Prescribe Beta-blockers (contd.)
Patient Characteristics

Mean

S.D.

IDDM

3.58

1.25

Hypotension

2.30

1.18

Bradycardia

1.72

0.99

Second degree AV block

1.69

1.05

Third degree AV block

1.31

0.92

Definitely not prescribe

S.D.: Standard deviation, MI: Myocardial infarction, EF: Ejection fraction, CHF: Congestive heart failure,
LV: Left ventricular, AV: Atrioventricular, COPD: Chronic obstructive pulmonary disease, IDDM:
Insulin dependent diabetes mellitus
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Table 36: Willingness to Prescribe Scores
Variables

Mean +S.D.

Range

Definitely prescribe score

36.65+4.28

8-40

May be prescribe score

42.36+8.26

17-60

Definitely not prescribe score

7.01+2.91

2.5-18

Number of patients prescribed betablockers

9.01+1.35

2-10

90.10+13.50

20-100

Prescribing percent/ behavior
S.D: Standard deviation
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Table 37: Correlation Matrix for Willingness to Prescribe
Variables

Prescribing
percent/
behavior

Prescribing
percent/
behavior

1.00

Definitely
Maybe
Definitely not
prescribe score prescribe score prescribe
score

Definitely
0.474*
prescribe score

1.00

May be
0.410*
prescribe score

0.648*

1.00

Definitely not 0.134*
prescribe score

0.194*

0.442*

* Significant at p < 0.05
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1.00

Discussion for Research Question 6
The willingness to prescribe beta-blockers as post-AMI medication was high
(means greater than 4 out of 5) for those conditions where beta-blockers should definitely
be prescribed for secondary prevention. For those conditions where beta-blocker maybe
prescribed as secondary prevention agents, the willingness to prescribe means were
between 2 and 5. In addition, the means for willingness to prescribe beta-blockers as
secondary preventive agents post-AMI in patients with conditions where it should
definitely not be prescribed were between 1 and 3. Thus, this indicates that willingness
to prescribe is evidence–based and physicians definitely are aware of the guidelines.
When the correlations of the three scores were calculated with prescribing percent, all
three were significant. Thus, reject null hypothesis G that there is no relationship
between physicians’ willingness to prescribe beta-blockers as post AMI secondary
preventive agents and physicians’ prescribing of these agents is rejected. The analysis
revealed a positive relationship between willingness to prescribe and prescribing behavior
among physicians for beta-blockers post-AMI irrespective of patient co-morbidities.

Results for Research Question 7
To assess the effects of demographic and practice characteristics on prescribing
behavior, t-tests, ANOVA's (Table 38) and correlations (Table 39) were conducted.
Gender and year of board certification was investigated using t-tests whereas, specialty,
location and practice site were investigated using F-tests. Association of age, size of
hospital, number of new AMI patients, and number of repeat AMI patients treated were
determined through Pearson’s correlations.
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Age and size of hospital were significantly correlated with prescribing percent.
Age was negatively associated with prescribing percent/behavior. Thus, older physicians
were less likely to prescribe beta-blockers in post-AMI patients. Size of hospital was
positively associated with prescribing percent. Thus, larger the size of the hospital the
physicians worked in, the more likely they were to prescribe beta-blockers in post-AMI
patients. Prescribing percent/behavior was not significantly different by gender,
specialty, location, practice site and year of board certification. Prescribing
percent/behavior was higher for cardiologists and physicians from internal medicine
compared to family practitioners and general practitioners, also physicians from urban
areas had higher prescribing percent compared to rural and sub-urban areas, females had
a higher prescribing percent compared to males, and finally physicians who were boardcertified after 1990 had higher prescribing percent compared to those who were board
certified before or during 1990, however, none of these were statistically significant.
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Table 38: Prescribing Behavior and Demographic Characteristics, Part 1
Variables

Prescribing percent/
behavior
(Mean+S.D.)

Gender
Males

89.60+14.21

Females

92.21+9.41

Specialty
Cardiology

90.40+13.38

Internal medicine

92.88+9.44

Family practice

88.29+15.11

General practice

84.29+20.70

Other

90.83+13.79

Location
Rural

92.63+14.47

Sub-urban

90.00+9.26

Urban

95.00+9.72

Practice site
Solo, office based

87.73+16.24

Group, office-based

90.18+12.48

Hospital-based

93.43+11.87

University-affiliated
hospital based

92.50+8.47

Other

90.77+9.54
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Statistic

Significance

t = -1.15

0.252

F = 1.73

0.143

F = 0.363

0.699

F = 1.41

0.230

Table 38: Prescribing Behavior and Demographic Characteristics, Part 1 (contd.)

Variables

Prescribing percent/
behavior
(Mean+S.D.)

Year of board certification
<1990

88.52+14.15

>1990

91.79+10.16

S.D: Standard deviation
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Statistic

Significance

t = -1.704

0.090

Table 39: Prescribing Behavior and Demographic Characteristics, Part 2
Variables

Prescribing
percent/
behavior

Age

Size of
hospital

Prescribing
percent/
behavior

1.00

Age

-0.199*

1.00

Size of
hospital

0.231*

-0.092

1.00

Number of
new AMI
patients

0.061

-0.074

0.184*

1.00

Number of
repeat AMI
patients

0.047

0.130

0.010

0.197*

* Significant at p < 0.05, AMI: Acute myocardial infarction
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Number of
new AMI
patients

Number of
repeat AMI
patients

1.00

Discussion for Research Question 7
Based on the analysis, the null hypotheses H that there is no relationship between
demographic and practice characteristics and prescribing behavior is rejected. Age and
size of the hospital do have an association with prescribing behavior. Younger
physicians and physicians who worked in larger hospitals had higher prescribing
percentages. Nicholls et al., (2001) reported higher prescribing rates in a large hospital
compared to a small hospital. However, the large hospital in this study was also affiliated
to a university and cardiologists treated patients in the large hospital. Thus, it is possible
that when other characteristics of the hospital are adjusted for, size of hospital may not
have an impact on prescribing behavior. Also, age has been reported to be associated
with prescribing behavior in other disease conditions such as hypertension (Mehta et al.,
1999). Younger physicians were more likely to prescribe recommended agents compared
to older physicians. Since beta-blockers are recommended medications post-AMI, this
study establishes a similar association between age and prescribing behavior for betablockers too. This study did not find an association between prescribing behavior and
other physician characteristics contrary to results of previous studies which have reported
that specialty, year of board certification, location, and university affiliation do affect
prescribing behavior of physicians for beta-blockers as secondary preventive agents post
AMI (Ayanian et al. 1994; Fehrenbach et al, 2001; Sheikh & Bullock, 2001).

Results for Research Question 8
Similar to the analyses in research question 7, t-tests, ANOVA’s and Pearson’s
correlations were conducted on the demographic and practice characteristics with the

196

three knowledge scores and the three willingness to prescribe scores. The results for the
three knowledge scores are reported in Tables 40 and 41 and the results for the three
willingness to prescribe scores are reported in Tables 42 and 43.
Thus, we see that the knowledge scores did not differ by gender, location and year
of board certification. However, the absolute contraindication score and the not a
contraindication score were significantly different by specialty, and the not a
contraindication score was also significantly different by primary practice site. The
general practitioners had a higher absolute contraindication score compared to physicians
from internal medicine. Thus, the general practitioners classified the absolute
contraindications more correctly than physicians in internal medicine. The cardiologists
had a higher not a contraindication score compared to family practitioners, which implies
that cardiologists classified those conditions which were not contraindications more
correctly compared to family practitioners. The not a contraindication score was also
significantly different by primary practice site. Those who practiced in universityaffiliated hospital settings classified those conditions which were not contraindications
for beta-blocker therapy more correctly compared those who practices in solo, officebased settings. The not a contraindication score was also negatively correlated to age.
Thus, older physicians were less likely to classify those conditions which were not
contraindications for beta-blocker therapy correctly. Similarly, the number of repeat
AMI patients treated was also negatively correlated to absolute contraindication score.
Thus, those physicians who treated more repeat AMI patients were less likely to classify
those conditions which were absolute contraindications for beta-blocker therapy
correctly.
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Willingness to prescribe scores (Tables 42 & 43) were also analyzed in a similar
manner. These scores were not different by gender, location, and year of board
certification. Specialty was significantly different for the definitely prescribe score and
the maybe prescribe score. The general practitioners had a lower definitely prescribe
score compared to internal medicine physicians. Thus, physicians in general practice
were less willing to prescribe beta-blockers as post-AMI medication to those patients in
whom it should definitely be prescribed when compared to physicians from internal
medicine. A similar relation was found for the maybe prescribe score, with the general
practitioners’ and family practitioners’ scores being significantly lower than physicians’
in internal medicine. Thus, physicians from general practice and family practice were
less willing to prescribe beta-blockers as post AMI medications in patients with those
conditions where they maybe prescribed when compared to physicians in internal
medicine.
Both ‘definitely prescribe’ score and ‘maybe prescribe’ score were significantly
different by primary practice site. Physicians in solo office-based practice had a
significantly lower definitely prescribe score compared to physicians at universityaffiliated hospitals. Also, physicians in solo practice had a significantly lower maybe
prescribe score compared to both physicians from hospital practice and physicians from
university-affiliated hospitals.
Age was significantly and negatively correlated to two scores, definitely
prescribe, and maybe prescribe. Thus, older physicians were less willing to prescribe
beta-blockers as post AMI medication in patients with conditions where they should be
definitely prescribed, and maybe prescribed. Size of hospital was positively associated
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with definitely prescribe and maybe prescribe scores. Thus, physicians from larger
hospitals were more willing to prescribe beta-blockers in patients where they should
definitely or maybe be prescribed. Number of new AMI patients and number of repeat
AMI patients treated by the physicians were not related to the willingness to prescribe
scores.
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Table 40: Knowledge of Contraindications and Demographic Characteristics, Part 1
Variables

Absolute
contraindication
score

Relative
contraindication
score

Not a
contraindication
score

Males

2.29+1.19

6.74+2.14

3.17+0.88

Females

2.27+1.21

6.64+1.87

3.22+0.67

Cardiology

2.28+0.98

6.04+2.09

3.60+0.58 a

Internal medicine

2.01+1.14a

6.80+2.03

3.24+0.82

Family practice

2.33+1.24

6.75+2.09

3.08+0.88 a

General practice

3.22+0.97 a

5.89+2.98

2.78+1.20

Other

2.76+1.25

7.41+1.66

3.18+0.64

Rural

2.38+1.36

6.71+1.79

3.10+0.70

Sub-urban

2.44+1.13

6.22+2.22

3.44+0.53

Urban

2.18+1.40

6.36+1.57

3.45+0.69

Solo, office based

2.21+1.25

6.42+2.20

2.96+1.03 a

Group, office-based

2.32+1.16

6.87+1.97

3.28+0.69

Hospital-based

2.29+1.39

6.87+2.17

3.34+0.62

University-affiliated
hospital based

2.35+0.94

6.88+2.08

3.46+0.70 a

Other

2.35+1.11

7.00+2.12

2.88+0.78

Gender

Specialty

Location

Practice site
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Table 40: Knowledge of Contraindications and Demographic Characteristics,
Part 1 (contd.)

Variables

Absolute
contraindication
score

Relative
contraindication
score

Not a
contraindication
score

<1990

2.24+1.46

6.45+2.19

3.17+0.83

>1990

2.35+1.11

6.94+1.91

3.33+0.68

Year of board
certification

t-tests: gender and year of board certification
ANOVA’s: specialty, location, and practice site. Significant ANOVA’s were investigated with post-hoc
Tukey comparisons
a: Significant at p < 0.05
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Table 41: Knowledge of Contraindications and Demographic Characteristics, Part 2
Variables

Absolute
contraindication
score

Relative
contraindication
score

Not a
contraindication
score

Absolute
contraindication
score

1.000

Relative
contraindication
score

0.114

1.000

Not a
contraindication
score

-0.053

0.098

1.000

Age

0.001

-0.047

-0.160*

1.000

Size of
hospital

-0.053

-0.059

0.069

-0.092

1.000

Number
of new
AMI
patients

-0.027

-0.060

-0.009

-0.074

0.184*

1.000

Number
of repeat
AMI
patients

-0.156*

-0.026

0.007

0.130

0.010

0.197*

* Significant at p < 0.05, AMI: Acute myocardial infarction
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Age

Size of
hospital

Number
of new
AMI
patients

Number
of
repeat
AMI
patients

1.000

Table 42: Willingness to Prescribe and Demographic Characteristics, Part 1
Variables

Definitely
prescribe score

Maybe prescribe
score

Definitely not
prescribe score

Males

36.68+4.43

42.32+8.55

7.00+2.94

Females

36.81+3.27

42.52+6.64

7.10+2.86

Cardiology

37.16+6.36

44.60+8.21

6.56+2.79

Internal medicine

37.45+3.22 a

44.99+7.13 a,b

7.29+3.00

Family practice

36.19+4.34

40.55+8.50 a

6.92+2.88

General practice

33.33+4.30 a

36.61+7.37 b

6.67+1.66

Other

37.97+3.06

42.76+7.71

7.59+3.50

Rural

37.48+3.44

43.31+8.18

7.81+4.06

Sub-urban

34.22+12.89

40.56+16.28

5.89+3.06

Urban

37.82+3.19

48.27+6.25

7.27+3.07

Solo, office based

35.59+4.79 a

39.77+8.84 a,b

6.68+2.63

Group, office-based

36.92+4.57

42.80+7.73

6.90+2.85

Hospital-based

37.68+2.82

45.09+7.18 a

7.76+3.72

University-affiliated
hospital based

38.19+2.38 a

45.92+7.25 b

7.23+2.75

Other

36.18+3.83

42.47+8.23

7.59+2.94

Gender

Specialty

Location

Practice site
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Table 42: Willingness to Prescribe and Demographic Characteristics, Part 1
(contd.)

Variables

Year of board
certification
<1990
>1990

Definitely
prescribe score

Maybe prescribe
score

Definitely not
prescribe score

36.34+4.83

42.64+8.29

6.79+2.62

37.36+3.02

43.05+7.50

6.97+2.99

t-tests: gender and year of board certification
ANOVA’s: specialty, location, and practice site. Significant ANOVA’s were investigated with post-hoc
Tukey comparisons
a,b: Significant at p < 0.05
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Table 43: Willingness to Prescribe and Demographic Characteristics, Part 2
Variables

Definitely
prescribe
score

Maybe
prescribe
score

Definitely
not
prescribe
score

Definitely
prescribe
score

1.000

May be
prescribe
score

0.648*

1.000

Definitely
not
prescribe
score

0.194*

0.442*

1.000

Age

-0.273*

-0.287*

-0.091

1.000

Size of
hospital

0.196*

0.193*

0.142

-0.092

1.000

Number
of new
AMI
patients

-0.002

0.085

0.028

-0.074

0.184*

1.000

Number
of repeat
AMI
patients

-0.047

0.071

0.002

0.130

0.010

0.197*

* Significant at p < 0.05, AMI: Acute myocardial infarction
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Age

Size of
hospital

Number
of new
AMI
patients

Number
of
repeat
AMI
patients

1.000

Discussion for Research Question 8
Based on the results, both the null hypotheses I and J are rejected. The analysis
revealed that specialty, type of practice site, age and number of repeat AMI patients
treated were associated with knowledge scores. Similarly, specialty, type of practice site,
age and size of the practice hospital were associated with willingness to prescribe scores.
The absolute contraindication score and the not a contraindication score were
significantly different by specialty. Physicians from general practice had a higher
absolute contraindication score compared to physicians from internal medicine and
physicians from family practice had a lower not a contraindication score compared to
cardiologists. Also, physicians from general practice had lower definitely prescribe score
compared to physicians from internal medicine and physicians from both general and
family practice had lower maybe prescribe score compared to physicians in internal
medicine. Degree of specialization has been reported to be associated with knowledge of
contraindications in other disease conditions like hypertension (Huse et al., 2001). An
association between degree of specialization and knowledge was also reported by
Sanchez et al. (2001) when they investigated cardiovascular diseases and Chlamydia
pneumoniae. It makes intuitive sense that correct knowledge would result in higher
willingness to prescribe scores, which in turn would eventually result in better
prescribing behavior. Thus, though knowledge did not demonstrate a direct effect on
prescribing behavior in research question 5, an indirect relationship may be present.
Type of practice site has not been reported to be associated with knowledge or
willingness to prescribe before. On the other hand, type of primary practice site has been
reported to be associated with prescribing behavior and this association usually involves
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presence of university or teaching affiliation, which results in higher prescribing rates of
certain recommended medications such as aspirin (Venturini et al., 1999). This study
revealed an association of university affiliation with both knowledge and willingness to
prescribe scores. Thus, it is possible that university affiliation results in updated
knowledge which increases willingness to prescribe and this may affect prescribing
behavior.
Older physicians were less likely to identify those conditions that are not
contraindications for beta-blockers correctly and were also less willing to prescribe betablockers in patients who should definitely receive them and those who may receive them.
Previous reports have revealed that younger physicians are more likely to select
medications consistent with guideline recommendations in other disease areas such as
hypertension (Mehta et al., 1999). This study revealed an association between age and
prescribing behavior, age and knowledge, and age and willingness to prescribe. Thus,
this suggests that younger physicians are more aware of clinical practice guidelines, in
other words are up to date with knowledge, which results in a higher willingness to
prescribe which in turn results in their prescribing behavior being more consistent with
such guidelines.
Among other variables, size of hospital was positively associated with two of the
three (‘definitely prescribe’ and ‘maybe prescribe’) willingness to prescribe scores. It is
possible that larger hospitals have better in-house seminars, and/or continuing medical
education which help keep their physicians up to date about changes in guidelines and
this results in a positive effect on their willingness to prescribe recommended therapies.
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Finally, number of repeat AMI patients was negatively associated with absolute
contraindication score. It is possible that higher workload gives physicians less time to
keep up with changes and this affects their knowledge.

Results for Research Question 9
Effect of all physician characteristics such as demographic, practice, knowledge
and willingness to prescribe on physician prescribing percent/behavior was investigated
by regression analysis. The dependent variable was prescribing percent/behavior. The
independent variables included; age, gender, specialty, practice site, absolute
contraindication score, relative contraindication score, not a contraindication score,
definitely prescribe score, maybe prescribe score, definitely not prescribe score, number
of new AMI patients and number of repeat AMI patients treated by the physician per
month. Specialty was converted to a dichotomous variable where 1 was cardiology and
all the other specialties were grouped together as 0, which implied non-cardiology or
internal medicine, family practice, general practice or others. Similarly, practice site was
converted into a dichotomous variable, where 1 implied university affiliation and 0
implied either solo or group office-based, non-university affiliated hospital or others.
Location and size of hospital was not included in the analysis as only those physicians
who worked in a hospital were asked to answer these questions. Year of board
certification was not included in analysis as the data was missing for more than 33% of
the respondents.
The resultant model was significant and had an R2 of 26.8%, implying that the
model explained almost 27% of the variance in prescribing percent/behavior (Table 44).
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The models were checked for violation of assumptions associated with linear regression.
The model had no problems with multicollinearity, heteroskedasticity and
autocorrelation. The analysis had a power of 95.6%. However, the only independent
variable that was a significant predictor of prescribing percent/behavior was the definitely
prescribe score. Thus, physicians with higher willingness to prescribe beta-blockers in
those patients where it should be definitely prescribed were more likely to have a higher
prescribing percent for beta-blockers as secondary prevention agents post-AMI.
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Table 44: Predictors of Prescribing Percent/Behavior
Predictor

Estimate

S.E.

t-Statistic

Significance

Age

-0.006

0.082

-0.084

0.934

Gender

-1.202

2.106

-0.571

0.569

Specialty- Cardiology

-0.518

2.905

-0.179

0.859

Practice site – University affiliation

-0.262

3.035

-0.086

0.931

Absolute contraindication score

0.529

0.753

0.703

0.483

Relative contraindication score

-0.107

0.383

-0.281

0.779

Not a contraindication score

-0.375

1.082

-0.346

0.730

Definitely prescribe score

1.138

0.251

4.538

0.000*

Maybe prescribe score

0.233

0.148

1.577

0.116

Definitely not prescribe score

0.276

0.337

0.818

0.415

Number of new AMI patients

0.057

0.194

0.295

0.768

Number of repeat AMI patients

0.02

0.023

0.862

0.390

R2 = 26.8%(F = 5.908, p < 0.000*), n = 206
* Significant at p < 0.05, S.E: Standard error, AMI: Acute myocardial infarction
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Discussion for Research Question 9
The null hypothesis K that there is no relationship between physicians prescribing
of beta-blocker therapy post-AMI and the interaction of physician characteristics
(demographic, practice, knowledge and willingness to prescribe) is rejected. Regression
analysis which included physician knowledge scores, willingness to prescribe scores and
demographic and practice characteristics helped in understanding how each of these traits
affected prescribing behavior when the others were adjusted for. The results revealed
that one of the willingness to prescribe scores explained a high percent of the variance in
prescribing behavior for beta-blockers when it is used as a post-AMI medication when all
the other characteristics were used as covariates.
Figure 11 provides a summary of the findings based on the results of research
questions 5, 6, 7, 8 & 9. The figure demonstrates all the significant associations that were
obtained. Thus, specialty of internal medicine and more number of repeat AMI patients
treated was associated with higher absolute contraindication score. The specialty of
cardiology, younger age of physician and university affiliation was associated with higher
not a contraindication score. Younger age, and university affiliation were also associated
with higher definitely prescribe score, in addition to larger size of practicing hospital, and
internal medicine specialty. Larger size of practicing hospital, internal medicine
specialty and practicing in a hospital was associated with higher maybe prescribe score.
Among all the tested variables, not a contraindication score, definitely prescribe score,
maybe prescribe score, definitely not prescribe score, younger age and larger size of
hospital were all associated in univariate analysis with higher prescribing rates or
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prescribing behavior. However, when all these variables were entered in a multivariate
model, definitely prescribe score was the only significant variable.
The knowledge scores, willingness scores and prescribing behavior, were all
proxy variables. Thus, the findings of this phase indicate a profile of a general
specialty/family practice physician, older in age, non-university or non-hospital affiliated
and attached to a smaller hospital as the target for interventions to improve beta-blocker
prescribing behavior.
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Figure 11: Summary of Univariate and Multivariate Findings

Internal Medicine
Number of repeat
AMI patients

Absolute Contraindication Score

Cardiology
Relative Contraindication Score

Not a Contraindication Score
Age
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Size
Internal Medicine

Definitely Prescribe Score

Prescribing Behavior

May be Prescribe Score
Hospital

Age
Size
Definitely not Prescribe Score

AMI: Acute myocardial infarction,

: Univariate association,
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: Multivariate association

Results for Research Question 10
This included a descriptive summarization of the various reasons reported by
physicians for not prescribing beta-blockers in their post-AMI patients. It was an openended question and most physicians reported multiple reasons. These reasons were
broadly categorized based on their similarities. For example bronchospasm, COPD,
severe COPD, lung disease, and severe lung disease were included in one category and
called as bronchospasm/COPD/lung disease. Similarly, contraindications, relative
contraindication, partial contraindication, intolerance, cannot tolerate, complications were
grouped together in contraindications/complications/intolerance.
The most important reasons reported by physicians for not prescribing betablockers as post-AMI medication were bronchospasm/COPD/lung disease,
Bradycardia/bradyarrhythmia, and contraindications/complications/intolerance (Table
45). Among other reasons reported some included relative contraindications such as
asthma/bronchial asthma, heart block, low blood pressure, low heart rate, pulse rate,
peripheral vascular disease, CHF or low EF, and diabetes. A few reported hypotension,
an absolute contraindication. A few reported side effects or adverse effects as the general
cause and one physician reported fatigue and another reported non-compliance as a
cause. Very few physicians reported co-morbidity, cost, depression, and severe systolic
dysfixia as a reason. The non-specific reasons were grouped in the other category and
included-already on medication, don’t treat MI, forgot, did not think about it, medication
has new indications, not in active patients, symptomatic, and patient transferred for care.
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Table 45: Reasons for Not Prescribing Beta-blockers in Post-AMI Patients
Reason 1 (n = 116)

Reason 2 (n = 57)

Reason 3 (n = 13)

Reason 4 (n = 3)

Bronchospasm/COP
D/lung disease (28)

Bronchospasm/COP
D/lung disease (11)

Diabetes (2)

CHF/ low EF (1)

Bradycardia/
Bradyarrhythmia (20)

Contraindications/
complications/intole
rance (10)

Low BP (3)

Depression (1)

Contraindications/co
mplications/intoleran
ce (17)

Bradycardia/
Bradyarrhythmia (8)

Bronchospasm/CO
PD/lung disease (1)

Side/adverse
effects (1)

Asthma/bronchial
asthma (13)

Hypotension (6)

Bradycardia/
Bradyarrhythmia
(1)

Side/adverse effects
(7)

Asthma/bronchial
asthma (4)

CHF/ low EF (1)

Hypotension (5)

Heart block (4)

Cost (1)

Low heart rate (5)

Low pulse (3)

Heart block (1)

Low BP (4)

Side/adverse effects
(3)

Low heart rate (1)

Heart block (3)

Low BP (2)

Peripheral Vascular
disease (1)

Co-morbidity (2)

Low heart rate (2)

Side/adverse effects
(1)

CHF/ low EF (1)

Diabetes (1)

Fatigue (1)

Peripheral Vascular
disease (1)

Non compliance (1)

Low EF (1)

Peripheral Vascular
disease (1)

Others (1)
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Table 45: Reasons for Not Prescribing Beta-blockers in Post-AMI Patients
(contd.)
Reason 1 (n = 116)

Reason 2 (n = 57)

Reason 3 (n = 13)

Reason 4 (n = 3)

Severe systolic
dysfixia (1)
Others (7)
Others: Already on medication, don’t treat AMI, forgot, did not think, new indications, not in active
patients, symptomatic, transferred for care
AMI: Acute myocardial infarction, n: Number of physicians, COPD: Chronic obstructive pulmonary
disease, BP: Blood pressure, CHF: Congestive heart failure, EF: Ejection fraction
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Discussion for Research Question 10
The above summarization reveals that the most common reasons reported for not
prescribing beta-blockers as post-AMI medications were COPD, bradycardia and
contraindications. Bradycardia is an absolute contraindication of beta-blockers and is a
correct reason for not prescribing as per the guidelines. However, COPD is a relative
contraindication and patients should be prescribed beta-blocker therapy, thus this
suggests inappropriate prescribing behavior. Also, the third most common reason given
by physicians was contraindications, most physicians did not specify what the
contraindication was. Thus, these could be relative contraindications or absolute
contraindications, but due to lack of sufficient information it cannot be determined
whether the reasons were appropriate or not. The other frequently mentioned reasons
were asthma, hypotension, low heart rate, and adverse or side effects of therapy. Asthma
and low heart rate are relative contraindications and not adequate reasons for not
prescribing. Hypotension is an absolute contraindication and thus a correct reason for not
prescribing as per the guidelines. Adverse reactions have been reported to be a barrier for
prescribing beta-blockers in a previous study too (Kennedy & Rosensen, 1995). This
study reported that physicians believed that adverse reactions of beta-blockers could
result in a negative quality of life. This study also reported exaggerated concerns for
relative contraindications. Thus, based on the previous report by Kennedy and Rosensen
and present findings, it appears as though physicians’ reasons for not prescribing betablockers in post-AMI patients for secondary prevention haven’t changed much. This is
despite additional studies which have reported that beta-blockers can be used in all
patients except those with absolute contraindications (Phillips et al., 2000). This gives
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rise to the need of increasing awareness of these newer study reports to physicians who
attend to post-AMI patients and thus increase prescribing rates of beta-blockers in postAMI patients. A few physicians in this study also reported reasons such as forgot, and
did not think. Effective reminder cards or services could be beneficial in increasing
prescribing rates of such physicians. Thus, this summarization illustrates that reasons
given by physicians for not prescribing beta-blockers may not necessarily be adequate
and there is room for improving prescribing rates of this important therapy in post-AMI
patients.

This chapter presented results and discussion for each research question that was
proposed by the study. The next chapter will give summarization and make conclusion
from these results.
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CHAPTER FIVE
SUMMARY AND CONCLUSIONS
This chapter presents a review of the study findings, draws conclusions, presents
research implications, lists limitations for each phase of the study, and provides
recommendations for future research.

Phase I
Acute myocardial infarction (AMI) is a condition responsible for high mortality
and has a lot of economic implications. Hence, therapeutic interventions that reduce
mortality and improve morbidity, as well as primary and secondary prevention strategies
for an AMI are important. Beta-blocker therapy has been proven to be effective when
used as a secondary preventive agent following an AMI. Due to its effectiveness, it has
been recommended by American College of Cardiology (ACC)/ American Heart
Association (AHA) guidelines for long-term use following an AMI. However, this
important therapy has been reported to be inappropriately prescribed (underused and
misused) in patients following an AMI. There have been a few investigations to
understand the consequences of under use of this therapy. However, very little has been
done to understand the effect of inappropriate use. Also, previous research has been in an
elderly population, despite the fact that this condition is present in younger age groups.
Thus, the goal of this phase of the study was to evaluate the prescribing of betablockers as long-term therapy following an AMI in a Medicaid population. Another aim
was to investigate the effect of appropriate and inappropriate prescribing of beta-blockers
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following an AMI on patient outcomes such as mortality, morbidity, health care
utilization and expenditures.

Conclusions for Phase I
The conclusions for this phase of the study are presented based on the research
questions proposed in the study:

Research Question 1: Prescribing Patterns for Beta-blocker Therapy in WV Medicaid
This was an exploratory question to assess prescribing of beta-blockers in the
Medicaid population with regards to the published guidelines. The prescription rates
were higher in eligible patients and lower in ineligible patients, compared to prescription
rates reported in previous research. Another important observation was that there was a
tendency to not prescribe in older patients. All these findings suggest that prescribing in
this patient population is better that the previously reported prescribing in other
populations, but there is abundant room for improvement in prescribing.

Research Question 2: Effect of Appropriate and Inappropriate Prescribing on Mortality
The null hypothesis this research question aimed to investigate was that there is
no difference in mortality and cardiac mortality between the appropriately and
inappropriately prescribed groups after controlling for confounding factors. Appropriate
therapy with beta-blockers did affect all-cause mortality. The appropriate group had
lower mortality compared to the inappropriate group. However, appropriate therapy was
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not significant when cardiac mortality was investigated. Thus, appropriate therapy did
not affect cardiac mortality in this cohort of patients.

Research Question 3: Effect of Appropriate and Inappropriate Prescribing on Morbidity
The null hypothesis this research question aimed to investigate was that, there is
no difference in morbidity due to: successive AMI, heart failure, stroke, angina, other
ischemic disease, essential hypertension, cardiogenic shock, disease of endocardium,
conduction disorders or cardiomyopathy between the appropriately and inappropriately
prescribed groups after controlling for confounding factors. Appropriate beta-blocker
therapy did affect morbidity due to these conditions. The inappropriate group had better
survival compared to the appropriate group in the 12-month follow-up period in this
patient population. The patients in the appropriate group were twice as likely to suffer
from a cardiac event in the follow-up period compared to the inappropriate group after
adjusting for all the co-variates available in the claims. However, there were indications
that the appropriate group had a more severe condition and thus in a worse health state
during the hospitalized AMI compared to the inappropriate group. Thus, whether the
increase in morbidity in the follow-up period was because of appropriate therapy or
because of patient severity could not be determined.

Research Question 4: Effect of Appropriate and Inappropriate Prescribing on Utilization
and Expenditure
The null hypothesis this research question aimed to investigate was that, there is
no difference in utilization of resources and expenditure due to successive AMI, heart
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failure, stroke, angina, other ischemic disease, essential hypertension, cardiogenic shock,
disease of endocardium, conduction disorders or cardiomyopathy between the
appropriately and inappropriately prescribed group after controlling for confounding
factors. Appropriate beta-blocker therapy did affect utilization, but it did not affect
expenditures. The inappropriate group had lower utilization-hospital visits, ER visits,
and total length of stay in the 12-month follow-up period in this patient population.
However, there were indications that the appropriate group had a more severe condition
and thus in a worse health state during the incident AMI compared to the inappropriate
group. Thus, whether the increase in utilization was because of appropriate therapy or
because of patient severity could not be determined.

Phase II
This phase of the study involved exploring the association of physician
characteristics such as physician knowledge of contraindications, physicians’ willingness
to prescribe and demographic and practice characteristics with their prescribing of betablocker therapy as a post-AMI secondary preventive agent. Previous studies have
reported ample variation of medication use by different physician characteristics. This
phase of the study aimed to understand effect of these factors individually and in
combination with prescribing behavior in the state of WV for beta-blockers in post-AMI
patients.
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Conclusions for Phase II
The conclusions of this phase of the study are presented based on the research
questions proposed in the study:

Research Question 5: Knowledge of Contraindications and Prescribing Behavior
The null hypothesis this research question aimed to investigate was that, there is
no relationship between knowledge of contraindications and prescribing behavior for
beta-blocker therapy in post AMI patients. Physicians’ knowledge of both absolute and
relative contraindications did not reveal any association with prescribing behavior. On
the other hand, knowledge of conditions which were not contraindications was positively
associated with prescribing behavior.

Research Question 6: Willingness to Prescribe and Prescribing Behavior
The null hypothesis this research question aimed to investigate was that, there is
no relationship between willingness to prescribe beta-blockers and prescribing behavior
for beta-blocker therapy in post AMI patients. Physicians’ willingness to prescribe betablockers was positively associated with their prescribing of this therapy in post-AMI
patients as secondary preventive agents irrespective of patient co-morbidity.

Research Question 7: Demographic and Practice Characteristics and Prescribing
Behavior
The null hypothesis this research question aimed to investigate was that, there is
no relationship between demographic and practice characteristics and prescribing
behavior for beta-blocker therapy in post AMI patients. Of the various characteristics
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investigated age and size of hospital were associated with physician prescribing of betablocker in post-AMI patients as secondary preventive agents. Age was negatively
associated with prescribing behavior and size of the hospital was positively associated
with prescribing behavior.

Research Question 8: Knowledge of Contraindications, Willingness to Prescribe and
Demographic and Practice Characteristics
The null hypothesis this research question aimed to investigate was that, there is
no relationship between demographic and practice characteristics and knowledge of
contraindications and willingness to prescribe beta-blocker therapy in post AMI patients.
Of the various characteristics investigated specialty, practice site, age, and number of
repeat AMI patients treated by physicians were associated with physicians’ knowledge of
contraindications. Similarly, specialty, practice site, age, and size of hospital were
associated with willingness to prescribe beta-blockers as secondary preventive agent in
post-AMI patients. Age was negatively associated with both knowledge and willingness
to prescribe scores. Primary practitioners from family practice and general practice
generally had lower knowledge and willingness to prescribe scores. University affiliation
of the practice site was associated with higher knowledge and willingness to prescribe
scores. More number of repeat AMI patients treated was associated with lower
knowledge score and larger size of the practice hospital was associated with higher
willingness to prescribe score.
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Research Question 9: Physician Characteristics and Prescribing Behavior
The null hypothesis this research question aimed to investigate was that, there is
no relationship of prescribing behavior and physician characteristics such as
demographics, practice characteristics, knowledge of contraindications, and willingness
to prescribe beta-blocker therapy in post AMI patients. The study revealed that when all
physician characteristics are controlled for, physician willingness to prescribe is the most
significant predictor of physicians’ prescribing behavior. However, when the various
associations were individually assembled; age, specialty, university affiliation and size of
the hospital emerged to be the modifiable factors which can be targeted with educational
efforts to increase prescribing of beta-blockers in post-AMI patients.

Research Question 10: Reasons for Not Prescribing Beta-Blockers
This was an exploratory question to enlist reasons reported by physicians for not
prescribing beta-blockers in post-AMI patients. The most common reasons were COPD,
bradycardia, and contraindications. Comparison of the reasons with those reported in
previous reports revealed that though prescribing has increased over the years, the
reasons for not prescribing haven’t changed much, thus there is a need to increase
awareness which would further improve prescribing of beta-blockers as secondary
preventive agents in post-AMI patients.

Implications of Study
This study was undertaken to study prescribing of beta-blockers as post-AMI
secondary prevention agents and its effects on patient outcomes in a Medicaid
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population. The study also aimed to assess the physicians’ role in prescribing betablockers following an AMI. The findings of the study should be useful to the Medicaid
program to help them improve prescribing of beta-blockers for post-AMI long-term use.
The study also has implications for patients, prescribers and decision-makers. These
implications are described in the following sections.

Implication to the Medicaid Program
The results of this study demonstrated that there is indeed inappropriate
prescribing of beta-blockers in this patient cohort of Medicaid. There is both under use
and misuse. Inappropriate use of an important therapeutic agent can have adverse
consequences on patient outcomes. This study revealed that appropriate use of betablocker therapy is associated with a significant lower mortality rate. Thus, this further
stresses the importance of increasing appropriate prescribing of beta-blockers in these
patients. However, the results did not show a significant association of appropriate
prescribing with cardiac mortality and also revealed that patients with appropriate
prescribing were associated with higher morbidity and utilization of resources. But it was
not clear whether this increase in morbidity and utilization was associated with
appropriate use of beta-blockers or patient severity. And the data suggests that patient
severity maybe responsible for higher utilization. Thus, there is a need to improve
appropriate prescribing of beta-blockers in these patients. The Medicaid program can
develop and implement active interventions such as group or one-on-one education, and
individual outreach visits that will increase the prescription of beta-blockers in eligible
patients, and decrease the prescription of beta-blockers in ineligible patients. This could
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improve patient quality of life and reduce healthcare utilization and costs, as this would
result in better quality of care, fewer deaths, better control of symptoms and
exacerbations due to cardiovascular (CV) disease.

Implication to Patients
The findings of this study are also relevant to patients. AMI is a condition that
affects quality of life, productivity, incurs high expenses to patients (Example; insurance
plans where patients pay a 80:20 deductible) and can result in death. This study is one of
the primary attempts to investigate outcomes of AMI in a younger population. Although
no significant difference was demonstrated, mortality was lower in the appropriate group
for cardiac conditions. Hence, increasing awareness of importance of beta-blockers
among patients would result in patients asking their physicians about prescribing this
therapy (they may want to know about contraindications). This will eventually lead to
increases in appropriate prescribing and thus better outcomes (postponement of death) for
AMI patients.

Implications to Prescribers
The study demonstrated lower mortality in the appropriately prescribed group.
This will help those physicians who are skeptical about prescribing beta-blockers in
patients with low risk, or presence of relative contraindications increase prescribing, and
those physicians who prescribe in patients with absolute contraindications decrease
prescribing. Both these scenarios will lead to increase in appropriate prescribing
behavior.
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Implications to Decision-Makers
Decision-makers can benefit from this study in two ways. First, the study shows
that beta-blockers are being inappropriately prescribed. Thus, they can develop and
implement strategies which will increase appropriate prescribing of beta-blockers.
Secondly, the study shows that a physician willingness to prescribe affects their
prescribing behavior, and is dependent on their demographics, practice characteristics,
and their knowledge about guidelines. Thus, they can target physicians who are older,
from general practice, who work in solo settings or who work in small hospitals with
interventions which will increase their willingness to prescribe beta-blockers. Ultimately,
this should affect their prescribing of beta-blockers in post AMI patients.

Limitations of Study
The study had two phases, phase I used secondary data and phase II used primary
data collection. Both phases have limitations, these are discussed in the following
sections:

Limitations of Phase I
The study group for the phase was continuously eligible recipients of Medicaid,
and excluded managed care and/or Medicare recipients. Beta-blockers are known to
provide more benefits for high-risk patients. Age greater 65 is one of the high-risk
criteria (ACC/AHA, 1996). Thus, a significant portion of those individuals, who would
probably have more benefits of appropriate prescribing, were eliminated in the study due
to unavailability of all utilization data. Also, since managed care recipients and those
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recipients who were not continuously eligible were excluded, the results cannot be
generalized for these excluded patients.
The study used data collected for claims purposes and not research purposes, thus,
errors due to billing and coding cannot be ruled out. Severity indicators which would
have helped to adjust for patient risk were not available. Also, some of the relative
contraindications could not be identified such as peripheral hypoperfusion, and
intolerance or allergy to beta-blockers.
The death records obtained from Vital Statistics did not contain detailed
information about the patients. This information would have helped determine the true
cause of death and aid in deciding whether the deaths were cardiac or non-cardiac. Due
to limitations of this missing information, a lot of deaths were excluded from the cardiac
death investigation and the result for cardiac mortality was not significant.
Patients are generally advised to modify certain life-style related characteristics
that affect their risk for future cardiac morbidity. These include smoking cessation,
cardiac rehabilitation, exercise, and dietary modifications. This information is not
available in Medicaid claims and could not be adjusted for in the analysis used.

Limitations of Phase II
This phase involved 1,019 physicians associated with post-AMI care. However,
only a response rate of 25.61 percent was obtained. The non-response bias analysis
revealed that the respondents and the non-respondents were significantly different from
each other on some of the variables compared. There are chances that they can also be
different in their prescribing behavior, knowledge and willingness to prescribe and thus
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the effect of non-response bias cannot be completely eliminated. This limits
generalization of the results to the entire state. Additionally, the survey was conducted in
the state of WV. The physicians in this state may have different characteristics compared
to physicians in other states. Thus, the results may not be as easily extrapolated to other
regions.
Another limitation of this phase is the way the instrument was designed. The
respondents had to give their willingness to prescribe beta-blocker therapy for patients
with different conditions. However, in clinical settings, patients may not have just one of
these conditions. They can have multiple conditions, with different severity levels.
These conditions will influence the prescribing of the physicians. This phase also suffers
from another drawback-the absence of patient preferences. With side effects of betablockers such as decreased libido, impotence, and fatigue there is a possibility that
patients’ preference will affect physician prescribing. Also, beta-blocker prescribing
percent or prescribing behavior was estimated based on prescription of beta-blockers to
the last 10 post-AMI patients treated by the physicians. Treatment of the last 10 patients
may not be representative of the physicians’ general prescribing behavior for betablockers in post-AMI patients. Also, it could not be determined through the survey
whether the prescribing of the physicians for the last 10 patients was appropriate or
inappropriate. However, due to time and resource constraints this method of getting a
proxy for prescribing behavior appeared to be the best. Another discrepancy was the fact
that the guidelines classify atrioventricular (AV) block as both relative and absolute
contraindication, hence there is uncertainty whether to classify it as an absolute
contraindication or relative contraindication. For study purposes, first degree AV block
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was considered to be a relative contraindication and second and third degree AV blocks
were considered to be absolute contraindications.
Based on the survey’s estimation, greater than 90% of the physicians were
prescribing beta-blockers to their post-AMI patients. Phase I of the study which
investigated beta-blocker prescribing for WV Medicaid demonstrated a 64% prescribing
rate. Recent data reported by Schade et al., (2002) for the WV Medicare population,
reported 59.4% prescribing rates for beta-blockers in Medicare AMI patients. Both these
rates are well below the rates obtained from the survey. Thus, it is likely that the
respondents of the survey gave desirable responses and this introduces bias due to selfreported data collection method.
Finally, other limitations of using a self-administered mail questionnaire for data
collection would apply for this study. Although mail questionnaires possess the
advantages of being relatively inexpensive to administer, access to larger population,
anonymity, and elimination of interviewer bias, there are substantial limitations. These
include measurement errors due to respondents not understanding the instructions and
items, item non-response, insensitivity to substitution, and recall bias.

Directions for Future Research
The two phases in this study have given rise to several interesting questions.
These questions will provide the impetus for future research purposes. The simplest
study that arises from phase I involves a prospective study evaluating utilization of betablockers and its effects on patient outcomes. The inability of this phase to adjust for
patient severity and risk levels and the inability to adjust for life-style modifications can
be adjusted by undertaking a prospective study where patients with AMI will be
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identified from one or multiple health systems and followed for a pre-specified duration
of time to determine outcomes such as mortality, morbidity, utilization and expenditures.
Patient chart information can be used to adjust for severity and patients can be
interviewed to know any life-style modification/s undertaken.
Another limitation of the study was the inability to determine beta-blocker use
and its effects on outcomes in the elderly. Linking Medicaid and Medicare records will
allow inclusion of this cohort and thus extending the results of phase I of this study and
hence should be pursued in future.
By conducting the study in Medicaid, phase I of the study involved younger
patients who belong to lower socio-economic status. It would be interesting to duplicate
this study in a third party setting, where the patients would be in a comparable age group
to Medicaid and belong to a higher socio-economic class.
Phase II of the study provided current knowledge and willingness to prescribe
among physicians. Interventions should be designed to educate the physicians about the
gaps in their knowledge and a post study should be undertaken to find out the
effectiveness of such interventions. This would help design interventions that enhance
adherence to practice guidelines.
And finally, since there hasn’t been much reported from the patient’s perspective,
a study that measures and compares effect of beta-blocker therapy on patients’ quality of
life in patients with AMI should be undertaken.
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APPENDIX A: CLAIM FILES
Demographic File
1. RECIPIENT NUMBER
2. RECIPIENT SOCIAL SECURITY NUMBER
3. DATE OF BIRTH
4. SEX
5. RACE
6. ELIGIBILITY BEGIN DATE
7. ELIGIBILITY END DATE

Hospital / ER File
1. RECIPIENT NUMBER
2. RECIPIENT SOCIAL SECURITY NUMBER
3. FIRST DATE OF SERVICE
4. LAST DATE OF SERVICE
5. BILLED AMOUNT
6. PAID AMOUNT
7. DRG CODE
8. PROCEDURE CODE
9. DIAGNOSIS CODES
10. HOSPITAL EXTRACT INDICATOR

244

Physician File
1. RECIPIENT NUMBER
2. RECIPIENT SOCIAL SECURITY NUMBER
3. FIRST DATE OF SERVICE
4. LAST DATE OF SERVICE
5. BILLED AMOUNT
6. PAID AMOUNT
7. DRG CODE
8. PROCEDURE CODE
9. DIAGNOSIS CODES
10. PHYSICIAN EXTRACT INDICATOR

Pharmacy File
1. RECIPIENT NUMBER
2. RECIPIENT SOCIAL SECURITY NUMBER
3. DATE OF PRESCRIPTION FILLED
4. BILLED AMOUNT
5. PAID AMOUNT
6. NDC CODE
7. GENERIC CODE
8. DAYS SUPPLY
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Managed Care File
1. RECIPIENT SOCIAL SECURITY NUMBER
2. MANAGED CARE BEGIN DATE
3. MANAGED CARE END DATE

Drug File
1. NATIONAL DRUG CODE
2. DRUG NAME
3. GENERIC CODE

DRG File
1. DRG CODE
2. DRG NAME

Procedure File
1. PROCEDURE
2. CODE DESCRIPTION

Diagnosis File
1. DIAGNOSIS CODE
2. CODE DESCRIPTION
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APPENDIX B: CODES FOR IDENTIFICATION
Relative Contraindications to Beta-blocker Therapy Post Acute Myocardial Infarction
(AMI)
Heart rate less than 60 bpm
Cannot be identified
Systolic arterial pressure less than 100 Hg

Cannot be identified

Moderate or severe left ventricular failure

ICD-9 code 428.1

Signs of peripheral hypoperfusion

Cannot be identified, Proxy ICD-9
code 443

Second or third degree atrioventricular(AV) block ICD-9 code 426.11, 426.13
PR interval greater than 0.24 second

proxy AV block

Severe Chronic Obstructive Pulmonary Disease

ICD-9 codes 490, 491.x, 492.x,
494.x, 495.x, and 496

Asthma

ICD-9 code 493.x

Severe peripheral vascular disease

CPT-4 code 35456, 35521, 35533,
35546, 35551-58, 35566, 35621,
35646, 35651-61, 35666, 35700
ICD-9 code 443

Insulin dependent diabetes mellitus

ICD-9 code 250.x1 and 250.x3

Beta-blocker intolerance

Cannot be identified

Absolute Contraindications to Beta-blocker Therapy Post AMI
AV block

ICD-9 code 426.0

Bradycardia

ICD-9 code 427.89

Hypotension

ICD-9 code 458.x
247

Identifying Codes for Other Conditions Utilized in the Study
AMI

ICD-9 code 410.x

Diabetes

ICD-9 code 250.x

Hypertension

ICD-9 code 401

Congestive heart failure

ICD-9 code 428.x

Coronary artery bypass graft

CPT-4 coded 33517-30, 33533-36,
33542, 33545 DRG-code 107, 109

Percutaneous transluminal coronary

CPT-4 codes 35470-73

angioplasty

DRG-code 112, 116

Stroke

ICD-9 code 430-436

Renal dysfunction

ICD-9 code 588.0

Cardiac Conditions
Essential hypertension

ICD-9 code 401.x

AMI

ICD-9 code 410.x

Acute Ischemia

ICD-9 code 411.x

Angina pectoris

ICD-9 code 413.x

Other Ischemia

ICD-9 code 414.x

Pulmonary heart disease

ICD-9 code 416.x

Disease of Endocardium

ICD-9 code 424.x

Cardiomyopathy

ICD-9 code 425.x

Conduction Disorders

ICD-9 code 426.x

Cardiac Dysrhythmias

ICD-9 code 427.x

Shock

ICD-9 code 785.5-785.51
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Medications
Aspirin
Angiotensin converting
enzyme inhibitor

Benazepril, Captopril, Cilazapril, Enalapril, Enalaprilat,
Fosinopril, Lisinopril, Moexipril, Perindopril, Quinapril,
Ramipril, Trandolapril

Calcium Channel blockers

Bepridil, Diltiazem, Felodipine, Flunarizine, Isradipine,
Nicardipine, Nifedipine, Nimodipine, Verapamil

Loop diuretics

Bumetanide, Ethacrynic Acid, Furosemide

Digoxin
Beta blockers

Acebutolol, Atenolol, Betaxolol, Bisoprolol, Carteolol,
Labetalol, Metoprolol, Nadolol, Oxprenolol, Penbutolol,
Pindolol, Propranolol, Sotalol, Timolol

Lipid Lowering Drugs

Atorvastatin, Cerivastatin, Fluvastatin, Pravastatin,
Simvastatin, Lovastatin

Nitroglycerine
Antiarrhythmics

Amiodarone, Flecainide, Mexeletine, Procanamide,
Propafenone
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COVER LETTERS, STUDY SURVEY AND NON-RESPONSE SURVEY
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APPENDIX C: FIRST COVER LETTER
January 6, 2003

Dear Doctor,
Acute Myocardial Infarction (AMI) is the number one killer among both men and
women in the United States. It is an area of high expenditures in the health care system.
Thus, therapeutic interventions that reduce morbidity, mortality, as well as prevention
strategies for AMI are extremely important and can have a significant impact on the
quality and cost of patient care in the US health system.
Therapy with beta-blockers and ACE-inhibitors has been investigated in
numerous clinical trials for reducing mortality following an AMI. The objective of this
study is to identify current opinions and beliefs among WV physicians about the use of
secondary preventive agents for long-term therapy in patients who have had an AMI.
This study is part of a doctoral research project and is being undertaken by West Virginia
University, School of Pharmacy. Information obtained from this study will be useful in
developing educational strategies for use of secondary preventive medications in postAMI patients.
We hope that you will choose to participate by completing the attached
questionnaire that asks about your opinions and beliefs regarding use of secondary
preventive agents in post-AMI patients. To assure confidentiality, your responses will be
coded and your name will not appear in any data analysis or study reports. Your
participation in this study is voluntary. Although we hope that you will answer all of the
questions, you do not have to answer any question that makes you uncomfortable.
Your response will provide valuable information and is critical to the results of
the study. Thank you for taking a few minutes to complete the survey. Please return it in
the enclosed postage-paid envelope. If you have any questions, please do not hesitate to
contact Ancilla Fernandes at (304) 293-6991 or Dr. Suresh Madhavan at (304) 293-1652.
Thank You.
Sincerely,

Ancilla Fernandes, M.S.
Ph.D. Candidate

Suresh Madhavan, M.B.A, Ph.D.
Professor and Chairperson
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APPENDIX D: SECOND COVER LETTER
January 20, 2003

Dear Doctor,
About two weeks ago, we sent you a survey asking your opinions and beliefs
related to use of secondary preventive agents in post-AMI patients. We have not yet
received your completed survey.
We understand that you are busy or may not have received the survey. However,
your responses are extremely important to us, and the information obtained for the study
will be very useful to develop educational strategies for enhancing use of secondary
preventive agents in post-AMI patients. Therefore, we are sending you another copy of
the survey and would appreciate it if you could take a few minutes to complete and return
it in the enclosed postage-paid envelope. If you have responded, please disregard this
letter and accept our gratitude for your time and effort.
This study is part of a doctoral research project and is being undertaken by West
Virginia University, School of Pharmacy. Your participation in this study is voluntary.
To assure confidentiality, your responses will be coded and your name will not appear in
any data analysis or study reports. Although we hope that you could answer all of the
questions, you do not have to answer any question that makes you uncomfortable.
Thank you for your participation. If you have any questions or concerns, please
do not hesitate to contact Ancilla Fernandes at (304) 293-6991 or Dr. Suresh Madhavan
at (304) 293-1652.

Thanks you.
Sincerely,

Ancilla Fernandes, M.S.
Ph.D. Candidate

Suresh Madhavan, M.B.A, Ph.D.
Professor and Chairperson
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APPENDIX E: THIRD COVER LETTER
February 3, 2003

Dear Doctor,
About two weeks ago, we made our second attempt to reach you regarding our
study, asking your opinions and beliefs related to use of secondary preventive agents in
post-AMI patients. We have not yet received your completed survey.
We have undertaken this study because it is our belief that your opinions should
be taken into account for developing educational strategies for enhancing use of
secondary preventive agents in post-AMI patients.
We are writing to you again to emphasize the significance of your response and
how important your opinions are in understanding patient care for AMI patients. We
have enclosed a questionnaire just in case your earlier copies have been misplaced. We
would appreciate it if you could take a few minutes to complete and return it in the
enclosed postage-paid envelope. If you have responded, please disregard this letter and
accept our gratitude for your time and effort.
This study is part of a doctoral research project and is being undertaken by West
Virginia University, School of Pharmacy. Your participation in this study is voluntary.
To assure confidentiality, your responses will be coded and your name will not appear in
any data analysis or study reports. Although we hope that you could answer all of the
questions, you do not have to answer any question that makes you uncomfortable.
Thank you for your participation. If you have any questions or concerns, please
do not hesitate to contact Ancilla Fernandes at (304) 293-6991 or Dr. Suresh Madhavan
at (304) 293-1652.

Thanks you.
Sincerely,

Ancilla Fernandes, M.S.
Ph.D. Candidate

Suresh Madhavan, M.B.A, Ph.D.
Professor and Chairperson
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APPENDIX F: STUDY SURVEY
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Opinions and Beliefs about Long-term Secondary Preventive Agents following an Acute Myocardial Infarction
(AMI)
INSTRUCTIONS: Your professional opinions and beliefs are extremely important for understanding the use of secondary preventive
agents following an AMI. Please answer the questions carefully. Your response will be kept absolutely confidential.

1.

2.

SECTION A
Of the following medications, which according to you are the important secondary preventive agents following an
AMI:(Check all that apply)
Aspirin

Angiotensin Converting Enzyme (ACE) inhibitors

Digitalis

Anti-arrhythymics

Calcium Channel blockers

Nitroglycerin

Beta-blockers

Lipid-lowering drugs

Anticoagulants

Magnesium

Others, please specify ___________________________________________________________

How likely are you, on a scale from 1 to 5 where 1 is least likely and 5 is most likely, to prescribe these medications for
secondary prevention following an AMI:
Please answer this question by using:
1
2
3
4
5
Least likely
Uncertain
Most likely

Enter response (any number from 1 to 5)

3.

1.

Aspirin

__________

2.

Angiotensin Converting Enzyme (ACE) inhibitors

__________

3.

Digitalis

__________

4.

Anti-arrhythymics

__________

5.

Calcium Channel blockers

__________

6.

Nitroglycerin

__________

7.

Beta-blockers

__________

8.

Magnesium

__________

9.

Lipid-lowering drugs

__________

10. Anticoagulants

__________

11. Others

__________

A) Of the last 10 new AMI/post-AMI patients that you treated, you prescribed a beta-blocker as long- term therapy for
secondary prevention in….( Please circle the appropriate number)
1

2

3

4

5

6

7

8

9

10

of these patients

B) If your answer for the previous question is less than 10 please specify the reasons for not prescribing beta-blockers in
these patients:
____________________________________________________________________________________________________
____________________________________________________________________________________________________
4.

A) Of the last 10 new AMI/post-AMI patients that you treated, you prescribed a ACE inhibitor as long-term therapy for
secondary prevention in….( Please circle the appropriate number)
1

2

3

4

5

6

7

8

9

10

of these patients

B) If your answer for the previous question is less than 10 please specify the reasons for not prescribing ACE inhibitors
in these patients:
____________________________________________________________________________________________________
____________________________________________________________________________________________________
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SECTION B
Clinical trials have consistently demonstrated lower mortality in AMI patients when they are treated with betablockers and ACE inhibitors. However, there are certain conditions in the presence of which beta-blockers and/or ACE
inhibitors are not beneficial and can be harmful.
Given the normal side effects of beta-blockers (fatigue, sexual dysfunction, nightmares and difficulty to detect
hypoglycemia in diabetics) and ACE inhibitors (dry cough, diarrhea, fatigue, dizziness) how likely are you, on a scale
from 1 to 5 where 1 is least likely and 5 is most likely, to prescribe these for long-term use for secondary prevention in
AMI patients with the following attributes:
Please answer this question by using:
1
2
Least likely

3
Uncertain

4

Enter response (any number from 1 to 5)
1. Age > 50 years

5
Most likely

Beta-blockers
ACE inhibitors
__________
__________

2. Age < 50 years

__________

__________

3. Large or anterior AMI

__________

__________

4. Small infarction

__________

__________

5. Previous infarction

__________

__________

6. EF<40%

__________

__________

7. History of Chronic Heart Failure

__________

__________

8. Had an angioplasty

__________

__________

9. Had by-pass surgery

__________

__________

10. Stroke

__________

__________

11. Hypotension (systolic pressure <90Hg)

__________

__________

12. Hypertension (systolic pressure >140Hg)

__________

__________

13. Systolic blood pressure <100 Hg

__________

__________

14. Bradycardia (heart rate <50 bpm)

__________

__________

15. Heart rate < 60 bpm

__________

__________

16. Left Venticular (LV) failure

__________

__________

17. Complex Ventricular ectopy

__________

__________

18. First degree Atrio-Ventricular (AV) block

__________

__________

19. Second degree AV block

__________

__________

20. Third degree AV block

__________

__________

21. Peripheral vascular disease

__________

__________

22. Chronic Obstructive Pulmonary Disease (COPD)

__________

__________

23. Asthma

__________

__________

24. Insulin dependent diabetes mellitus

__________

__________
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SECTION C
Patient conditions in the presence of which medications such as beta-blockers and ACE inhibitors are not
beneficial are divided into absolute contraindications (i.e. medication should not be used), and relative contraindications
(i.e. medication can be used if patient is monitored). There are other conditions that are not contraindications (i.e.
medication can be used without concern).
Which of the following conditions in your opinion are – absolute contraindications (AC), relative
contraindications (RC), or are not contraindications (NC) for long-term use of these drugs (beta-blockers and ACE
inhibitors) in AMI patients. Please answer this question by marking (X) in the box that represents your answer.
Patient conditions:

Beta-blockers
AC

RC

ACE inhibitors

NC

AC

RC

NC

1. Hypotension (systolic pressure <90 Hg)

1

1

1

1

1

1

2. Systolic blood pressure < 100Hg

1

1

1

1

1

1

3. Hypertension (systolic pressure >140Hg)

1

1

1

1

1

1

4. Heart rate < 60 bpm

1

1

1

1

1

1

5. Bradycardia (heart rate <50 bpm)

1

1

1

1

1

1

6. Peripheral vascular disease

1

1

1

1

1

1

7. Peripheral hypoperfusion

1

1

1

1

1

1

8. EF<40%

1

1

1

1

1

1

9. First degree Atrio-Ventricular (AV) block

1

1

1

1

1

1

10. Second degree AV block

1

1

1

1

1

1

11. Third degree AV block

1

1

1

1

1

1

12. Chronic Obstructive Pulmonary Disease (COPD)

1

1

1

1

1

1

13. Asthma

1

1

1

1

1

1

14. Non-insulin dependent diabetes mellitus

1

1

1

1

1

1

15. Insulin dependent diabetes mellitus

1

1

1

1

1

1

16. PR interval on Electrocardiogram (ECG)>0.24 second

1

1

1

1

1

1

17. Stroke

1

1

1

1

1

1

18. Beta-blocker intolerance

1

1

1

1

1

1

19. ACE-inhibitor intolerance

1

1

1

1

1

1
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SECTION D
A few questions about you and your primary site of practice.
1. Age:

_________ Years ________

2. Gender:

Male

Months

Female

3. Specialty or Primary Area of Practice:

______________________________________

4. Year of board certification in this specialty/primary area of practice:

_______________

5. Your primary practice site is:
Hospital based

(go to question 6)

University-affiliated Hospital (go to question 6)
Solo, office-based

(go to question 8)

Group, office-based

(go to question 8)

Others, please specify _____________________________________________(go to question 8)
6. The hospital where you practice is: Check all that apply
Rural

Government/Non-Federal

Urban

Government/Federal

Sub-urban

Private Not-For-Profit

Provides Tertiary Care

Private Investor Owned
Others, please specify ___________________________________________________________
7. Number of beds at this hospital:

_______________

8. Average number of new AMI patients you see per month:

_______________

9. Average number of repeat AMI patients you see per month: _______________

COMMENTS
If there is anything else that you would like to tell us about your beliefs or opinions with using beta-blockers and ACEinhibitors as secondary preventive agents after an AMI, please use this space to provide your comments.

THANK YOU
Please return the complete survey in the enclosed business reply envelope.
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APPENDIX G: NON-RESPONSE SURVEY
February 17, 2003
Dear Doctor,
During the past two months you may have received two-three mailings of a questionnaire regarding your
opinions and beliefs for use of secondary preventive agents in post-Acute Myocardial Infarction (AMI) patients. We
realize that you have been very busy and have chosen not to answer the survey or did not have the time. Since your view
is extremely important to us, we would like to know your reason for not responding and obtain some key information for
the study. This study is part of a doctoral research project and is being undertaken by West Virginia University, School of
Pharmacy. Your participation in this study is voluntary. To assure confidentiality, your responses will be coded and your
name will not appear in any data analysis or study reports. Although we hope that you could answer all of the questions,
you do not have to answer any question that makes you uncomfortable. Please answer the few questions below and mail
it to us in the business reply envelope provided. If you have any questions or concerns, please do not hesitate to contact
us at (304) 293-6991 or (304) 293-1652.
Sincerely,
Ancilla Fernandes, M.S.
Ph.D. Candidate

Suresh Madhavan, M.B.A, Ph.D.
Professor and Chairperson

Q1. I did not respond to the survey because:
Did not have enough time to complete it
Did not receive it
Forgot about the survey
Survey was too long
Survey was misplaced
Don’t like to respond to surveys
No incentive to complete it
Not enough information about benefits
Not interested in such studies
Topic was irrelevant
Others (Please specify) ______________________________________________
Q2. Demographics:
1. Age:

_________ Years ________

2. Gender:

Male

3. Specialty or Area of Practice:

Months

Female
______________________________________

4. Year of board certification in this specialty/area of practice:

_______________

5. Your primary practice site is:
Solo, office-based
Group, office-based
Hospital based
University affiliated-Hospital based
6. Average number of new AMI patients you see per month:

_______________

7. Average number of repeat AMI patients you see per month: _______________
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